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RNA DYSREGULATION IN METASTATIC BREAST CANCER 
 
Christina Beate Marney, Ph.D. 
The Rockefeller University 2014 
 
Breast cancer is the most commonly diagnosed and second highest 
cause of cancer-related mortality in women, with the majority of deaths 
associated with metastatic spread of tumors to distal organs. The 
metastatic process involves multiple sequential steps including invasion 
of the surrounding stroma, intravasation into lymph or blood vessels, 
survival during transport with successful evasion of the immune system, 
extravasation and final outgrowth in the new microenvironment. At each 
step cells acquire new properties through the alteration of gene expression 
profiles. While a great deal of effort has been made towards 
understanding the underlying genetic mutations associated with 
enhanced motility and invasiveness, it is becoming increasingly apparent 
that post-transcriptional modification of gene expression at the RNA level 
contributes substantially towards gain of metastatic potential. 
 
 In eukaryotic cells RNA is subject to multiple layers of regulation 
that together generate extensive phenotypic and temporal complexity 
from a relatively small number of genes. RNA regulation is achieved 
through the concerted action of multiple RNA binding proteins (RBPs) 
which themselves are subject to tight regulation. Recent studies have 
implicated the aberrant expression of multiple RBPs in tumor 
development and metastatic spread, while technological advances have 
provided methods by which unbiased, transcriptome-wide footprints of 
RBP-RNA interactions can be mapped. High-throughput cross-linked 
immunoprecipitation (HITS-CLIP) provides both the identity of regulated 
transcripts and the location of RBP regulation within a transcript. For the 
post-transcriptional regulatory protein Argonaute (AGO), which binds 
mRNA in complex with small non-coding microRNAs (miRNAs), HITS-
CLIP derived 3’UTR binding sites have been shown to correspond to sites 
of functional miRNA-mediated target downregulation.  
 
In this study, a molecularly characterized cell culture based model 
system of breast cancer metastasis has been employed to investigate the 
role of RNA binding proteins in the inhibition of metastatic progression. 
AGO-mRNA regulation mediated by endogenous miRNAs and 
exogenous anti-metastatic pre-miR-335 has been interrogated by HITS-
CLIP to identify on a genome-wide scale differentially regulated targets 
with respect to metastatic potential. Furthermore, HITS-CLIP has been 
used to characterize a novel anti-metastatic RNA binding protein, RBM47, 
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CHAPTER 1: INTRODUCTION 
 
Breast cancer is the most commonly diagnosed tumor in women, 
with an estimated ~230,500 newly diagnosed invasive cases expected in 
2011, and is the second highest cause of female cancer-related mortality 
(American Cancer Society, 2012). Metastasis, a complex multistep process 
in which cells shed from the primary tumor disseminate throughout the 
body to colonize and proliferate in organs distant from the site of the 
original tumor, is the leading cause of death from breast cancer. The 5-
year relative survival rate of patients presenting with distal metastases 
drops to 23.3% from 98.6% in patients with localized disease (Siegel et al., 
2012). Dissemination of tumor cells can occur early in primary breast 
cancer progression leading to both primary tumor re-seeding and 
accelerated primary tumor growth (Kim et al., 2009b), and colonization of 
secondary metastatic niches leading to eventual outgrowth as distal 
metastatic lesions (Husemann et al., 2008). The metastatic process is 
inherently inefficient (Luzzi et al., 1998, Cameron et al., 2000) and is 
thought to require both tumor cell intrinsic adaptation and cell extrinsic 
metastatic niche modulation (Nguyen et al., 2009). 
 
Metastatic cells show differing abilities to grow in certain organs 
with varying latencies to outgrowth that are dependent upon tumor type 
or sub-type, and in a way that cannot be solely be explained by circulatory 
patterns (Mendoza and Khanna, 2009, Nguyen et al., 2009). In breast 
adenocarcinoma, metastases are most commonly found in the auxiliary 
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lymph nodes, bone, lung, brain and liver (Hess et al., 2006, Patanaphan et 
al., 1988). Both general poor-prognosis and tissue-specific gene expression 
signatures have been described that clinically correlate with metastatic 
relapse (van 't Veer et al., 2002, van de Vijver et al., 2002, Bos et al., 2009, 
Kang et al., 2003, Li et al., 2011a, Minn et al., 2005a). However, 
understanding the exact molecular and cellular processes involved in both 
gain of metastatic ability and organ-specificity remains challenging (Sethi 
and Kang, 2011). 
 
RNA Binding proteins and cancer-associated alterations in RNA 
metabolism  
RNA metabolism is an integral part of both normal cellular 
complexity and the altered transcriptomes observed during both 
tumorigenesis and gain of metastatic ability. Central to this complexity are 
the concerted actions of multiple RNA binding proteins (RBPs) that 
regulate the spatial, temporal and functional dynamics of target RNAs 
from transcription to maturation, from modulation of content through to 
eventual degradation (Moore and Proudfoot, 2009). This includes (but is 
not limited to) alternative splicing, alternative polyadenylation and the 
regulation of transcript stability predominantly mediated through 
interactions in 3’ untranslated regions (3’UTRs). Thus, RNA is no longer 
considered solely as a template for protein synthesis; rather its precise 
regulation is fundamental in the generation of biological complexity in 




In eukaryotes precursor messenger RNA (pre-mRNA) is subjected 
to multiple post-transcriptional modifications including the 
intramolecular joining (splicing) of regions of coding sequence that will be 
transcribed into protein (exons), and the removal of intervening non-
coding sequences (introns). Splicing reactions are catalyzed by a large 
multi-component ribonuclear complex called the spliceosome, which is 
comprised of five subcomponent small nuclear ribonucleoproteins 
(snRNPs U1-6) that assemble in a stepwise manner on core sequence 
elements within the intron to be removed. The sequences recognized by 
the spliceosome are relatively degenerate and in most cases the strength of 
the splicing signal is influenced by flanking pre-mRNA sequences, 
intronic or exonic splicing silencers or enhancers, which mediate their 
effects primarily by serving as binding sites for additional trans-acting 
regulatory RBPs (Wahl et al., 2009). 
 
Alternative splicing was first described in 1980, when it was 
discovered that two protein products, one soluble and one membrane 
bound, could be produced from the same immunoglobulin gene (Alt et al., 
1980, Early et al., 1980). Multiple types of alternative splicing have since 
been described; alternative 5’ and 3’ splice site selection, single exon 
(cassette-exon) inclusion or exclusion, mutually exclusive cassette-exon 
inclusion or exclusion, intron retention, and alternative promoter or 
3’exon selection (Keren et al., 2010). Recent studies using high-throughput 
sequencing of the human transcriptome indicate that alternative splicing 
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is major contributor to proteomic diversity, with over 90% of human 
genes showing evidence of alternative transcripts (Pan et al., 2008, Wang 
et al., 2008). Additionally, patterns of tissue-specific regulation have been 
observed indicating that the enormous diversity of proteins that can 
potentially be generated by alternative splicing is regulated in a 
coordinated manner (Wang et al., 2008). For example, the neuronal 
specific splicing factor Nova has been found to regulate the alternative 
splicing of a biologically coherent set of transcripts involved in synaptic 
plasticity, providing the first demonstration of an RBP-coordinated 
biological network (Ule et al., 2003, Ule et al., 2005b, Licatalosi et al., 2008).  
 
The regulation of alternative splicing is dependent upon 
interactions between multiple RBPs, and between splicing factor RBPs and 
their binding motifs in target pre-mRNAs (Licatalosi and Darnell, 2010). It 
has been shown that splicing factors can be differentially expressed 
between human tumors and normal tissues, although for most splicing 
factors it is not known whether these tumor specific expression patterns 
are a consequence or causative of the oncogenic process (Kirschbaum-
Slager et al., 2004). It is interesting to note that alternative splicing patterns 
can be used to distinguish normal tissue from serous ovarian tumors 
(Venables et al., 2009), breast tumors (Venables et al., 2008) and colon 
cancers (Gardina et al., 2006) suggesting that alteration in alternative 




Cancer-associated mutations resulting in alternative splicing 
Germline mutations in high penetrance susceptibility genes such as 
BRCA1, BRCA2, PTEN and TP53 contribute approximately 20% of familial 
genetic risk in breast cancer (Thompson and Easton, 2004), with BRCA1 
and BRCA2 mutations conferring a lifetime risk of 80-90% (Meindl et al., 
2011). The BRCA proteins are tumor suppressors involved in homologous 
recombination and error-free repair of DNA double strand breaks (Roy et 
al., 2012). Interestingly, previously unclassified germline variants of 
BRCA1/2 associated with breast cancer, those that do not have predicted 
effects on protein function, are being characterized as anomalous splicing 
variants resulting from disruption of regulatory splicing elements (Sanz et 
al., 2010, Wappenschmidt et al., 2012) or by activation of cryptic exons 
(Anczukow et al., 2012a).  
 
It is estimated that 10% of human inherited diseases result from 
mutations disrupting components of 5’- or 3’-splice sites (Cooper et al., 
2009). However, this estimate does not take into consideration exonic 
mutations as these are generally presumed to result in missense mutations 
and altered protein function, or to be neutral due synonymous mutations. 
Exonic mutations have the potential to create or destroy regulatory 
sequences known as exonic splicing enhancers (ESE) or silencers (ESS). 
Recent bioinformatic analyses of exonic disease-causing human mutations 
have found a strong association between single nucleotide 
polymorphisms (SNPs) and both the creation of ESS motifs and ablation of 
ESEs suggesting that exon skipping may play a prominent role in human 
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inherited disease (Sterne-Weiler et al., 2011, Lim et al., 2011). Furthermore, 
trait associated SNPs, mutations significantly and reproducibly associated 
with but not causative of particular inherited diseases, are also enriched 
for exon-exclusion inducing intronic mutations (Lee et al., 2012) 
suggesting that mis-splicing is a common feature of genetic disease. 
 
Large-scale changes in splicing patterns have been observed in 
multiple tumor types during the transition from normal to cancerous 
tissue, making widespread germline or gain of tumor-associated 
mutations highly unlikely. Mutations in proteins involved in the core 
splicing machinery have been found in myelodysplasia, a neoplasm that 
predisposes for acute myeloid leukemia (Yoshida et al., 2011), however 
deregulation of trans-acting alternative splicing modulators are more 
commonly described.  
 
Splicing regulators as oncogenes – SRSF1  
The SR protein family members, serine/argenine rich splicing 
factor (SRSF) 1-12, are defined based on the presence of 1-2 RNA 
recognition motif (RRM) domains followed by an ~50nt >40% 
serine/argenine domain of consecutive RS or SR repeats (Manley and 
Krainer, 2010). SR proteins are involved in both constitutive and 
alternative splicing of pre-mRNA through binding to ESEs (Busch and 
Hertel, 2012). Karni et al. (2007) discovered that SRSF1 (previously known 
as SF2/ASF) is upregulated in lung, colon and breast tumors when 
compared to normal tissues, and that ectopic expression of SRSF1 is 
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oncogenic both in vitro and in vivo. Over-expression of SRSF1 leads to the 
alteration of alternative splicing patterns of endogenous target genes, 
including increased expression of an oncogenic isoform of RPS6KB1, and 
increased inclusion of an alternative exon12a of BIN1 that abolishes its 
tumor suppressor activity (Karni et al., 2007). 
 
Subsequently it has been shown that SRSF1 is transformative in 
mammary epithelial cells (Anczukow et al., 2012b), and is upregulated in 
lung adenocarcinoma and squamous cell lung cancer (Gout et al., 2012), 
non-small cell lung cancer (Ezponda et al., 2010), and pediatric acute 
lymphoblastic leukemia (Zou et al., 2012). SRSF1 regulates the inclusion of 
exon 3b of Rac1 in colon cancer cells (Goncalves et al., 2009) resulting in 
the expression of a constitutively active Rac1b isoform that has been 
shown to promote transformation of NIH3T3 cells through AKT 
phosphorylation and activation (Singh et al., 2004). Additionally, the 
transforming ability of SRSF1 in immortal fibroblasts has been 
demonstrated to be dependent upon mTORC activity (Karni et al., 2008), 
while SRSF1 expression is both directly regulated by, and necessary for, 
the oncogenic activity of Myc in lung cancer cells (Das et al., 2012). A 
genome-wide binding map of SRSF1 has been generated in mouse 
embryonic stem cells using high-throughput cross-linked 
immunoprecipitation (HITS-CLIP) which, in conjunction with splicing-
sensitive microarray analysis, has identified 498 SRSF1-dependent 
alternative splicing events (Pandit et al., 2013), although it is not known 
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how many of these targets are expressed and regulated in the tumor 
tissues associated with SRSF1 transformation. 
 
Splicing regulators as oncogenes – FOX2 
Using genome-wide, high throughput RT-PCR, Venables et al. 
(2009) identified multiple alternative splicing events common to tumors of 
the breast and ovary that can discriminate between normal and cancer 
tissues. Analysis of sequences in the 100nt flanking regions of these cancer 
associated-exons revealed enrichment of FOX1/2 binding motifs. FOX1 
mRNA is detected almost exclusively in the brain and striated muscle, 
while FOX2 is more broadly expressed in heart, brain and the ovary (Jin et 
al., 2003, Lieberman et al., 2001, Underwood et al., 2005). Subsequent 
analysis of breast cancer and non-malignant immortalized breast 
epithelial cell lines have revealed that FOX2 regulates alternative splicing 
patterns associated with claudin-low, basal breast cancer sub-types 
(Lapuk et al., 2010). Computational analyses of the genome-wide 
distribution of FOX1/2 binding motifs have revealed a position-
dependent relationship between alternative exon inclusion or exclusion 
(validated by semi-quantitative RT-PCR) in transcripts enriched in gene 
ontology terms associated with cytoskeletal organization and 
neuromuscular functions (Zhang et al., 2008). Genome-wide mapping of 
FOX2 on target mRNAs in human embryonic stem cells (hECS) has 
confirmed this positional bias in splicing and identified FOX2 as necessary 
for hECS survival, although this phenotype was not found in 293T cells or 
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human fetal neural stem cells suggesting cell type specific FOX2 target 
regulation (Yeo et al., 2009). 
 
Splicing regulators as tumor suppressors – RBM5 
Allele loss at 3p21.3 is both the earliest pre-malignant change thus 
far detected in lung cancer (Sundaresan et al., 1992) (Hung et al., 1995, 
Sundaresan et al., 1992, Wistuba et al., 1999), and the most frequent lung 
cancer-associated genetic alteration (Zabarovsky et al., 2002). This ~630kb 
deletion is also observed in multiple other tumor types including breast, 
and spans multiple putative tumor suppressor genes including the RNA 
binding protein RBM5 (Lerman and Minna, 2000, Zabarovsky et al., 2002). 
RBM5 encodes two RRM domains, a zinc finger motif, a bipartite nuclear 
signal and a G-patch domain (Timmer et al., 1999). Unlike the pro-
tumorigenic splicing factors mentioned above, RBM5 is tumor 
suppressive; inhibiting growth in MCF-7 breast cancer cells (Oh et al., 
2002), A549 non-small cell lung cancer (NSCLC) cells (Oh et al., 2006, Shao 
et al., 2012) and CEM-C7 leukemia cells (Mourtada-Maarabouni et al., 
2003).  
 
RBM5 is reported to promote apoptosis (Mourtada-Maarabouni et 
al., 2003, Shao et al., 2012) in part through binding to and positively 
regulating the splicing of a pro-apoptotic isoform of caspase 2, casp-2L 
(Fushimi et al., 2008). Conversely, RBM5 can interfere with a late step in 
spliceosome assembly, promoting exon exclusion and production of a 
non-membrane-bound Fas molecule that inhibits apoptosis (Bonnal et al., 
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2008, Cheng et al., 1994). Additionally, RBM5 causes cell cycle arrest in G1 
in lung cancer cells, and induces the expression of the apoptotic activator 
BCL2-associated protein X (Bax) although the mechanisms by which this 
occurs remain unknown (Oh et al., 2006). 
 
Alternative splicing in metastasis 
 Multiple transcripts that promote tumor cell invasive behavior are 
regulated by alternative splicing (David and Manley, 2010). The 
transmembrane protein CD44 is encoded by 20 exons, 10 of which can be 
regulated by alternative splicing leading to multiple different functional 
proteins (Ponta et al., 2003). Alternative splice isoforms of CD44 were 
among the first to be associated with induction of metastasis (Gunthert et 
al., 1991) and have subsequently been found to promote metastasis in 
multiple tumor types. Regulation of CD44 splicing is reported to be 
controlled by multiple candidate RBPs including SFRS10 (Watermann et 
al., 2006, Takeo et al., 2009), PCBP-1/hnRNP-E1 (Zhang et al., 2010b, Lian 
et al., 2012), Sam68 (Matter et al., 2002) in association with SRm160 (Cheng 
and Sharp, 2006), and ESRP1 (Reinke et al., 2012, Yae et al., 2012). While 
the majority of these RBPs enhance inclusion of various combinations of 
alternative CD44 exons, PCBP-1/hnRNP-E1 promotes exon exclusion 
suggesting that over-all splicing outcome in any given cellular context 
depends upon the regulatory proteins expressed. 
 
 Altered patterns of alternative splicing have been observed when 
comparing primary tumors with differing metastatic capacity (Dutertre et 
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al., 2010), and during the acquisition of the invasive phenotype that 
accompanies the epithelial-mesenchymal transition (EMT) (Warzecha et 
al., 2010, Shapiro et al., 2011). The EMT involves loss of cell polarity and 
cell-cell junctions and the acquisition of a more motile, invasive cellular 
phenotype via extensive transcriptional changes and reorganization of the 
actin cytoskeleton. While direct evidence linking EMT to metastasis in vivo 
is difficult to obtain, the same processes commonly involved in 
developmental EMT bear striking similarity to those involved in 
metastasis (Yilmaz and Christofori, 2009).  
 
 Three RBPs are currently implicated as major regulators of EMT-
associated alterations in alternative splicing patterns: ESRP1 and ESRP2, 
and RBFOX2 (Shapiro et al., 2011). The switch between the mutually 
exclusive inclusion of fibroblast growth factor receptor 2 (FGFR2) exon3b 
(epithelial) or exon3c (mesenchymal) that occurs during EMT and 
metastasis (Yan et al., 1993) is thought to be a direct result of 
downregulation of the epithelial specific splicing factors ESRP1 and 
ESRP2 (Warzecha et al., 2009). Knockdown of ESRP1 and 2 in mammary 
epithelial cells induces both the cellular changes indicative of EMT and 
extensive alterations in splicing of transcripts associated with vesicular 
transport (Warzecha et al., 2010), while re-expression of ESRP1 in 
mesenchymal cells causes partial reversion to the epithelial phenotype 
(Shapiro et al., 2011). Analysis of RBP expression levels in mammary 
epithelial cells undergoing EMT have confirmed both the loss of ESRP1/2, 
and identified a slight up regulation of RBFOX2 (Shapiro et al., 2011) a 
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known driver of mesenchymal-specific splicing patterns (Venables et al., 
2013). Depletion of RBFOX2 in mesenchymal cells leads to partial 
reversion to the epithelial phenotype, while EMT associated up-regulation 
of RBFOX2 leads to altered splicing patterns of predicted targets 
associated with invasion (Braeutigam et al., 2013).  
 
RNA binding proteins and modulation of transcript stability 
 The relative abundance of mRNA is a function both of the rate of 
transcription and degradation, with each altered in response to stimuli in 
order to adjust the resulting protein level. Aberrant gain or loss of a 
transcript in disease may reflect either DNA mutation or dysregulation of 
trans-activating transcription factors, or could result from altered post-
translational regulation of stability of the message. mRNA stability can be 
regulated by RBPs, either alone or in complex with non-coding RNAs, 
through binding to cis-regulatory elements within the transcript (Wu and 
Brewer, 2012). Several well characterized mRNA stabilizing and 
destabilizing factors are known to be deregulated in tumorigenesis and 
metastasis, influencing the establishment of aberrant target mRNA 
expression profiles. 
 
Nonsense mediated decay in cancer 
 Nonsense mediated decay (NMD) is a translation-coupled mRNA 
surveillance process that selectively eliminates transcripts containing 
premature stop codons to minimize synthesis of truncated proteins. 
During splicing of pre-mRNA, the exon junction complex (EJC) is 
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deposited approximately 20-24 nucleotides upstream of the exon-exon 
junction, providing a position dependent memory of the splicing event (Le 
Hir et al., 2000, Le Hir et al., 2001). If a translating ribosome encounters a 
stop codon >50-55nt upstream of an EJC, translational pausing occurs 
leading to the recruitment of the SMURF complex (SMG1, UPF1 and 
eukaryotic release factors) and SMG1 phosphorylation of UPF1 (Kashima 
et al., 2006). This in turn leads to the recruitment of decapping enzymes, 
the endoribonuclease SMG6 and deadenylation, resulting in the rapid 
decay of the mRNA (Lejeune et al., 2003, Huntzinger et al., 2008).  
 
 Meta-analysis of predicted human disease-causing mutations has 
revealed a disproportionately high number of nonsense mutations in 
tumor suppressor genes when compared to missense mutations, with the 
opposite being true for oncogenes (Mort et al., 2008). NMD has been 
shown to prevent the translation of truncated proteins in breast cancer 
that arise from germline mutations in BRCA1, CHK2 and TP53 (Perrin-
Vidoz et al., 2002, Anczukow et al., 2008). In hereditary diffuse gastric 
cancer, ~80% of the causative germline mutations in e-cadherin generate 
premature stop codons leading to NMD and transcript down regulation 
(Karam et al., 2008). In addition to DNA mutation, introduction of 
premature stop codons can also be achieved through alternative splicing, 
by inclusion of occult, poorly conserved exons that result in frame-shift 
mutations (Green et al., 2003, Lewis et al., 2003).  
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While it has been argued that the inclusion of the majority of 
mammalian alternatively spliced NMD exons results from “noisy” 
splicing rather than regulated events (Zhang et al., 2009), the onconeural 
antigen proteins Nova1 and Nova2 have been shown to bind and regulate 
the alternative splicing of multiple NMD exons in brain in an activity 
dependent manner (Eom et al., 2013). This would suggest that inclusion of 
NMD exons and hence down regulation of target mRNA can proceed in a 
coordinately regulated manner. The NOVA proteins were first identified 
as the target antigens in paraneoplastic opsoclonus-myoclonus ataxia 
(POMA) syndrome (Darnell et al., 1991), a neurological degenerative 
disorder commonly associated with ectopic NOVA expression in breast 
and gynecological cancers (Luque et al., 1991). Ectopic NOVA expression 
is also reported in Hodgkin lymphoma cells (Relogio et al., 2005) and in 
primary serous ovarian tumors (Darnell lab, unpublished data). 
Additionally, multiple splicing factors have been shown to be auto- or 
trans-regulated via inclusion or exclusion of NMD exons. For example, 
PTBP1-dependent skipping of exon11 in PTBP2 leads to a frame-shift 
mutation that targets PTBP2 mRNA for NMD and establishes mutually 
exclusive expression patterns of the two splicing factors (Rahman et al., 
2002, Boutz et al., 2007). It has been discovered that NMD is inhibited in 
the tumor microenvironment leading to enhanced tumorigenesis (Wang et 
al., 2011b) that is dependent upon c-myc activity (Wang et al., 2011a). 
Since many NMD isoforms are expressed at extremely low levels, the 
extent of NMD-associated transcript regulation by RBPs in tumorigenesis 
and metastasis may currently be underestimated. 
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Transcript stability, ARE-binding proteins and cancer 
AU-rich elements (AREs) are 50-150nt sequences rich in adenosine 
and uracil bases predominantly found in the 3’UTRs of mRNAs with short 
half-lives, including those involved in transient biological processes such 
as immune responses, cellular growth and external stress-mediated 
pathways (Bakheet et al., 2001). AREs were first identified as destabilizing 
sequences when it was found that fusing the AT-rich 3’UTR segment of 
the unstable granulocyte-macrophage colony stimulating factor (GM-CSF) 
to the normally stable rabbit globulin transcript induced rapid 
degradation (Shaw and Kamen, 1986). Many of the over twenty ARE-
binding proteins identified to date have been shown to promote target 
instability by recruiting mRNA decay proteins to their targets (Wu and 
Brewer, 2012). Among this destabilizing cohort is AUF1/hnRNP-D, a 
family of four proteins generated from a single gene through alternative 
splicing (Wagner et al., 1998) that interact with AREs via two tandemly 
arranged, non-identical RRM domains (DeMaria et al., 1997). AUF1 has 
been shown to interact with and destabilize the mRNA of multiple cancer 
related proteins, including Bax and junD (Mazan-Mamczarz et al., 2008b, 
Zou et al., 2010, Zucconi and Wilson, 2011). 
 
Conversely, direct interactions with ARE-binding proteins can lead 
to stabilization of targets, for example, binding by the ELAVL family of 
proteins (ELAVL1/HuR, nELAV: HuB/C/D) generally stabilizes mRNAs 
bearing AREs and U-rich sequences. The neuronal ELAVL family 
members (nELAV) (Okano and Darnell, 1997) were discovered as the 
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auto-antigens in paraneoplastic encephalomyelitis (PEM) (Szabo et al., 
1991), a neurological disorder associated with small cell lung cancer 
(SCLC) (Dalmau et al., 1990, Manley et al., 1995). PEM is one of a diverse 
group of paraneoplastic neurologic disorders (PNDs) characterized by 
high-titer antibodies recognizing neuronal antigens that are expressed in 
occult tumors. Patients with PEM have high titers of anti-nELAVL 
antibodies (anti-Hu, which were used to clone the cDNAs encoding HuC 
and HuD (Szabo et al., 1991)), but while all SCLCs appear to express 
nELAVL antigens (Budde-Steffen et al., 1988, Dalmau et al., 1995) the 
neurological syndrome is rare. HuD expression has also been associated 
with neuroblastoma (Dalmau et al., 1992, Ball and King, 1997) where it is 
believed to stabilize N-myc (Lazarova et al., 1999), with loss of 
heterozygosity of HuD associated with N-myc gene amplification 
(Grandinetti et al., 2006). Upregulation of the ubiquitously expressed 
ELAVL1 is associated with multiple cancers including colon (Lopez de 
Silanes et al., 2003), lung (Blaxall et al., 2000), and breast (Denkert et al., 
2004, Heinonen et al., 2005, Mazan-Mamczarz et al., 2008a, Mazan-
Mamczarz et al., 2008b). The repertoire of ELAVL-family regulated 
transcripts has been greatly expanded by use of RNA cross-linking 
methodologies (Keene et al., 2006, Mazan-Mamczarz et al., 2008a, 
Mukherjee et al., 2011, Lebedeva et al., 2011, Ince-Dunn et al., 2012 and 
Darnell lab unpublished data), with many of the identified targets 




MicroRNA mediated control of gene expression in oncogenesis and metastasis 
 MicroRNAs (miRNA) are a major class of evolutionarily conserved, 
small (~22nucleotide (nt)) non-coding RNA (ncRNA) molecules that are 
associated with diverse biological processes including proliferation, 
differentiation, and stress response through post-transcriptional 
regulation of target mRNAs. miRNA are transcribed by either RNA 
polymerase II or III from intergenic regions of the genome, or as introns in 
the pre-mRNA of coding and ncRNAs, and can be transcribed either as 
the sole miRNA in that region or as part of a co-regulated cluster. miRNA 
begin as longer RNA molecules (primary or pri-miRNA) that are cleaved 
in the nucleus by the RNase III endonuclease Drosha to liberate a ~60-70nt 
stem loop with one defined mature miRNA end. This pre-miRNA is 
actively exported out of the nucleus by Ran-GTP and Exportin-5, and 
processed by a second RNase III endonuclease, Dicer. Dicer recognizes the 
double stranded portion of the pre-miRNA hairpin structure and cuts at a 
fixed distance to generate a double stranded imperfect duplex with a 
characteristic ~2nt 3’-overhang. One of these strands (mature miRNA) is 
loaded into Argonaute (AGO), the core component of the miRNA-induced 
silencing complex (miRISC). The second, passenger strand (miRNA*) is 
generally found at lower levels than the mature miRNA and is presumed 
to be degraded (Bartel, 2004). Complementarity between the 5’ end of the 
mature miRNA in positions 2-8, or seed region, targets the AGO-miRNA 
complex predominantly to 3’UTRs of target mRNA. AGO-ternary 
complex binding leads to translational repression and/or target mRNA 
destabilization (Filipowicz et al., 2008), although miRNA mediated 
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upregulation of targets has also been described under certain cellular 
conditions (Vasudevan, 2012). 
 
 A general downregulation of miRNAs has been observed in 
tumors, with patterns of individual miRNA expression being highly 
informative for both classification and prognosis (Lu et al., 2005, Calin et 
al., 2005, Rosenfeld et al., 2008). Such general downregulation may be 
achieved by transcriptional repression of multiple miRNAs by oncogenic 
transcription factors such as Myc (Chang et al., 2008), by loss of p53 
transactivation (Suzuki et al., 2009), or downregulation/altered activity of 
the miRNA biogenesis pathway (Thomson et al., 2006, Kumar et al., 2007). 
Haploinsufficiency of Dicer has been detected in multiple human tumors 
(Hill et al., 2009, Kumar et al., 2009), with loss of a single allele leading to 
accelerated tumor formation in vivo (Kumar et al., 2009, Lambertz et al., 
2010). 
 
 In addition to being regulated by oncogenes and tumor 
suppressors, individual miRNA or miRNA clusters can themselves be 
either pro- or anti-tumorigenic depending on cellular context. Greater 
than 50% of miRNAs are located in fragile chromosomal regions that 
frequently undergo deletion and amplification in human tumors (Calin et 
al., 2004, Zhang et al., 2006), and many can be epigenetically regulated 
(Choudhry and Catto, 2011, Scott et al., 2006). Loss or gain of a single 
miRNA can have a profound effect on cellular physiology due to the 
concordant regulation of potentially hundreds of target mRNAs 
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(Hendrickson et al., 2009, Lim et al., 2005). Multiple miRNAs have been 
implicated in the development of breast cancer as both tumor suppressive 
and oncogenic factors (Spizzo et al., 2009, Tang et al., 2012a). For example, 
upregulation of miR-155 has been found in multiple breast cancer 
subtypes where it is associated with more aggressive tumors and poor 
prognosis (Mattiske et al., 2012).  Overexpression of miR-155 in breast 
cancer cells leads to enhanced proliferation and survival, while deletion 
sensitizes cells to apoptosis and chemotherapeutic reagents (Jiang et al., 
2010, Kong et al., 2010). Interestingly, wild-type BRCA1 function has been 
associated with the epigenetic silencing of miR-155 through promoter 
region binding and recruitment of HDAC2 (Chang et al., 2011). 
Conversely, loss of the tumor suppressive miR-205 promotes anchorage-
independent breast cancer cell growth (Wu et al., 2009b), in part through 
derepression of HER3 tyrosine-protein kinase receptor and subsequent 
increased activation of the PI3K/AKT survival pathway (Iorio et al., 2009). 
 
 Recent studies have identified several miRNAs with roles in both 
metastasis suppression and promotion. miR-10b is upregulated in 
metastatic breast cancer cells compared to immortalized human 
mammary epithelial cells (hMECs), with knockdown reducing the 
invasive ability of MDA-MB-231 cells and ectopic expression enhancing 
the invasion and migration of weakly metastatic cells both in vitro and in 
vivo (Ma et al., 2007). miR-10b expression is positively associated with 
high-grade malignancy of various cancer types, with expression shown to 
be eleveated in the primary breast tumors of metastasis-positive patients 
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(Baffa et al., 2009). Systemic treatment with a miR-10b antagonist has been 
shown to suppress lung metastasis in a mouse breast cancer model if 
given during early stages of tumor cell dissemination (Ma et al., 2010b). In 
contrast, down regulation of multiple endogenous miRNAs has been 
shown to promote metastasis in breast cancer. Loss of miR-335, miR-126 
and miR-206 promotes a highly aggressive metastatic breast cancer 
phenotype both in vivo and in vitro (Tavazoie et al., 2008), while re-
expression of miR-31 both inhibits breast cancer metastasis (Valastyan et 
al., 2009) and can elicit regression of already established lung metastases 
(Valastyan et al., 2011). While some progress has been made in identifying 
targets of these pro- and anti-metastatic miRNAs, current studies have 
been limited by lack of knowledge of direct sites of AGO-mRNA binding 
and by restricting target searches to only those transcripts that both 
contain bioinformatically predicted or conserved seed sites and show 
large miRNA-dependent downregulation.  
 
Alternative polyadenylation site selection  
With the exception of some histone transcripts, all eukaryotic 
mRNAs undergo a two-step maturation process involving 
endonucleolytic cleavage and subsequent untemplated polyadenine 
(polyA) tail addition. The specificity and efficiency of 3’end processing is 
dependent upon a multiprotein complex binding to cis-acting sequence 
elements in the pre-mRNA known as the polyA signal (Danckwardt et al., 
2008). Approximately 50% of human transcripts exhibit conserved 
alternative polyadenylation site usage as a result of tandem polyA sites, 
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polyA sites within the terminal intron, alternative splicing of the terminal 
exon, or polyA site usage within an internal exon (Tian et al., 2005, Yan 
and Marr, 2005). While the intrinsic strength of the polyA site sequence 
and the concentration/activity of polyadenylation factors can together 
determine alternative polyA site usage, various other tissue or stage-
specific RBPs can also influence polyA site choice (Barabino and Keller, 
1999). For example, alternative polyA site usage can be regulated by Nova 
binding in 3’UTR regions flanking polyA sites (Licatalosi et al., 2008). 
 
Use of alternative polyA sites has the potential to alter transcript 
stability via elimination of large stretches of the 3’UTR, enabling escape 
from any negative cis-regulatory elements located in the longer 3’UTR 
isoform. Systematic analysis of human and mouse transcriptomes have 
shown that shorter 3’UTR isoforms are most abundant when transcripts 
are expressed at high levels, while longer 3’UTRs are associated with 
lower expression levels (Ji et al., 2011). Oncogenic chromosomal 
rearrangements in benign tumors that involve the loss of the c-terminal 
coding sequence and entire 3’UTR of HMGA2 (Geurts et al., 1997, 
Schoenmakers et al., 1995) have been shown to result in relief of let-7-
mediated repression (Mayr et al., 2007). Widespread shortening of 3’UTRs 
with subsequent loss of miRNA regulatory sites has been described both 
in activated T cells compared to resting T cells, and as a general feature of 
proliferating cells (Sandberg et al., 2008). Furthermore, cancer cell lines 
have been found to express shorter 3’UTR isoforms than non-transformed 
cells, with 3’UTR shortening leading to activation of oncogenes (Mayr and 
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Bartel, 2009). The mechanism (or RBPs responsible) for the phenomena of 
alternative polyA site selection and global shortening of 3’UTR length in 
oncogenic activation remains unexplored. 
 
Mapping the transcriptome-wide regulatory networks of RNA binding 
proteins 
 Evidence of functional roles for RBPs in tumorigenesis and 
regulation of metastasis is extensive. In the studies outlined above, a 
reductionist approach is commonly taken to identify one or two targets 
that can partially explain the pro- or anti-metastatic consequences of 
altered RBP expression. However many RBPs are multifunctional and can 
regulate multiple steps in RNA metabolism. For example, the onconeural 
Nova proteins can regulate transcript content via alternative splicing, and 
stability through regulation of NMD and alternative polyA site usage. The 
ELAVL proteins while generally recognized as ARE-binding modulators 
of transcript stability also have roles in alternative splicing (Ince-Dunn et 
al., 2012, Lebedeva et al., 2011). Additionally, the FET family of RBPs 
(FUS/TLS, EWSR1 and TAF15) associated with chromosomal 
rearrangements in Ewing’s sarcoma, a highly aggressive primary tumor of 
the soft tissue and bone with a high propensity to metastasize (Sankar and 
Lessnick, 2011), have multiple roles in RNA metabolism, including 
regulation of transcription (Bertolotti et al., 1996, Bertolotti et al., 1998, 
Lagier-Tourenne et al., 2012), alternative splicing (Paronetto et al., 2011, 
Ishigaki et al., 2012, Lagier-Tourenne et al., 2012, Rogelj et al., 2012, 
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Ibrahim et al., 2013) and the biogenesis of miRNAs (Gregory et al., 2004, 
Ballarino et al., 2012, Morlando et al., 2012).  
 
  Given the potential for complex patterns of RNA regulation, 
comprehensive evaluation of directly regulated transcripts is necessary to 
fully understand the downstream mediators of the anti- or pro-metastatic 
activities of any given RBP or miRNA. While it is possible to predict 
targets via observations of genome-wide changes in transcript levels upon 
RBP/miRNA modulation in combination with bioinformatic assessment 
of associated cis-elements (where consensus regulatory sequences are 
known), this type of analysis does not discern direct versus indirect 
effects. This is particularly pertinent when considering regulation by RBPs 
that have the potential to influence the activity of multiple other RBPs, for 
example, PTBP1 down regulation of PTBP2 via alternative splicing. These 
limitations also apply to AGO-mediated miRNA regulation of transcripts 
as bioinformatic predictions of regulatory sites suffer from high false 
positive rates even when taking conservation and extended regions of 
seed match into consideration (Baek et al., 2008, Selbach et al., 2008). 
Furthermore, reporter assays may produce false-positive or false-negative 
results if not carefully designed to include the native 3’UTR context, 
particularly when considering the potential for regulated alternative 
polyA site usage. 
 
Multiple techniques have been developed to biochemically identify 
functional RBP-RNA interactions in vivo. Immunoprecipitation of an RBP 
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under mild conditions coupled with purification of co-precipitating RNA, 
either in the presence or absence of formaldehyde crosslinking, allows for 
coarse mapping of an RBP on target RNA (Keene et al., 2006). However 
this technique suffers from low signal-to-noise, has poor binding site 
resolution, and favors capture of the most stable RBP-RNA interactions 
(Mukherjee et al., 2011). Additionally, this technique does not discriminate 
between direct RBP-RNA interactions and those occurring due to either 
co-immunoprecipitation of other RBPs or random RNA-RBP reassociation 
post-lysis (Mili and Steitz, 2004, Riley et al., 2012).  
 
 Direct mapping of RNA-protein complexes became possible with 
the development of crosslinking immunoprecipitation (CLIP) strategies  
(Ule et al., 2003, Ule et al., 2005a, Jensen and Darnell, 2008). UV-irradiation 
induces covalent bond formation between closely opposed RNA and 
protein molecules within physiologically relevant distances (on the order 
of Angstroms apart) but does not induce protein-protein crosslinks 
(Darnell, 2010). Such UV-induced covalent bonds allow for rigorous 
purification of RBP-RNA complexes from live cells or whole tissues, 
which after reverse transcription and sequencing yield a population of 
cDNA clones corresponding to the regions of RNA directly bound by the 
protein of interest. By coupling CLIP to next generation sequencing (high-
throughput CLIP, HITS-CLIP (Licatalosi et al., 2008)), high-resolution 
unbiased transcriptome-wide footprints of RNA-protein interactions can 
be generated. Furthermore, with the growing number of HITS-CLIP 
binding maps now available from different tissues (brain, stem cells, 
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tissue culture) and multiple RBPs with known RNA metabolic activities, it 
is possible to predict functional outcomes from binding patterns on target 
transcripts with no prior knowledge of an RBP of interests function. For 
example, robust binding in intronic regions has been associated with the 
regulation of alternative splicing by multiple RBPs, including but limited 
to Nova (Licatalosi et al., 2008, Ule et al., 2003, Ule et al., 2006, Ule et al., 
2005b), the ELAVL proteins (Ince-Dunn et al., 2012, Lebedeva et al., 2011, 
Mukherjee et al., 2011), and FUS (Ishigaki et al., 2012, Lagier-Tourenne et 
al., 2012, Nakaya et al., 2013, Rogelj et al., 2012). Binding sites in 3’UTR 
regions have been used to both delimit the functional regulatory sites of 
AGO and to identify the targeting miRNA through narrowed search for 
complementary seed sites within these footprints (Chi et al., 2012, Loeb et 
al., 2012, Zisoulis et al., 2010, Hafner et al., 2010). 
 
Perspectives 
 HITS-CLIP provides a tractable methodology with which to study 
both RBP regulated events in tumor cells, and by differential analysis, to 
identify altered sites of regulation associated with gain in metastatic 
potential. To our knowledge HITS-CLIP has not been used to interrogate 
the targets of endogenous RBPs in breast cancer cells, nor has it been used 
to investigate RBP-associated regulation of metastasis. Although several 
cancer-related RBPs have been interrogated by HITS-CLIP, none of these 
experiments were carried out in cancerous cells or tissue, therefore the 
relevance of identified targets to cancer biology is unknown. Given the 
important dual role of miRNAs in the positive and negative regulation of 
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metastasis and the potential for the regulation of hundreds of targets 
(Hendrickson et al., 2009, Lim et al., 2005), AGO HITS-CLIP provides an 
attractive method by which the entire network of miRNA regulation in a 
cancer cell can be mapped. In this study we have generated HITS-CLIP 
binding maps of endogenous AGO in weakly and highly metastatic breast 
cancer cells leading to the identification of altered AGO association with 
both miRNA and target mRNAs with respect to metastatic ability and 
tissue tropism. Furthermore, we have assessed the genome-wide 
regulatory network of miR-335, a known anti-metastatic miRNA. 
Additionally, we have used HITS-CLIP as general platform for discovery 
of transcriptome-wide regulation by the previously uncharacterized, 
putative metastasis suppressor RBM47.  
  
 27 
CHAPTER 2: EXPERIMENTAL PROCEDURES 
 
Cell Culture 
Triple reporter MDA-MB-231, 4175LM2, 1833BoM2 and 831BrM2 cell lines 
were obtained from the Massagué laboratory at MSKCC. Triple reporter 
4175LM2 shID and 4175LM2 miR-335 over expressing cells, plus non-
reporter MDA-MB-231 and 4175LM2 cells were obtained from the 
Tavazoie lab at Rockefeller University. All MDA-231 and derivative cell 
lines were cultured in D10F - DMEM (Corning) supplemented with 10% 
FBS (Hyclone), 1% sodium pyruvate, 1% penicillin-streptomycin and 0.4% 
fungizone (Gibco). HEK293T cells were obtained from ATCC and cultured 
in DMEM with 10% FBS. Non-clonal dox-inducible 831BrM2 triple 
reporter stable cell lines expressing WT FLAG-tagged RBM47 or Tet-On 
(empty vector) and the clonal 831BrM2 WT FLAG-tagged RBM47#10 cell 
line were generated by Sakari Vanharanta (Massagué Laboratory, 
MSKCC). RBM47 expression was induced using 1ng/ml or 10ng/ml 
doxycycline (Sigma) respectively for three days. All cells were maintained 
at 37°C in 5% CO2. 
 
Analysis of miRNA and mRNA expression levels by quantitative-PCR 
Total RNA was purified by Trizol extraction (Invitrogen) followed by 
ethanol precipitation, DNase treatment (RQ1 RNase-free DNase 
(Promega) and phenol-chloroform extraction. 90ng of total RNA was used 
for reverse transcription with the miScript II RT Kit (Qiagen) followed Q-
PCR in using the equivalent of 2ng starting RNA with FastStart SYBR 
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Green Master mix (Roche Applied Science) and commercially available 
miScript miRNA specific primers (Qiagen) as per the miScriptII RT 
protocol. Primers specific to SNORD44 were used as a normalization 
control. For mRNA expression analysis, 1!g of total RNA was reverse 
transcribed using the iScript cDNA synthesis kit and 100ng used per 
FastStart SYBR reaction. Genorm analysis (Vandesompele et al., 2002) was 
carried out using the BioGazelle software on MDA-231 and its metastatic 
derivatives to select a control gene for normalization. TATA-binding 
protein (TBP) showed the least variation between cell lines and was used 
as the control gene for all mRNA Q-PCR. For all analyses, Q-PCR was 
done in triplicate for each independently prepared RNA sample 
(minimum of three per condition/cell line) using a BioRad IQ5 Real Time 
PCR machine and 58°C annealing temperature, with both melt curves and 
-RT controls performed. All Q-PCR primers were designed using 
Primer3Plus.  
 
HMGA1 F – agcgaagtgccaacacctaa R – tttccttcctggagttgtgg  
CD59 F - cacaatgggaatccaaggag   R - tgcagtcagcagttgggtta  
CETN3 F – tggacaaaacaaagaggaaaaa R – acatcaaaccccaaggctct 
SEL1L F – agaaggcagccaggatgaat  R – gaatcaagaaatatttgaccagca 
FAM105B F – agcaatggaaacttggactg R – tttgtgaatagttcatcacaagcta 
SMAD5 F – tctgcttgggtttgttgtca  R – ctgctgtcactgaggcattc 
TWSG1 F – aatgttcacgcgccttattc  R - aaccagcgatatttggatgc 
DKK1 F – gatcatagcaccttggatggg  R – ggcacagtctgatgaccgg 
RBM47 F – ctgtcattcccactgtgtcg  R - gtaactggccccgtagatcc 
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SERPINB2 F – ggtcctggtgaatgctgtct R - ctgtacaggtgtgcgctgag 
CTGF F – ggagtgggtgtgtgacgag  R – ccaggcagttggctctaatc 
ANKRD1 F – gagataccccgttgcatgat R- ttctgccagtgtagcaccag 
TBP F – ggggagctgtgatgtgaagt   R- tttccagaaacaaaaataaggagaa 
SNORD44 F – tgctgactgaacatgaaggtc 
 
AGO HITS-CLIP 
Bead Preparations for Immunoprecipitation 
Protein A Dynabeads (Invitrogen) were resuspended and washed 
3x in PBS 0.02% Tween-20. 200!l beads were used per 10cm2 dish of 80% 
confluent cells. Beads were rotated with 25!l bridging antibody (rabbit 
anti-mouse IgG, Jackson ImmunoResearch, 315- 005-008 at 2.3mg/ml) per 
200!l beads for 35min at room temperature, then washed 3x in PBS 0.02% 
Tween-20. 3!l AGO antibody (2A8 ascites provided by Dr. Zissimos 
Mourelatos, (Nelson et al., 2007)) was loaded per 200!l beads. For 
irrelevant antibody controls, no 2A8 AGO antibody was added. Beads 
were rotated for 2hrs at 4°C then washed 3x in 1X PXL lysis buffer (1X PBS 
[tissue culture grade; no Mg2+, no Ca2+, GIBCO], 0.1% SDS, 0.5% Na-
DOC, 0.5% NP-40) containing complete protease inhibitor (mini EDTA 
free tablets, Roche, 1 tablet/10 ml buffer). 
 
Cell Lysate Preparation 
Media was removed from MDA-231, 4175LM2, 1833BoM2 and 
831BrM2 cells, and the cells washed with cold 1X PBS before 254nm UV 
crosslinking 1x at 400mJ/cm2 on a bed of ice (Stratalinker2400, 
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Stratagene). Cells were harvested by scraping in 1X PBS and pelleted. 
Non-crosslinked samples were collected at the same time for RNAseq 
analysis. Crosslinked cell lysates were prepared by adding 1ml PXL lysis 
buffer plus complete protease inhibitor and vortexing to disrupt cells. 
Lysates were DNase treated with RQ1 RNase-free DNase (Promega) for 
5min, shaking at 1000rpm at 37°C. Aliquots from each cell line were 
pooled to the same total volume as experimental lysates and 10!l of a 
1:100 RNaseA solution (diluted in lysis buffer) added for the high 
RNAseA control. 10!l of a 1:5000 RNaseA solution was added to all other 
lysates, and all samples incubated at 37°C, 5min, 1000rpm. Lysates were 
spun at 4°C, 30,000rpm, 20min to clear cell debris and the supernatant 
harvested to a new tube for immunoprecipitation (IP). Aliquots of each 
low RNase treated sample were again pooled for the control IgG IP. 
 
Samples were rotated with antibody-loaded beads at 4°C for 2hs. 
Following IP, beads were washed sequentially (all washes 1ml) twice with 
1X PXL lysis buffer, twice with 5X PXL (5X PBS [tissue culture grade; no 
Mg2+, no Ca2+, GIBCO], 0.1% SDS, 0.5% Na-DOC, 0.5% NP-40), twice 
with high stringency buffer (15mM Tris-HCl, pH7.5, 5mM EDTA, 2.5mM 
EGTA, 1% TritonX-100, 1% Na-deoxycholate (DOC), 0.1% SDS, 120mM 
NaCl, 25mM KCl), high salt buffer (15mM Tris-HCl, pH 7.5, 5mM EDTA, 
2.5mM EGTA, 1% TritonX- 100, 1% Na-DOC, 0.1% SDS, 1M NaCl) and 
twice with low salt buffer (15mM Tris-HCl, pH7.5, 5mM EDTA) followed 
by two washes with PNK buffer (50mM Tris-HCl, pH7.5, 10mM MgCl2, 
0.5% NP-40). After each capture on the magnet beads, the beads were 
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resuspended by end-over-end rotation, with the samples washed in a 
random order throughout. 1.5ml SlickSeal microfuge tubes (National 
Diagnostics) were used throughout the CLIP protocol to reduce non-
crosslinked RNA binding to tubes. 
 
Dephosphorylation of RNA, 3’ Linker Ligation, and Rephosphorylatoin of 5’ end 
of RNA Tags 
IPs were treated with calf intestinal phosphatase to remove the 5’ 
phosphate from RNA crosslinked to AGO to prevent RNA circularization 
during ligation, an otherwise competing intramolecular reaction. Beads 
were resuspended in 60!l 1X dephosphorylation buffer with 3 units of 
CIAP (Roche) and RNAsin Plus RNase Inhibitor (Promega), and 
incubated at 37°C, shaking at 1000rpm for 15s every 2min, 20 min. This 
was followed by 5X 1ml washes, once with PNK Buffer, twice with PNK 
buffer plus EGTA (10mM Tris pH7.5, 20mM EGTA, 0.5% NP-40), and 
twice again with PNK buffer (no EGTA). 
 
For AGO CLIP, 32P-labeled RNA linker is ligated to the 3’ end of 
crosslinked RNA. 50pmol of puromycin-blocked linker (L32, 5’-OH-
GUGUCAGUCACUUCCAGCGG-3’-puromycin, Dharmacon) was labeled 
using T4 phosphonucleotide kinase (PNK, NEB) by adding 15!l 32P-"-
ATP, 1!l RNAsin and 2!l of T4 PNK in a 50!l total volume 1X PNK buffer 
and incubating for 30min at 37°C. 0.02ml 1mM ATP was added with an 
additional 5min incubation to drive the reaction to completion. 
Radiolabeled linker was purified from free ATP by spinning through a G-
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25 column (Amersham). 30pmol labeled 3’RNA linker was used per 60!l 
T4 RNA ligase reaction (Fermentas) according to kit instructions. On-bead 
ligation reactions were incubated at 16°C for 1hr, 1000rpm 15s every 4min, 
then 80pmol of unlabeled L32 RNA linker (with 5’ phosphate) added and 
the reaction incubated overnight. Following linker ligation, beads were 
washed once each with 1XPXL and 5XPXL, and 3X with PNK buffer to 
remove any free linker. 80!l of T4 PNK mix (6!l 1mM ATP, 4!l T4 PNK 
enzyme [NEB], 1!l RNasin in 1X T4 PNK buffer) was added to sample 
and incubated at 37°C, 1000rpm 15s every 4min, for 20 min to 
phosphorylate the 5’ end of the AGO bound RNA for later 5’ linker 
ligation. 
 
SDS-PAGE Separation of RNA-binding Protein:RNA Complexes 
Beads were washed three times with 1ml PNK buffer then 
resuspended in a 60!l solution of 1X NuPAGE loading buffer (LDS, 
Invitrogen), 1X NuPage Reducing Agent (Invitrogen) and 1X PNK buffer. 
Beads were incubated at 70°C, 1000rpm for 10min. Supernatants were run 
on Novex NuPAGE 8% Bis-Tris gels (Invitrogen) in SDS-MOPS running 
buffer (Invitrogen) for 2.5hrs, 175V, at 4°C. Two lanes per sample were 
used to prevent over-loading. Protein-RNA complexes were transferred to 
Protran BA85 nitrocellulose (Whatman) using a Novex wet transfer 
apparatus (Invitrogen). After transfer, the nitrocellulose was rinsed with 




Recovery of AGO-RNA  Complexes, Protease Digestion, and 5’ Linker Ligation 
Nitrocellulose membranes were aligned carefully with the exposed 
film and regions of membrane excised from low RNase IP lanes at a size 
directly above that of the over-digested band, approximately 110-125kD 
for AGO-miRNA and 130-150kD for AGO-mRNA. The nitrocellulose 
membrane sections were cut into smaller pieces and proteinase K treated 
with a 0.2ml 1:5 dilution of proteinase K (4mg/ml, Roche) in PK buffer 
(100mM Tris-HCl pH 7.5, 50mM NaCl, 10mM EDTA)) at 37°C, 1100 rpm 
for 20min. 0.2ml of 1X PK buffer 7M urea solution was added and 
incubated for further 20min at 37°C, 1100 rpm. RNA fragments were 
isolated by adding 0.4ml of RNA phenol (pH 6.8, Applied 
Biosystems/Ambion) and 0.13ml of 49:1 CHCl3:isoamyl alcohol, 
incubating a further 20min at 37°C, 1100rpm, and spinning at 20,000g in a 
desktop microcentrifuge at room temperature. The aqueous phase was 
taken to a new tube, 0.8!l glycogen (Applied Biosystems/Ambion), 50!l 
3M NaOAc pH 5.2, and 1ml of 1:1 ethanol:isopropanol added, and RNA 
precipitated overnight at -20°C. 
 
RNA was pelleted by spinning at 20,000g, 4°C for 30min, and 
washed twice with 75% ethanol. The dried pellet was dissolved in 6!l 
RNase-free H2O. 1!l 10X T4 RNA ligase buffer (Fermentas), 1!l BSA (0.2 
!g/!l), 1!l ATP (10mM), 0.1!l T4 RNA ligase (3U, Fermentas), and 
20pmol of 5’ RNA linker (RL5D) were added in a total volume of 10!l and 
incubated for 5hrs at 16°C with intermittent shaking. (RL5D: 5’-OH- 
AGGGAGGACGAUGCGGr(N)r(N)r(N)r(N)G3’-OH). Ligated RNA was 
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DNase digested by adding 79!l H2O, 11!l 10X RQ1 DNase buffer, 5!l 
RQ1 DNase and 5!l RNasin and incubating at 37°C for 20 min, then 
purified by phenol:chloroform extraction (300!l H2O, 300!l RNA phenol 
(Ambion), 100!l CHCl3). RNA was precipitated from the aqueous phase 
overnight at -20°C by adding 50!l 3M NaOAc pH5.2, 0.5!l glycogen and 
1ml 1:1 ethanol:isopropanol. 
 
RT-PCR and High-Throughput Sequencing of PCR Products 
RNA was pelleted, washed, dried as before, and then resuspended 
in 10!l RNase-free H2O. 2!l of RNA per sample plus an additional 6!l 
H2O were taken for a –RT control. RNA was mixed with 2!l of 5pmol/!l 
P32 primer (3’ DNA primer 32, 5’- CTTCACTCACCTCGCAACCG-3’, 
Operon) and 3!l 3mM dNTPs, incubated at 65°C for 5 min in a 
thermocycler, chilled, and spun briefly. 1!l 0.1M DTT, 4!l 5X SuperScript 
RT buffer, 1!l RNasin, and 1!l SuperScript III (Invitrogen) were added 
and the mix incubated in a thermocycler at 50°C for 45min, 55°C for 
15min, 90°C for 5min and then moved onto ice. Superscript III was 
omitted from –RT control reactions. PCR was performed immediately 
with 27!l Accuprime Pfx Supermix (Invitrogen), 0.75!l 20pmol/!l P51 (5’ 
DNA primer 51, 5’- AGGGAGGACGATGCGG-3’, Operon), 0.75!l 
20pmol/ul P32 primer, and 2!l of the RT reaction, 4 reactions per sample. 
PCR conditions were: 95°C for 2min, 20-35 cycles 95°C 20s denature, 58°C 
30s anneal, and 68°C 30s extension. Purified miRNA were amplified to 20, 
22, 24 and 26 cycles, mRNA to 24, 26, 28 and 30 cycles, while –RT reactions 
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were taken to +4 and +6 cycles above the highest corresponding +RT 
reaction.  
The entire PCR reaction was loaded in 95% formamide (Sigma), 5% 
100mM EDTA pH8, bromophenol blue, xylene cyanol buffer in a 10% 
denaturing polyacrylamide gel, using 3!l Amplisize Molecular Ruler 
(Biorad). To visualize DNA, gels were immersed in a 1:10,000 dilution of 
SYBR Gold (Molecular Probes) in 1X TBE for 10min. PCR product was 
excised from the lowest cycle number giving visible signal, and the 
remaining RT reaction was then brought up to this minimal cycle number, 
gel purified and the products pooled. Acrylamide bands containing DNA 
of ~60nts were excised from miRNA samples, and ~100-150nt for mRNA. 
DNA was purified by crushing gel slices in diffusion buffer (0.5M 
ammonium acetate, 10mM Mg acetate, 1mM EDTA, 0.1% SDS), incubating 
at 50°C for 30min, 1200rpm, then filtering through Whatman GF/D filters 
in Nanosep columns (VWR). DNA was recovered from filtrate using 
Qiaquick gel purification buffers and columns (Qiagen) and eluted in 30!l 
TE. An additional PCR reaction was performed using the following fusion 





PCR amplification was performed using Accuprime Pfx (Invitrogen) and 
ranged between 6 and 10 cycles. The PCR product was separated on 2% 
Metaphor agarose gel (Lonza) and the lowest cycle number visible 
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purified using Qiaquick spin columns (Qiagen). A total of 10-30!l of 10nM 
DNA (quantified using Quant-IT, Invitrogen) was sequenced using primer 
SSP1 on an Illumina HiSeq. 
 SSP1: CTATGGATACTTAGTCAGGGAGGACGATGCGG.  
All data analysis was done using the Galaxy platform (Hillman-Jackson et 
al., 2012) and the R Statistical Analysis Software (http://www.R-
project.org) running edgeR (Robinson et al., 2010). 
 
RBM47 polyA-tailed HITS-CLIP 
Immunoprecipitation, CIP treatment, direct 32P-!-ATP labeling, SDS-PAGE 
and nitrocellulose transfer 
Beads were prepared as per the AGO HITS-CLIP protocol, omitting the 
bridging antibody and using 50!l of ProteinG dynabeads loaded with 5!l 
anti-FLAG mouse monoclonal (Sigma F3165) per sample. Cell lysates were 
prepared as for AGO HITS-CLIP from duplicate dishes of UV crosslinked 
1ng/ml dox treated 831BrM2 Flag-RBM47 WT, one crosslinked dox 
treated Tet-On control dish, and one non-crosslinked dox treated RBM47-
WT dish. A lower concentration of RNaseA was used as a 1:10,000 
dilution was shown to give optimal digestion of RBM47 bound fragments. 
IPs and subsequent washing was carried out as described. RBM47-RNA 
complexes were treated on bead with calf intestinal phosphatase, washed, 
then directly labeled on bead with 32P-"-ATP using 4!l 10X PNK Buffer 
(NEB), 2!l 32P-"-ATP, 2!l T4 PNK enzyme (NEB) and 32!l H2O at 37C, 
1200rpm 15s/2min, 20min. 1!l of non-radiolabeled 10mM ATP was added 
and the reaction incubated a further 5min. Beads were then washed once 
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with 1XPNK, once with high salt buffer, then twice with 1XPNK. SDS-
PAGE and nitrocellulose transfer were carried out as for AGO with the 
addition of 10X Reducing Agent (NuPage) during elution of complexes 
from the bead.  
 
RNA Purification, polyA Tailing and BrdU Reverse Transcription 
RNA was purified as in AGO HITS-CLIP from excised membrane 
fragments corresponding to RBM47-WT crosslinked lanes at ~76-100kD. 
Pelleted RNA recovered from the first phenol:chloroform extraction were 
resuspended in 6.25!l H2O and denatured at 65C for 5min with no 
shaking, then placed on ice. The polyA tailing reaction mix was prepared 
on ice by adding 1!l 10X E-PAP Buffer (Promega), 1.5!l 1mM ATP, 1.5!l 
RNAsin Plus (diluted to 5U/!l) and 1!lE-PAP (3U/!l, NEB M0276) to the 
purified RNA. The reaction was incubated for 15min at 37C, then 20min at 
65C in a pre-warmed thermocycler. 2.5!l of each polyA-tailed reaction 
was taken for a –RT control with an additional 2.5!l H2O. Reverse 
transcription was carried out using 5!l polyA tailed RNA, 1!l 0.752M 
Tris, 1!l 8.2mM dATP, 1!l 8.2mM dCTP, 1!l 8.2mM dGTP (all 
Invitrogen), 1!l 8.2mM Br-dUTP (Sigma), 1!l 25!M RT Primer and 1!l 
H2O. This mix was incubated for 3min at 75C then ramped down to and 
held at 48C. 1!l 82mM DTT, 1!l 10U/!l RNasin and 1!l SuperscriptIII (or 
H2O for –RT) pre-warmed to 48C were added to the mix, then incubated 
for 45min 48C, 15min 55C, 5mi 85C then held at 4C. RT-primers with 










50!l of ProteinG dynabead per sample were washed three times in 1XPBS 
0.02% Tween-20, resuspended in 22!l of wash buffer plus 25!l 50X 
Denhardt’s Solution (Sigma) and rotated at room temperature for 1hr. 
Beads were washed three times with 1X IP buffer (0.3X SSPE (Ambion), 
1mM EDTA, 0.05% Tween-20), resuspended in 25!l IP buffer plus 25!l of 
anti-BrdU antibody (5g, Santa Cruz, sc-32323), rotated at room 
temperature a minimum of 45min then washed 3X in 1X IP buffer. The 
equivalent of 25!l starting volume of beads were used per anti-BrdU IP. 
After completion of the RT reaction, 1!l of 2U/!l RNaseH (Invitrogen) 
was added and the mix incubated at 37C for 20min, 10!l RNase-free H2O 
added and the cDNA purified by spinning through a G-25 column. The 
total volume of cDNA was brought up to 40!l with H2O, and 10!l 50X 
Denhardt’s solution plus 50!l 2X IP buffer added, and incubated for 5min 
70C, 2min 25C. This mixture was added to the equivalent of 25!l starting 
volume of the prepared anti-BrdU beads per sample. Tubes were rotated 
at room temperature for 30mins and washed once with 1X IP buffer plus 
5X Denhardt’s, twice with low salt buffer plus 2.5X Denhardt’s, twice with 
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stringent buffer plus 2.5X Denhardt’s, and twice with 1X IP buffer. cDNA 
was eluted from the beads via BrdU competitive elution by adding 50!l 
100!M BrdU (Sigma) in 1X IP buffer, rotating for 30min and collecting the 
eluate. Eluted cDNA was purified by spinning through a G-25 column, the 
volume adjusted to 97.5!l with H2O, and 37.5!l 4X IP buffer, and 15!l 
Denhardt’s solution added. Purified cDNA was heated to 70C 5min, then 
25C for 2min then added to the remaining 25!l of prepared anti-BrdU 
beads and rotated again for 30min, room temperature. Beads were washed 
once with 1X IP buffer plus 5X Denhardt’s, twice with low salt buffer plus 
2.5X Denhardt’s, twice with stringent buffer plus 2.5X Denhardt’s, and 
twice with 1X CircLigase Wash Buffer (33mM Tris-acetate, 66mM KCl, 
pH7.8). 
 
On-bead cDNA Circularization and ApeI Linearization 
cDNA was circularized by incubation for 1hr, 160C, 1300rpm 15s/30s with 
2!l CircLigase 10X Reaction Buffer (Epicentre), 4!l 5M betane, 1!l 50mM 
MnCl2, 0.5!l CircLigase ssDNA Ligase II (50U, Epicentre) and 12.5!l H2O. 
Beads were washed by rotating for 5min twice each with low salt buffer, 
stringent buffer and ApeI buffer (50mM potassium acetate, 20mM Tris-
acetate, 10mM magnesium acetate, pH7.9). cDNA was linearized by 
adding 2!l 10X NEB Reaction Buffer 4, 1.25!l ApeI (10U/!l NEB) and 
16.75!l H2O, and incubating 1hr, 37C 1300rpm 15s/30s. Beads were 
washed twice with low salt buffer, twice with stringent buffer and twice 
with Phusion wash buffer (50mM Tris, pH8.0). 
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PCR Amplification, DNA purification and quantification 
To elute cDNA from beads 10!l 5X Phusion HF Buffer (NEB), 1!l 10mM 
dNTPs and 37.5!l H2O were added, the mix transferred to a thin walled 
PCR tube and incubated at 98C for 45 seconds. Beads were transferred 
back to a microfuge tube and the eluate collected from the beads by 
magnet and transferred to a fresh PCR tube. To this was added 0.5!l 
20!M P5 primer, 0.5!l 20!M P3 primer, 0.5!l Phusion DNA polymerase 
and 0.5!l 50X SYBR Green I (Invitrogen).  
P5 – aatgatacggcgaccaccgacaggttcagagttctacagtccgacg 
P3 - caagcagaagacggcata 
PCR amplification was carried in an iQ5 real-time PCR machine in order 
to monitor amplification, with the samples being removed when the RFU 
signal reached ~1000. PCR cycle conditions were as follows: 1X 98C 30s, 
15-20 cycles as necessary 98C 10s, 60C 15s, 72C 20s. PCR products were 
purified using MinElute columns (Qiagen) as per manufacturers 
instructions and quantified using Quant-It (Invitrogen). Before sequencing 
samples were analyzed by Tapestation (Agilent) and pooled for Illumina 
high-throughput sequencing using the Illumina small RNA sequencing 
primer – cgacaggttcagagttctacagtccgacgatc. All data analysis was done 
using the Galaxy platform (Hillman-Jackson et al., 2012) and the R 
Statistical Analysis Software (http://www.R-project.org) running edgeR 





RNAseq Library Preparation 
RNA was prepared following the TruSeq RNA sample Preparation v2 
Guide (Illumina FC-122-1001). An additional size selection step was added 
by running cDNA on a 2% agarose gel, excising fragments at 250bp (+/-
25bp) with Genecatcher Disposable Tips (Gel Company PKB6.5) and gel 
purification (QIAquick Gel Extraction Kit 28704). cDNA was sequenced 
on an Illumina HiSeq 2000. All data analysis was done using the Galaxy 
platform (Hillman-Jackson et al., 2012). 
 
3’UTR Cloning into psiCheck2 and generation of mutants 
Full length 3’UTRs of human genes, or shorter fragments as indicated, 
were PCR amplified from MDA-MB-231 cDNA (iScript cDNA synthesis 
Kit, Bio-Rad) using Accuprime Supermix1 (Life Technologies) and 
individually cloned into psiCheck2 dual luciferase reporter vector 
(Promega) via XhoI and NotI digestion (New England Biolabs).  Mutant 
constructs were made using the QuikChange Lightning Site-Directed 
Mutagenesis Kit with primers designed using the Agilent Technologies 
primer design program. Mutant 3’UTR vectors were sub-cloned into 
psiCheck2, and all constructs were sequence verified before transfection. 
 
HMGA1 3’UTR F – tatctcgagcccatgcgtgccgcctgctc 
HMGA1 FL 3’UTR R- tatgcggccgctccagaaaaaggatattttttttattc  
HMGA1 SH 3’UTR R – tatgcggccgcgtccaggagggcatgtgtgtatg 
HMGA1 S1 22 MUT F – ctcctcactggaggaggtccttccttctgggactg 
HMGA1 S1 22 MUT R – cagycccagaaggaaggacctcctccagtgaggag 
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HMGA1 S1 28-5p MUT F – ccatgcgtgccgcctggaggtcactggaggagcagc 
HMGA1 S1 28-5p MUT R – gctgctcctccagtgacctccaggcggcacgcatgg 
HMGA1 S1 320 MUT F – cttccttctgggactggagaccaatgc 
HMGA1 S1 320 MUT R – ggtgggagcggagcattggtctccag 
HMGA1 S2 138 MUT F – tcaccaccacactacacagcacaggtcccgctgcagggc 
HMGA1 S2 138 MUT R – gccctgcagcgggacctgtgctgtgtagtgtggtggtga 
HMGA1 S2 142-3p MUT F- tgtgccctcaccaccactgatcacagcacaccagccgc 
HMGA1 S2 142-3p MUT R- gcggctggtgtgctgtgatcagtggtggtgagggcaca 
HMGA1 S2 ALL MUT F - tgccctcaccaccactcttcacacct 
HMGA1 S2 ALL MUT R - ggagccctgcagcgggtcgagaggt 
CD59 3’UTR F- tatctcgagtgcagtgacagcttgagtgggg  
CD59 3’UTR R – tatgcggccgcaactcgattttcagccacttgt 
CETN3 3’UTR F – tatctcgagagaattacaaggataaacact 
CETN3 3’UTR R – tatgcggccgcttaaaattctaataaaataaatat 
CETN3 miR335* MUT F – gcctggagccatgtgatataaaccaacttagttc 
CETN3 miR335* MUT R – gaactaagttggtttatatcacatggctccaggc 
SDAD1 3’UTR F – tatctcgagcttcctggcaagttttccattc 
SDAD1 3’UTR R – tatgcggccgctatttggcattagaaaccttttattg 
CDH11 3’UTR F – tatctcgagcaataacgatacaaatttggcc 
CDH11 3’UTR R – tatgcggccgccaaaagattgcttcttatattg 





MicroRNA mimic transfections and dual Luciferase 3’UTR Reporter 
Assays 
All transfections were carried out using Dharmafect Duo (Dharmacon) as 
per manufacturers guidelines. For Q-PCR analysis, 20x103 cells/well of 
non-reporter 4175LM2 cells were plated in 12 well format 24 hours before 
transfection in triplicate with 50nM specific miRNA mimic, negative 
control mimic A, or with transfection reagent alone (miRIDIAN mimics, 
Dharmacon). Cells were harvested at 48hrs. To assess the role of 
individual miRNAs on psiCheck2 3’UTR reporter constructs, 20x103 
cells/well non-reporter 4175LM2 were plated in 12 well format 24 hours 
before transfection in quadruplicate with either 50ng or plasmid alone, or 
with 50nM specific miRNA mimic or negative control mimic. For 
endogenous miRNA regulation of 3’UTR constructs, 5x103/well of non-
reporter MDA-231 or 4175LM2 cells were plated 24 hours before 
transfection of 5ng of plasmid in 96-well format (n=6 or 10). Cells were 
lysed 30 hours post transfection and the ratio of Renilla to firefly luciferase 
measured by dual-luciferase reporter assay (Promega) using a Lumat 
LB9507 luminometer (Berthold Tech) as per kit instructions. Each 
construct was assayed in two independent experiments to verify 
regulation. 
 
Generation of CETN3 overexpressing stable cell lines 
The coding sequence of human CETN3 was PCR amplified from MDA-
231 cDNA and cloned into pBabePuro (Morgenstern and Land, 1990) via 




Retroviruses were generated by transfecting pBabePuro-CETN3 into 
HEK293T packaging cells with pCMV-VSV-G & pGAG-Pol (ratio 2:1:2) 
using TransIT-292 transfection reagent (Mirus). Virus particles were 
collected 48hrs after transfection, filtered and applied to triple reporter 
MDA-231 and 4715LM2 miR-335OE cells in the presence of 0.8!g/ml 
polybrene. Virally transduced cells were selected using 2!g/ml 
puromycin. CETN3 overexpression was verified by Q-PCR. 
 
Invasion assays 
Cells were plated at ~50% confluence in 10cm dishes in D10F, with media 
changed to D0.2F (as per D10F but with 0.2% FBS) 12hrs before plating in 
invasion chambers. Matrigel invasion chambers (BD BioCoat™ Growth 
Factor Reduced BD Matrigel™ Invasion Chamber) were thawed at room 
temperature then equilibrated with D0.2F (500ul above and below the 
insert) at 37°C in 5% CO2 for one hour. Cells were trypsinized, neutralized 
with D10F then washed twice with 1XPBS to remove serum before 
resuspending in D0.2F. The equilibration media was aspirated from the 
top of the invasion chamber and 500ul of 100k/ml cells added to each 
well. Cells were allowed to invade for 24hrs at 37°C in 5% CO2, then 
membranes were washed twice with 1X PBS. Non-invaded cells were 
scraped from the top of the membrane, and those cells that had invaded 
fixed with 4% paraformaldehyde for 15min at 37°C. Membranes were 
washed again with 1XPBS, excised and mounted using Vectorshield 
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Mounting Medium plus DAPI (Vector Labs). Each cell line was tested in 
quadruplicate. Invasive cells were imaged using a Zeiss Axiovert S100 
fluorescence microscope (4X optic) in triplicate per membrane, a cells 
counted using ImageJ. 
 
Flow Cytometry Surface Staining 
CD59 antibody (clone p282 (H19)) was purchased from BD Biosciences. 
Cell surface expression was measured using fluorescently-conjugated 
antibodies according to the manufacturer’s instructions. Cells were 
resuspended in 100!l FACS buffer (PBS supplemented with 1% PHS, 1% 
FBS (HyClone)), 1!g of each antibody was added and incubated for 10 
minutes at room temperature in the dark. Cells were washed twice with 
FACS buffer and collected immediately on a BD FACScaliber machine and 
analyzed using Flowjo software (Treestar). 
 
Western blotting 
For the test of RBM47 as an RNA binding protein, after exposure of the 
radioactive nitrocellulose membrane to x-ray film it was blocked for 1hr in 
5% non-fat milk in PBS, followed by incubation with anti-FLAG (Sigma, 
F7425) overnight at 4C. The membrane was washed 4X 5min 1X TBST 
after each antibody incubation. Secondary anti-rabbit-HRP (Jackson 
ImmunoResearch Labs) was added at 1:10,000 in 5% non-fat milk 1XPBS 
for 40min at room temperature. HRP signal was detected by Enhanced 
ChemiLuminescence (Western Lightning detection kit, Perkin Elmer) 
using Kodak MR film. For all other western blots, cells were lysed in 1X 
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PXL plus protease inhibitors (mini EDTA free tablets, Roche, 1 tablet/10 
ml buffer), and sonicated to shear DNA. NuPAGE loading sample buffer 
and reducing agent (Invitrogen) were added to 30!g protein to final 
concentration of 1X, and samples heated at 70C for 10min. Lysates were 
separated on 4-12% Bis-Tris NuPAGE gels (Invitrogen) is SDS-MOPS 
buffer and transferred to Protran BA85 nitrocellulose by standard 
methods. Membranes were blocked for 1hr at room temperature with 
Odyssey Blocking Buffer (LI-COR) followed by the addition of primary 
antibody (RBM47 Sigma HPA006347, HSP90 Cell Signaling) in LI-COR 
Antibody buffer (50mM Tris-HCl pH7.5, 150mM NaCl, 0.1% Tween-20, 
2% BSA and 0.02% sodium azide) for two hours at room temperature or 
overnight at 4C. Blots were washed 4X 5min in 1X TBST after each 
antibody incubation. Fluorescently conjugated secondary antibody (Goat 
anti-mouse IgG IRDye, Goat anti-rabbit IgG IRDye LI-COR) was added in 
1X TBST for 40min, blots washed 3X 1XTBST and 1X 1XTBS and 
fluorescence detected using an Odyssey LI-COR machine. 
 
Alternative splicing semi-quantitative RT-PCR 
Total RNA was purified from triplicate dishes of RBM47-WT#10 and 
RBM47 Tet-On cells treated for three days with 10ng/ml doxycycline, or 
MDA-231 and 831BrM2 cells as described above. Reverse transcription 
was carried out using random hexamers and Transcriptor Reverse 
Transcriptase (Roche). For each alternative splicing event investigated, 
pilot RT-PCR reactions were carried out with increasing cycle number to 
ensure amplification was within the linear range. Radiolabelled 32P-dCTP 
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was added to each PCR reaction for the last two cycles. RT-PCR products 
were separated by electrophoresis on 6% polyacrylamide/7M Urea gels 
and exposed to x-ray film. In all cases, the first three lanes correspond to 
an equal mixture of cDNA from each cell line tested amplified at n-2, n, 
n+2 cycles. Lane 4 corresponds to PCR at cycle n+2 using an equal mixture 
of –RT control reactions.  The ratio of included isoforms was determined 
using ImageJ analysis of scanned x-ray film. All primers were designed 
using the hg18 reference genome and Primer3Plus. 
MDM4 F – ccctctctatgatatgctaagaaagaa R – tagaatgtatgcatttatgctctga 
MBLN1 F – catttgcaagccaagatcaa  R - agggaacacttgtggcagat 
MACF1 F – cctactcgttccagctccag  R – gcaagggatgtccgactaga 
KIFAP3 F – aggagccataagtcccgatt  R - acccaacccacacagatttc 
SLK F – agactatcgaacgcctggaa  R – aactctgccttctgctgctg 




CHAPTER 3:  
DIFFERENTIAL AGO-REGULATION IN WEAKLY AND HIGHLY 
METASTATIC BREAST CANCER  
 
INTRODUCTION 
 The metastatic progression of breast cancer has been modeled in 
vivo in mice using two general strategies, genetic engineering and 
transplantable model systems. The latter includes both syngenic models 
using mouse tumor cells, and xenograft models making use of human 
derived breast cancer cell lines (reviewed in Bos et al., 2010). The 
xenograft model chosen for this study was developed in the Massagué 
laboratory, using in vivo selection to isolate organ specific sub-lines from 
the metastatic human breast cancer cell line MDA-MB-231 (MDA-231) that 
was isolated from a patient with metastatic relapse years after removal of 
the primary tumor (Cailleau et al., 1978). When injected into the arterial 
circulation of mice, MDA-231 are able to extravasate and colonize in vivo 
the organs characteristically seen in human breast cancer patients albeit at 
low penetrance. By recovering those populations of cells able to 
metastasize to lung, bone and brain, expanding in culture and re-
inoculating into mice, highly aggressively metastatic sub-lines have been 
developed with specific organotropisms (Figure 1.1, (Bos et al., 2009, Kang 












FIGURE 3.1: In vivo selection of human breast cancer cell lines with 
enhanced metastatic ability and organ specificity. “Parental” MDA-MB-
231 cells, derived from the pleural effusion of a breast cancer patient with 
widespread metastasis years after the removal of the primary tumor 
(Cailleau et al., 1978), were inoculated into the arterial (intercardiac) or 
the venous circulation (tail vein) of immunodeficient mice allowing for 
systemic distribution to all organs. Organ-specific metastatic sub-lines, 
visualized by bioluminescence imaging of luciferase-transduced cells, 
were recovered, expanded in culture and re-inoculated to further enrich 
for highly aggressive, tissue-specific cells.  The three MDA-MB-231 
derivative sub-lines used in this study are highly metastatic to the bone 
(1833BoM2, Kang et al., 2003; Minn et al., 2005b), lung (4175LM2, Minn 
et al., 2005a; Minn et al., 2005b), and brain (831BrM2, Bos et al., 2009). 




 Extensive molecular characterization of the aggressively metastatic 
sub-lines of MDA-231 has revealed that they, like their parental cell line, 
express a “poor-prognosis” signature for breast cancer metastasis that is 
associated with a clinically poor outcome and highly prognostic for the 
development of distal metastases (Minn et al., 2005b, van 't Veer et al., 
2002, van de Vijver et al., 2002). Layered on top of this common gene set 
are tissue specific gene expression signatures that both distinguish the 
MDA-231 sub-lines from the parental line, and clinically correlate with 
specific site of secondary tumor formation in large cohorts of breast cancer 
patients. For example, those patients found to express the 54-gene lung 
metastasis signature identified from multiple lung metastatic sub-lines 
have markedly worse lung-metastasis-free survival (p<0.0001) but not 
bone-metastasis-free survival (p=0.15, (Minn et al., 2005a, Minn et al., 
2007)).  
 
More recently the regulatory role of small RNAs in the acquisition 
of the aggressively metastatic phenotype has been investigated using this 
xenograft model. Array-based profiling of miRNAs expressed in MDA-
231, bone and lung specific derivative cell lines has identified miRNA 
expression patterns that correctly classify the three different groups, plus 
and additional eight miRNAs that show consistently decreased expression 
in all highly metastatic sub-lines (Tavazoie et al., 2008). Of these, miR-335, 
miR-206 and miR-126 were found to inhibit both lung and bone metastasis 
in vivo and to be markedly downregulated in patients with shorter times 
to metastatic relapse. Together with the previous gene expression profiles, 
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this data indicates the utility of this xenograft model system for 
identifying clinically relevant molecular events associated with tissue 
specific metastasis, in particular for identifying the role of AGO-miRNA 
mediated mRNA regulation in the suppression of metastasis.  
 
 Identification of miRNA targets has classically been carried out by 
searching for conserved seed matches in the 3’UTR of transcripts that 
show differential gene expression above an arbitrary threshold after the 
manipulation of a single miRNA. For example, in HeLa cells transfected 
with miR-124 canonical 6nt seed matches have been found in the 3’UTRs 
of 76% of microarray-identified downregulated transcripts, an enrichment 
that is reduced when transfecting with seed mutated miR-124 mimics 
(Lim et al., 2005). Inferring direct miR-124 regulation from this kind of 
data set is problematic. The bioinformatic prediction of regulatory seed 
sites is limited by high false positive rates and reliance on conservation 
(Baek et al., 2008, Selbach et al., 2008), hindering the identification of direct 
target gene expression levels changes that occur in a background of 
indirect alterations in transcript abundance. Additionally, the degree to 
which individual miRNAs are able to regulate targets is dependent upon 
the concentration of both the miRNA and target mRNA (Mukherji et al., 
2011). Therefore, for any given target the degree of miRNA mediated 
repression may be small yet functionally relevant and may not pass the 
arbitrary threshold set.  
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While it has been proposed that at least 84% of miRNA target 
repression can be attributed to mRNA degradation (Guo et al., 2010) 
repression can occur over a broad range (Hendrickson et al., 2009, 
Mukherji et al., 2011) or can occur at the translational level without mRNA 
degradation in a target dependent manner (Eulalio et al., 2007). In certain 
cellular conditions, miRNA targeting can lead to activation of translation 
(reviewed in Vasudevan, (2012)). Given the potential for a single miRNA 
to coordinately regulate hundreds of targets (Hendrickson et al., 2009, Lim 
et al., 2005), low-level miRNA-mediated changes in multiple nodes within 
the same cellular pathway may sum to large physiological effects on 
downstream targets that are not directly regulated by the miRNA (Ebert 
and Sharp, 2012). 
 
 To address these limitations, we propose using HITS-CLIP to 
identify on a genome-wide scale direct RNA-protein interactions in living 
cells (Licatalosi et al., 2008), which for AGO includes both miRNA and 
target mRNA interactions (Figure 3.1A) (Chi et al., 2009). By mapping the 
fragments of mRNA that are covalently bound to AGO after UV-
irradiation, we can define sites of direct endogenous interaction in vivo, 
delimiting the sequence space on a per transcript basis in which seed-
match search need be carried out (Figure 3.1B). By comparing the 
simultaneously derived AGO-bound miRNA profile to the sequences 
found in robust and reproducible AGO-mRNA footprints, high 
confidence prediction of the miRNA (or miRNA seed family) involved in 
AGO targeting at any given sitecan be obtained (Chi et al., 2009). 
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Furthermore, comparative AGO HITS-CLIP can be utilized to identify 
sites of de novo AGO regulation, as was demonstrated by transfection of 
the neuron-specific miR-124 into HeLa cells (Figure 3.1C, (Chi et al., 
2009)), or binding loss as in the genetic ablation of miR-155 in mouse T 
cells (Loeb et al., 2012).   
 
By applying the AGO HITS-CLIP methodology to the MDA-231 
based xenograft model of metastatic breast cancer, we aim to produce 
genome-wide binding maps of endogenous human AGO in both the 
weakly metastatic parental MDA-231 cell line and the molecularly 
characterized, highly metastatic bone (1833BoM2), lung (4175LM2) and 
brain (831BrM2) sub-lines. Given the known contribution of miRNAs to 
metastasis suppression in this model, we aim to identify differentially 
regulated targets with respect to metastatic ability and tissue tropism with 






FIGURE 3.2: Argonaute HITS-CLIP produces two simultaneous data 
sets – AGO-miRNA and AGO-mRNA. A: The X-ray crystal structure of 
wild-type T. thermophiles AGO-miRNA-mRNA ternary complex (Wang et 
al., 2008) reveals sufficiently close contacts between AGO-miRNA and 
AGO-mRNA to allow for UV-induced covalent crosslink formation to 
both RNA species. B: Overlaying robust, reproducible AGO mRNA peaks 
(orange) reveals striking enrichment of seed sequences corresponding to 
the top 30 CLIPed miRNAs from the same sample (purple-red) within a 
62nt AGO-bound mRNA footprint centered at the peak of AGO-mRNA 
binding. No enrichment of seed sequences is found for the 30 least CLIPed 
miRNAs (black-grey). C: AGO HITS-CLIP can be used to identify sites of 
de novo AGO-miRNA regulation. The top panel shows unique AGO 
mRNA CLIP tags from non-transfected HeLa cells on known miR-124 
target CD164. The lower panel shows unique AGO CLIP tags from miR-
124 transfected HeLa cells (each color indicating a biological replicate) 
with a de novo AGO-mRNA binding site centered upon a predicted miR-





AGO-HITS CLIP in MDA-MB-231 and its highly aggressive metastatic 
derivatives with tissue tropism to the lung, bone and brain 
In order to map the direct sites of AGO action on mRNAs and to 
identify the guide strand miRNAs in complex with AGO, HITS-CLIP was 
carried out in triplicate for MDA-231, 4175LM2, 1833BoM2 and 831BrM2 
triple reporter expressing cell lines (herpes simplex virus 1 thymidine 
kinase:eGFP:luciferase), as outlined in Figure 3.3 and previously 
published by (Chi et al., 2009). Briefly, cells were grown in parallel until 
~80% confluent, rinsed in PBS and UV-B irradiated once at 400mJ/cm2. 
Cells were lysed, DNAse treated and partially RNAseA digested before 
being stringently immunoprecipitated using a mouse monoclonal 
antibody to human AGO2 (2A8, (Nelson et al., 2007)). A portion of lysate 
from each sample was taken pre-IP, pooled and subsequently split for 
control IgG IP (to identify any non-specific pull down of RNA), and an 
AGO IP under high RNAseA conditions to aid in later size selection of 
AGO-RNA complexes.  
 
After harsh washing, purified crosslinked AGO-RNA species were 
ligated to a 5’-"P32 labeled 3’-RNA linker and size separated via SDS-
PAGE. AGO-RNA complexes were transferred to a nitrocellulose 
membrane that was then exposed to x-ray film to allow for visualization 
of radiolabelled RNA (Figure 3.4A). Regions corresponding to AGO-
bound miRNA and mRNA of increasing modal size were excised as 
indicated, proteinase K treated and the RNA purified.  
 
 
FIGURE 3.3: Argonaute HITS-CLIP schematic. A: 4 dishes each of 
weakly metastatic MDA-MB-231 cells, and the three tissue-specific 
aggressively metastatic sub-lines were grown to ~80% confluency. 3 
dishes per cell line were UV-B crosslinked once in preparation for HITS-
CLIP, with the remaining dish harvested without crosslinking for 
RNAseq.  B: UV-B irradiation penetrates live cells inducing covalent bond 
formation between RNA and protein complexes in close association 
(~1Angstrom), which for AGO includes both miRNA and mRNA species. 
Irradiated cells are lysed and DNAse treated before partial RNAseA 
digestion to reduce the modal size of bound RNA fragments. Purification 
of RNA-AGO complexes is achieved by IP under stringent conditions to 
remove both non-crosslinked RNA and potential contaminating proteins. 
While still on bead a 3’-RNA linker is ligated to the bound RNA that is 
then radiolabelled on the 5’end and further purified by SDS-PAGE and 
transfer to nitrocellulose. Bound RNA is visualized by autoradiogram to 
allow for size selection of sections of nitrocellulose corresponding to AGO 
plus ~22nt (miRNA) and ~50nt (mRNA). These sections are excised, 
proteinaseK treated and RNA purified. A 5’ degenerate linker is ligated to 
allow for reverse transcription, followed by PCR amplification and high-




FIGURE 3.4: AGO HITS-CLIP in MDA-231 and derivative cell lines. A: 
Autoradiogram of crosslinked immunoprecipitates from breast cancer cell 
lines with irrelevant antibody (IgG lane) and 2A8, a mouse monoclonal 
antibody to human AGO. 32P-labeled RNA is evident in only the 2A8 
immunoprecipitated lysates. With high RNaseA treatment (+++) the 
RNA-protein complexes approach the modal size of AGO bound to 
miRNA (~110kD, bounded by blue dots) and AGO bound predominantly 
to short mRNA fragments (~130kD, red dots). With low RNaseA 
treatment (+), a smear of radiolabelled AGO-RNA of increasing modal 
size is evident for each cell line immunoprecipitation.  The regions excised 
for purification and amplification are outlined (blue-miRNA, red-mRNA). 
B: PCR products amplified from the excised portions of the 1833BoM2 
lanes in A, after 5’ linker ligation and reverse transcription. cDNA from 
the lowest PCR cycle at which product is visible (dashed boxes) were 
purified and used for high-throughput sequencing. Minus RT reactions at 
cycle numbers +2 and +4 above that of the highest plus RT PCR reaction 
show no amplification. 
57
 58 
After 5’-linker ligation and a second DNAse digestion to remove any 
contaminating DNA, isolated RNA fragments were reverse transcribed 
and PCR amplified (Figure 3.4B) in preparation for high-throughput 
sequencing. Fragments corresponding to AGO-bound mRNA and miRNA 
from each replicate experiment were pooled before sequencing. 
 
 The bioinformatics pipeline used for processing AGO-bound RNAs 
is summarized in Figure 3.5. Reads were filtered to remove exact 
duplicates and low quality sequences, adapter sequences trimmed, and 
reads then aligned to both the human genome (hg18) and a database of 
mature human miRNAs downloaded from the current release of miRBase 
(Kozomara and Griffiths-Jones, 2011). Tags that map to single unique 
locations in the hg18 reference genome are collapsed to retain single 
representative tags and remove presumed PCR duplicate sequences based 
on multiple criteria; a 4nt degenerate sequence in the 5’-linker, an 
algorithm that estimates sequencing error through mismatches in 
alignment to the genome, and genomic coordinates. The multiple filtering 
steps applied to mRNA reads returns a highly curated set of sequences, 
termed “tags”, representing 20-50nt mRNA fragments directly bound by 
AGO. miRNA reads are not collapsed in this manner due to the restriction 
in possible 5’ degenerate linker sequences and the pre-determined length 
of miRNAs. The number of miRNA and unique mRNA tags obtained for 





FIGURE 3.5: Bioinformatic pipeline for processing AGO HITS-CLIP 







TABLE 3.1: Summary of AGO HITS-CLIP sequencing results from 
triplicate experiments in MDA-231, 4175 LM2, 1833BoM2 and 831BrM2. 
Read counts are shown for each stage of data processing outlined in 
Figure 3.5. Total miRNA and unique mRNA tags per replicate library are 
bold, with the total number of unique mRNA tags for each cell line boxed. 
831BrM2 sample B was sequenced on the Illumina HiSeq platform giving 









AGO-miRNA profiles of MDA-231 and its metastatic sub-lines are highly 
similar 
 AGO-miRNA tags were mapped against a reference set of 1,100 
miRNAs including star strand sequences obtained from miRBase 
(Kozomara and Griffiths-Jones, 2011). Individual miRNAs were deemed 
expressed if they were represented by a minimum of 10 tags in two or 
more libraries derived from an individual cell line (termed biological 
complexity greater than 2, or BC≥2, although it is noted that duplicate cell 
culture based experiments may more accurately represent technical rather 
than true biological replicates). 660 miRNAs were expressed representing 
542 seed families, defined as groups of miRNAs sharing the same 7-mer 
seed sequence in positions 2-8. This number is higher than the previously 
reported 179 expressed miRNAs identified in MDA-231 and derivative 
lines by microarray (Tavazoie et al., 2008), which may be due to increased 
sensitivity of crosslinked AGO-miRNA deep sequencing versus array 
hybridization and the ongoing addition of newly identified human 
miRNAs to the miRBase database.  
 
 To assess the global distribution of miRNA reads between cell lines, 
miRNA tags per 7-mer seed family were normalized for read depth per 
individual HITS-CLIP library and expressed as a percentage of the total 
number of miRNA reads in that library, then percentages averaged across 
triplicates for each cell line. The top 30 miRNA seed families for each cell 
line ranked by average percentage are shown in descending order in Table 
3.2. miR-27a/b is the most frequently cloned AGO-associated miRNA  
TABLE 3.2: Top 30 miRNA seed families represented in the AGO HITS-









family representing between ~24% to ~38% of all miRNAs, with miR-27a 
being the predominant family member. The top three miRNA seed 
families identified by HITS-CLIP represent >50% of all the miRNA reads 
in each cell line. The variation in the total number of relatively rare 
miRNA families represented in each cell line is reflected in the total 
number of the most CLIPed miRNA families that together contribute 95% 
of the miRNA profile for each cell line (Figure 3.6). 6.14% of the total 
4175LM2 miRNA profile is comprised of seed families that individually 
represent <1% of the total population compared to 11.13% of the 
1832BoM2 profile, 8.6% in MDA-231 and 8.0% in 831BrM2.  
 
Identification of differentially CLIPed miRNA with respect to tissue tropism 
 To identify potential differences in the AGO-miRNA profiles of the 
highly versus weakly metastatic cell lines we used EdgeR, a Bioconductor 
software package which examines changes in counts (AGO-miRNA reads) 
between two or more groups (cell lines) with replicated measurements 
(Robinson et al., 2010). AGO-miRNA HITS-CLIP reads for each individual 
miRNA were tabulated and normalized to total read depth in that library 
to give counts per million (cpm). miRNAs with cpm>2 in >9/12 HITS-
CLIP libraries were retained for difference analysis (296 miRNAs). EdgeR 
was used to calculate log2 fold change, p-values and associated FDR in a 
pairwise fashion between cell lines using an estimation of dispersal 
calculated on a per miRNA basis (“tagwise dispersal”). Given the 













FIGURE 3.6: Distribution of miRNAs bound to AGO in MDA-231, 
4175LM2, 1833BrM2 and 831BoM2 cells. The cumulative percentage of 
miRNA reads per seed family averaged across triplicate libraries shows 
that for all cell lines >95% of all reads are represented by the top 30 
miRNA families. 4175LM2 cells show the least diversity in AGO-miRNA 
seed families with 16 7mer seed sequences representing 95% of sequenced 
miRNAs, followed by MDA-231 and 1833BrM (20 and 21 seed families), 










profile of each cell lines, the search for differentially CLIPed miRNAs was 
limited to the top 30 miRNA seed families listed in Table 3.3.  
 
Microarray analysis of MDA-231, 4175 and 831BoM cells had 
previously identified 20 miRNAs specifically downregulated in bone 
metastatic derivatives, lung metastatic derivatives or both (Tavazoie et al., 
2008). Of those 20 miRNAs previously identified, the majority of are either 
absent from miRNA profile (less than 10 AGO-miRNA reads, 35%) or are 
present at very low levels with no statistically significant difference in the 
AGO-miRNA profile by EdgeR analysis (60%). However, four miRNAs in 
the top 30 list of AGO-miRNA were found to have statistically significant 
miRNA tag counts with FDR≤0.01 when comparing MDA-231 to one or 
more metastatic sub-lines. 4175LM2 cells showed significant decrease in 
miR-99a, let-7c, miR-20b and miR-142-3p counts compared to all other cell 
lines, while both 1833BoM2 and 831BrM2 had significantly more AGO-
miRNA reads corresponding to miR-142-3p than both MDA-231 and 
4175LM2 (Table 3.3).  
  
Global analysis of AGO-mRNA binding 
Before looking for differential binding between cell lines, the AGO-
mRNA binding events in each cell lines were characterized. Unique tags 
mapping to single locations on hg18 were analyzed based on two 
definitions of robust binding sites: clusters (Figure 3.7A) and significant 
peaks (Figure 3.7B) with detailed definitions of each provided in the figure 





TABLE 3.3:  EdgeR analysis of AGO-miRNA HITS-CLIP reads. Reads 
counts for each miRNA were tabulated and converted to counts per 
million (cpm) on a per library basis to normalize for read depth. miRNAs 
with cpm>2 in >9 of the 12 libraries were retained for further analysis (296 
miRNAs). Using EdgeR, log2 fold change in miRNA count, p-values and 
FDR were calculated in a pairwise fashion between cell lines using an 
estimation of dispersal calculated on a per miRNA basis (“tagwise” 
dispersal, see (Robinson et al., 2010)). miRNAs in top 30 seed families 
with significant difference in CLIP tag counts between more than two cell 
lines are shown. Consistent significant decrease in the number of CLIP 
AGO-miRNA reads for miR-142-3p, miR-99a, miR-20b and let-7c is seen in 
4175LM2 cells when compared to all other cells, while a significant 
increase in miR-142-3p is seen in both 1833BrM2 and 831BoM2. Line 




miR-142-3p  Log2 FC p-value FDR 
 
miR-99a Log2 FC p-value FDR 
LM2/MDA -2.64 1.10E-05 0.0019 
 
LM2/MDA -6.23 1.83E-05 0.0019 
BoM/MDA 3.99 1.27E-07 3.76E-05 
 
BoM/MDA - - - 
BrM/MDA 4.67 1.05E-10 3.10E-08 
 
BrM/MDA - - - 
BoM/LM2 6.63 3.74E-17 1.11E-14 
 
BoM/LM2 6.91 3.82E-07 5.65E-05 
BrM/LM2 7.31 1.05E-20 3.10E-18 
 
BrM/LM2 4.65 2.87E-07 4.25E-05 
BrM/BoM - - - 
 
BrM/BoM - - - 
         let-7c  Log2 FC p-value FDR 
 
miR-20b Log2 FC p-value FDR 
LM2/MDA -3.30 4.37E-05 0.0032 
 
LM2/MDA -3.64 0.0007 0.0223 
BoM/MDA - - - 
 
BoM/MDA - - - 
BrM/MDA - - - 
 
BrM/MDA - - - 
BoM/LM2 3.83 4.88E-06 0.0005 
 
BoM/LM2 3.54 0.0003 0.0099 
BrM/LM2 2.53 5.00E-06 0.0004 
 
BrM/LM2 3.55 2.91E-05 0.0014 
BrM/BoM - - - 
 











FIGURE 3.7: Definition of HITS-CLIP clusters and significant peaks A: 
Schematic representation of cluster definition. Genomic localization of 
unique mRNA tags from triplicate experiments from one cell line (red 
lines, each shade representing a replicate library) are shown on a pre-
mRNA transcript (blue). Clusters are considered reproducible if they 
contain tags derived from ≥2 replicates that overlap my a minimum of 3 
nucleotides (biological complexity, BC≥2), and robust if they contain a 
minimum scaled number of unique tags proportional to the total read 
depth of the cell line (tag≥5 - MDA & LM2, ≥12 – BoM2, ≥13 – BrM2). 
Therefore, binding sites 2 & 4 would be considered clusters in MDA or 
LM2 despite differing peak height and widths, but only site 2 would be a 
cluster in BoM2 or BrM2. B: Schematic representation of significant peak 
definitions with binding events as described in A. In silico normalization 
on a per transcript basis defines a threshold of significance (dotted line) 
for AGO-binding sites based the observed vs. expected peak height 
calculated from random shuffling of unique tags along the exonic regions 
of the gene. Reproducibility and robustness were determined as for 
clusters (dashed line) therefore only binding site 2 is considered a 




overlap that are reproducible (BC≥2), and contain a minimum scaled 
number of unique tags proportional to the total read depth of the cell line. 
“Significant peaks” represent those clusters whose maximal number of 
overlapping tags (peak height) is above that of the expected peak height 
resulting from random shuffling of all CLIP tags mapping to that 
transcript along its genic length. As per (Chi et al., 2009), a narrow 
footprint of +/-32nt centered on the significant peak is used to determine 
the AGO footprint while clusters are delimited by the genomic 
coordinates of the most exterior tags in that cluster. Significant peak 
analysis allows for more stringency in defining binding sites by narrowing 
the footprint of AGO binding to -30nt/+32nt centered on the peak which 
is useful for identification of the regulatory miRNA involved in targeting 
(Chi et al., 2009). However, cluster analysis is more sensitive when 
searching for differential binding, allowing for identification smaller 
clusters may not reach statistical significance due to a background of 
robust, common binding elsewhere on a transcript.  
 
The threshold for the minimum number of tags required to define a 
binding site (cluster or significant peak) was set at 5 tags for MDA-231 and 
4175LM2 cells, with the threshold increasing proportionally to 12 and 13 
tags for 1833BoM2 and 831BrM, respectively due to ~2.5 fold greater 
unique tag numbers in these cell lines. All binding sites were required to 
be BC≥2, and those mapping to chrY, RNA genes (defined by the 
RNAgenes track on the UCSC genome browser) and pre-miRNA loci were 
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removed from the analysis. Setting these thresholds defined 6947, 8802, 
7716 and 8514 clusters, and 3422, 2636, 3233, and 3259 significant peaks in 
MDA-231, 4175LM2, 1833BoM2, and 831BrM cells respectively. 
 
The genomic localization of BC≥2 clusters was highly reproducible 
between cell lines, with the majority of binding occurring in genic regions 
(5’UTR, coding sequence and 3’UTR, Figure 3.8A). Despite the well-
defined role of Argonaute in regulation of transcripts via interactions in 
the 3’UTR and to a lesser extent in coding sequence and 5’UTRs, a 
surprisingly high proportion of binding was evident in intronic regions. 
While the biologic consequence of AGO intronic binding is not fully 
understood, it is highly reproducible and has been consistently observed 
in published AGO HITS-CLIP data sets (Chi et al., 2009), (Loeb et al., 
2012), including those derived from Dicer null mouse embryonic stem 
cells (Leung et al., 2011), and multiple unpublished data sets (Darnell 
Lab). Annotation of significant peaks revealed a relative enrichment of 
3’UTR binding (Figure 3.8B). 
 
AGO-mRNA binding patterns are highly reproducible between cell lines 
 Unique tags from all 12 AGO HITS-CLIP mRNA libraries were 
pooled and clustered as one data set to define all possible AGO binding 
sites. Cluster analysis was chosen rather than significant peak analysis due 
to the uneven sequencing depth between cell lines. Clusters were filtered 
to remove those that did not meet the minimum criteria outlined in Figure 









FIGURE 3.8: Genomic distribution of reproducible AGO-mRNA 
binding. A: Unique mRNA reads from each cell line were clustered based 
genomic coordinates and annotated to give genomic location. Binding 
sites on chrY, RNA genes (coordinates derived from the RNAgenes track 
from UCSC genome browser) and pre-miRNA loci were removed before 
annotation. B: Reproducible significant peaks as defined in Figure 3.7B 









BoM, or tags≥13 BrM), leaving a total of 18,444 robust and reproducible 
AGO binding sites. To globally assess AGO binding between the four cell 
lines, the number of tags contributed by each cell line in each cluster were 
plotted and pairwise correlation coefficients calculated (Figure 3.9). The 
global distribution of AGO-mRNA tags in clusters from each of the four 
cell lines were highly reproducible, with correlation coefficients between 
0.80 and 0.92, indicating that the majority of AGO binding is common to 
all cell lines. The top two clusters, corresponding to the full-length 
transcripts of the non-coding RNAs MALAT1 and NEAT1, were removed 
from this analysis as inclusion artificially increased the correlation 
coefficients.  
 
Bioinformatic identification of differential AGO binding sites  
To identify AGO-mRNA binding sites disproportionally enriched 
in one of two compared cell lines, the total number of tags per cluster from 
each cell line were analyzed in a pair-wise fashion, normalized to the total 
number of tags in clusters in that cell line. Fold change and associated p-
value for each cluster were calculated using scripts developed in-house by 
Chaolin Zhang for the Galaxy bioinformatics platform (Hillman-Jackson et 
al., 2012), and an FDR derived using the Benjamini-Hochberg correction 
for multiple hypothesis testing. Clusters were annotated to give both gene 
identity and genomic location, with differential binding search 






FIGURE 3.9: Pairwise correlation of tags in AGO-mRNA clusters. All 
unique tags from the 12 HITS-CLIP experiments were pooled and 
clustered with minimum 3nuclotide overlap. Clusters meeting the 
minimum definition of a robust and reproducible cluster in any single cell 
line were retained (BC2 tags≥5 - MDA or LM2, BC2≥12 – BoM2, or BC2≥13 
– BrM2, 18,466 clusters), and the number of tags contributed from each 
cell line per cluster was counted. Upper half of figure: Pairwise scatter 
plots of unique tags per cluster for each cell line as indicated. Lower half 





The most robust differential binding site commonly gained in the 
three metastatic sub lines compared to MDA-231 was located in the 3’UTR 
of secreted protein, acidic, cysteine-rich (osteonectin), SPARC. The 3’UTR 
of SPARC is shown in Figure 3.10A, with the unique mRNA tags from 
each library shown as horizontal bars grouped by cell type (indicated by 
color), with each individual replicate library shown in a different shade. 
Multiple peaks of BC=3 AGO binding are evident in the 4175LM2 and 
1833BrM data sets, while AGO binding is relatively absent in the parental 
MDA-231 cells. The 831BoM2 data set predominantly contains tags from 
one replicate HITS-CLIP library (118/120 tags), therefore after visual 
inspection this cluster was not deemed reproducible despite being BC=2. 
Given the variable sequencing depth between cell lines, the number of 
overlapping unique tags at any given genomic position were calculated 
and normalized to the total read depth in that cell line (tags per million 
unique tags) in order to more easily visualize binding differences (Figure 
3.10B). The major AGO-binding site on SPARC is centered on two 
previously validated, TargetScan predicted miR-29 seed sequences 
(Kapinas et al., 2009, Wang et al., 2012). 
 
SPARC has previously shown to be highly expressed in 4175LM2 
and 831BrM2 cells, but is absent from MDA-231 and bone metastatic sub-
lines (Minn et al., 2005a). Therefore the de novo AGO binding identified in 
4175LM2 and 831BrM2 when compared to MDA-231 occurs as a function 
of target expression level. While this type of binding is not informative for 












FIGURE 3.10: Identification of de novo AGO binding sites on the 
SPARC 3’UTR in metastatic derivatives of MDA. The most robust 
changes in AGO-mRNA binding between cell lines identified by 
difference analysis occurs in the 3’ UTR of SPARC, a gene previously 
shown to be highly expressed in 4175LM2 and 831BrM but absent from 
MDA-231 & bone metastatic sub-lines. A: Unique tags are plotted for each 
cell line as indicated by color, with different hue indicating tags derived 
from different replicates. Several robust, reproducible AGO-binding sites 
are evident on the 3’UTR of SPARC in LM2 and BoM2 cell lines, with the 
largest peak proximal to the stop codon and centered on two miR-29 seed 
sites. Although BC2 binding is evident in BoM2 cells, these clusters are 
predominantly comprised of unique tags from one data set (118/120 tags 
from BoM2 replicate A) and therefore are not reproducible. MDA cells 
lack any robust, reproducible AGO binding sites, consistent with the lack 
of expression of SPARC in these cells. B: The same view of SPARC as in A, 
showing normalized AGO-mRNA binding calculated on a per cell line 
basis as: number of overlapping unique tags/(total number of unique 
tags/106). Normalization reveals that the poorly reproducible BoM2 AGO 
binding occurs at a much lower level than that in LM2 and BrM2 






with respect to gain in metastatic potential, it is a valuable independent 
read out of transcript steady state mRNA level changes between cell lines. 
Inspection of all genes previously identified as part of the 54 gene lung 
metastasis signature revealed de novo AGO binding events in the majority 
of transcripts known to be upregulated in 4175LM2 cells relative to MDA-
231, while known downregulated genes showed no evidence of additional 
AGO regulation in 4175LM2 cells (data not shown). This was not 
unanticipated given that the relative impact of miRNAs on a target 
transcript levels is generally small (Ebert and Sharp, 2012), and the 
expression level changes of the genes defining the lung metastasis 
signature were high, 3-fold or greater, although once expressed the 
majority show evidence of robust AGO-mRNA binding. 
 
To control for transcript steady state levels between cell lines, 
previously published Affymetrix microarray data was incorporated into 
the difference analysis (Kang et al., 2003, Minn et al., 2005a, Bos et al., 
2009), with the assumption that loss of AGO binding, and hence loss of 
negative regulation, should lead to increase in expression and vice versa. 
Given that non-expressed targets cannot by definition be bound by AGO, 
differentially bound transcripts were required to be expressed in both cell 
lines in which differential binding was detected. RNAseq libraries were 
prepared from non-crosslinked dishes of cell harvested at the same time 
as those samples used for AGO HITS-CLIP analysis, however due to low 
numbers of reads obtained from 1833BoM2 and 831BrM2 samples these 
were not reliable indicators of differentially expressed transcripts across 
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the four cell lines. The RNAseq profiles for MDA and LM2 were used to 
corroborate the previously published microarray profiles (data not 
shown). 
 
Identification of AGO-mRNA binding sites gained in metastatic derivatives of 
MDA-231 
Two 3’UTR clusters were found to have significantly enriched AGO 
binding in all three metastatic sub-lines (p≤0.05) that was coupled with 
reduced expression levels when compared to MDA-231. These clusters 
were located in an ~1kb region of cyclin-dependent kinase 6 (CDK6) 
spanning the terminal exon and extending into the 3’UTR, and in an 
~330bp region of the tumor suppressor candidate 2 (TUSC2/FUS1). The 
AGO binding sites on the 3’UTRs of CDK6 and TUSC2 are shown in 
Figure 3.11, with the AGO clusters identified as being significantly 
differentially bound highlighted. Both clusters identified are comprised of 
multiple peaks of AGO binding embedded in a background of low-level 
scattered tags. Adding to the complexity of regulation is a background of 
extensive AGO binding in other regions of the 3’UTR that is particularly 
pronounced in CDK6, with multiple cell type specific gains and losses in 
binding that may play equally as important a role in down regulation of 









FIGURE 3.11: Identification of AGO-mRNA binding sites gained in 
metastatic derivatives of MDA-231. A: CDK6 shows gain of AGO binding 
a section of the 3’UTR spanning in an ~1kb region containing multiple 
individual peaks of binding (black dashed box). Upper panel: Unique 
mRNA AGO tags aligned to the 3’UTR of CDK6. Lower panel: 
Normalized binding maps reveal increased AGO binding at the proximal 
end of the annotated 3’UTR in the three metastatic sub-lines relative to the 
parental MDA-231.  The number of tags in the highlighted cluster is 
increased 2.5-fold in 4175LM2 (p=0.0003, FDR 0.039), and 1.7-fold in 
1833BoM2 cells (p=0.031, FDR=0.316) and 2.5-fold in 831BrM2 cells 
(p=2.56e-5, FDR= 0.027). B: TUSC2 3’UTR contains a cluster gained in all 
three metastatic sub lines when compared to MDA-231. The number of 
tags in the highlighted cluster is increased 2.5-fold in 4175LM2 (p=0.022, 
FDR 0.498), and 2.4-fold in 1833BoM2 cells (p=0.011, FDR=0.215) and 2.8-





Identification of AGO-binding sites commonly lost in highly metastatic sub-lines 
To identify loss of 3’UTR AGO-binding events common to all 
highly metastatic cell line derivatives of MDA-231, clusters were filtered 
to return positive and significant fold changes in tags per AGO CLIP 
clusters (MDA/sub-line, p≤0.01) with corresponding transcript level 
changes greater than 0.8 fold by microarray. Unexpectedly, only three 
clusters passed this threshold (Table 3.4), located in ras-related C3 
botulinum toxin substrate 1 (RAC1), high mobility group AT-hook 1 
(HMGA1) and tumor protein p53 binding protein, 2 (TP53BP2). 
Subsequent Q-PCR analysis of TP53BP2 levels in MDA-231 and LM2 cells 
revealed strong down regulation in LM2 cells contrary to the microarray 
data (6.4 fold decrease in LM2, p= 0.0017, data not shown).  HMGA1 was 
selected for follow up assays due to the relatively high tag counts in AGO 
clusters, positive confirmation by Q-PCR of increased steady state 
transcript levels both 4175LM2 and 831BoM2 cell lines correlating with 
loss of AGO-mRNA binding (Figure 3.12), and the extensive literature 
associating increased HMGA1 expression with multiple aggressively 
metastatic cancers (Fedele and Fusco, 2010). 
 
Differential AGO binding in the 3’UTR of HMGA1 
The HMGA1 3’UTR cluster identified by differential AGO binding 
analysis is proximal to the stop codon (Figure 3.13, black dashed box). 
Multiple additional peaks of AGO binding with equal normalized peak 
height are seen in all four cell lines at more distal 3’UTR positions, 















TABLE 3.4:  AGO 3’UTR binding sites lost in all three highly metastatic 



















FIGURE 3.12: Loss of AGO binding correlates with increased steady 
state levels of the HMGA1 transcript. HMGA1 mRNA steady state levels 
are higher in 4175LM2 and 1833BoM2 cells relative to the parental MDA-
231. Normalized to TATA-binding protein (TBP), selected as the least 
variable housekeeping gene across the four cell lines from a panel of ten 
potential normalization genes (GeNorm analysis (Vandesompele et al., 





FIGURE 3.13: HMGA1 shows evidence of differential AGO binding 
between parental and metastatic derivative sub-lines. Upper panel: 
Unique mRNA AGO tags aligned to the 3’UTR of HMGA1. Lower panel: 
Normalized binding maps reveal decreased AGO binding X proximal to 
the stop codon in the cluster identified in Table. Binding on other regions 
of the transcript is unchanged suggesting specific loss of AGO regulation 
at this site. The two peaks of binding within the differentially bound 




No alternative splicing of the HMGA1 3’UTR in the region bound 
by AGO differential binding was evident in EST tracks on the UCSC 
genome browser, the RNAseq profiles of MDA-231 and 4175LM2, or by 
RT-PCR analysis (data not shown). The MDA-231 enriched cluster is 
comprised of two individual peaks of binding, designated site 1 and 2, 
with low levels of adjoining tags bridging the two peaks. None of the 
published HMGA1 miRNA regulatory sites are located within the 
differentially bound cluster region of the HMGA1 3’UTR (D'Angelo et al., 
2012, Kaddar et al., 2009, Palmieri et al., 2012, Wei et al., 2011). Shown 
below the HMGA1 3’UTR in Figure 3.13 are Targetscan miRNA target 
predictions showing miR-142-3p and miR-138 regulatory sites 
overlapping binding site 2, while no miRNA seed sites are predicted for 
site 1. miR-142-3p was is significantly lower in the 4175LM2 AGO-miRNA 
profile than MDA-231 by EdgeR consistent with a loss of binding, 
however, however miR-142-3p levels are significantly increased in both 
1833BoM2 and 831BrM2 inconsistent with loss of binding in these cell 
lines (Table 3.3). miR-138 is not within the top 30 most CLIPed miRNA in 
any cell line, but shows slight decreases in AGO-miRNA profile in both 
4175LM2 (log2 FC=-1.5, p=0.03, FDR=0.35) and 831BoM2 (log2 FC=-2.0, 
p=0.14, FDR=0.99) when compared to MDA-231. The miRNA seed 
matches in binding site 1 corresponding to the most frequently cloned 
AGO-miRNA reads include miR-22, a top 30 miRNA, and miR-320a/b/c. 
Neither of these miRNAs showed significant differences in AGO-miRNA 









FIGURE 3.14: Seed sites of expressed miRNAs in the differentially 
bound region of the HMGA1 3’UTR. The sequences defined by the two 
peaks of MDA AGO-mRNA binding were searched for seed matches to 
miRNAs expressed in MDA-231 cells as determined by the AGO-miRNA 
profile. Site 1 contains a seed match to a top 30, miR-22 (see Table 3.2), 
plus seed matches to miR-320a (ranked 45th MDA, 50th LM2, 35th BoM, 48th 
BrM). Mutant constructs were made as indicated in either in the context of 
full-length HMGA 3’UTR or in a shorter fragment corresponding to chr6: 
34,320,641-34,320,915. miR-28-5p mutants were used as a negative control 
due the consistent, low level representation in the miRNA profile of all 





To determine whether the loss of AGO binding to HMGA1 in 
metastatic cells occurs as a result of any of the above AGO-miRNA 
interactions, dual luciferase reporter constructs were made in psiCheck2 
using either full length HMGA1 3’UTR or a shorter fragment 
corresponding to the region spanning the differential AGO-binding (chr6: 
34,320,641-34,320,915). The rationale behind using a smaller fragment was 
based on the hypothesis that relatively minor alterations in AGO-
mediated regulation might be difficult to detect in a background of more 
robust distal regulation. Mutations were made as indicated in Figure 3.14 
to attempt to disrupt the most likely AGO-miRNA seed sites as predicted 
by AGO-miRNA sequencing, with the expectation that derepression 
would only be evident in MDA-231 where endogenous AGO binding 
occurs. Mutations in the miR-28-5p seed site were used as a negative 
control since this miRNA is cloned at consistently low levels in all cell 
lines, representing less than 0.015% of the total AGO-miRNA population. 
 
Pilot experiments using 50ng of vector showed no significant 
change in luciferase activity with any mutant constructs in either MDA-
231 or 4175LM2 cells (data not shown). Given the relatively low 
expression of the miRNAs whose seeds are represented in the differential 
binding sites, the amount of transfected plasmid was decreased to 5ng to 
attempt a more stoichiometric relationship between target and 
endogenous miRNA. Transfections were carried out in sextuplet in 96-
well plates using either full length (Figure 3.15A) or short HMGA1 3’UTR 
(Figure 3.15B) and are shown normalized to empty vector control.  
 
 
FIGURE 3.15: HMGA1 3’UTR Dual luciferase reporter assays in MDA 
and LM2 cells reveal unexpected differential miRNA regulation. 
Reporter constructs were transfected into MDA-231 and 4175LM2 non-
reporter cell lines and luciferase activity assayed at 30hrs. Relative 
luciferase activity is shown normalized to empty vector, mutants are as 
outlined in Figure X. A: Relative expression of luciferase fused to full 
length HMGA1 3’UTR is unaffected by single seed mutations in site 1 and 
2 in both MDA and LM2 cells. Combinatorial mutations of miR-142-3p 
and miR-320 seeds lead to increase in luciferase activity in MDA cells, 
although this increase failed to reach significance (MUT ALL Site2, 
p=0.089). Mutations in the seeds miR-138 or miR142-3p of site 2 (but not 
both) lead to repression in LM2 cells. B: 3’ UTR reporter assays using a 
short fragment of HMGA1 spanning only the region of differential 
binding reveal significant de-repression in MDA cells transfected with 
miR-320a mutant, while unexpectedly all mutations lead to significant de-
repression in LM2. N=10, p-values calculated by t-test compared to WT in 
that cell line, * p≤0.05 **p≤0.01, error bars = s.e.m.  
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As anticipated, mutations in seed sequences in the differentially bound 
AGO-mRNA cluster region of the full length HMGA1 3’UTR had no effect 
on relative luciferase activity 4175LM2 cells when compared to WT. In 
MDA-231cells, no significant derepression was seen in luciferase activity 
with mutant full length 3’UTRs, but a trend towards derepression in 
mutants with combined abrogated miR-142-3p and miR-138 seed sites was 
seen in multiple replicate experiments (MUT ALL site 2), suggesting that 
combinatorial loss of AGO regulation of these two miRNAs may influence 
HMGA1 expression levels to a small degree (Figure 3.15A).  
 
In the context of the short HMGA1 3’UTR, mutations in the miR-
320a/b/c seed sequence lead to significant increase in luciferase activity 
in MDA-231 cells. Surprisingly, in the context of the shorter HMGA1 
3’UTR fragment significant derepression of all mutant constructs was 
observed in 4175LM2 cells, contrary to the predicted lack of AGO-
regulation in these cells (Figure 3.15B). This would suggest that deletion of 
the distal region of the HMGA1 3’UTR allows for 4175LM2-specific 
derepression of the luciferase reporter construct independent of the seed 
mutated, and therefore, that loss of AGO binding on the HMGA1 3’UTR 
in metastatic cells may result from a decrease in accessibility of the 








FIGURE 3.16: The 3’UTR of CD59 shows differential binding of AGO in 
single location with reduced binding in both 4175LM2 and 831BrM2 
cells. Normalized AGO binding maps a single peak of AGO binding in 
the 3’UTR of CD59 that is decreased 1.6-fold in 4175LM2 (p=0.002) and 
1.5-fold in 831BrM2 cells (p=0.0003), but is unchanged in 1833BoM2 cells 





Differential AGO binding in the 3’UTR of CD59 
In order to simplify the search for metastasis-associated loss of 
AGO binding, the criteria for selection was relaxed to identify clusters 
with significant enrichment in binding in any two metastatic sub lines 
compared to MDA-231, where AGO binding occurred predominantly in a 
single location in the 3’UTR. Complement regulatory protein 59 (CD59) 
was identified as having a single peak of AGO binding in the 3’UTR that 
decreased 1.6-fold in 4175LM2 (p=0.002) and 1.5-fold in 831BrM2 cells 
(p=0.0003) relative to MDA-231, but is relatively unchanged in 1833BoM2 
cells (0.8-fold, p=0.05) (Figure 3.16). Previous microarray data and 
subsequent Q-PCR validation (Figure 3.17A) confirmed that CD59 
transcript levels are approximately two-fold higher in 4175LM2 than 
MDA-231, consistent with a loss of negative regulation. FACS analysis of 
CD59, a cell surface protein, confirmed that this increase in mRNA 
translated into increased CD59 protein expression in 4175LM2 but not 
831BrM2 relative to MDA-231 (Figure 3.17B). 
 
The ~80bp footprint of AGO binding on the 3’UTR of CD59 
contains seed sequences for multiple miRNAs, of which miR-125a-5p/a 
and miR-183 are the most highly represented in the combined AGO-
miRNA HITS-CLIP profile (Figure 3.18A, ranked 13th and 39th in MDA-231 
respectively). Neither miR-125a-5p/b nor miR-183 show significant 
changes in AGO-miRNA tag counts between cells lines. The regulation of 
CD59 3’UTR by miR-183 was assessed in a 326nt CD59 3’UTR fragment 





FIGURE 3.17: Decreased AGO 3’UTR binding in CD59 correlates with 
increase in both mRNA and protein levels in 4175LM2 cells. A: Q-PCR 
for CD59 reveals a two-fold increase in mRNA levels in LM2 cells 
consistent with previous microarray studies. (n=3, normalized to TBP, t-
test, error bars = s.e.m). B: FACS staining for CD59 reveals increased 




Co-transfection of this WT sequence construct into 4175LM2 cells 
with 50nM of miR-183 mimic or a negative control mimic had no effect on 
relative luciferase activity (Figure 3.18B) suggesting that miR-183 does not 
mediate the AGO-mRNA interactions identified by AGO HITS-CLIP. 
Further mimic transfections need to be carried out in order to establish the 
identity of the miRNA targeting AGO to CD59 at this site. Alternatively, a 
modification of the HITS-CLIP protocol that utilizes intermolecular 
ligation to produce chimeric AGO-miRNA-mRNA, termed CLASH 
(Helwak et al., 2013), may be useful to identify with high confidence the 




FIGURE 3.18: The differentially bound site in CD59 3’UTR contains 
seed sequences for miR-183 and miR-125a-5p/b, but it not regulated by 
miR-183. A: The AGO footprint region of the CD59 3’UTR with seed 
matches to miR-183 and miR-125a-5p highlighted. B: Dual luciferase 
reporter assays show that miR-183 does not regulate the full-length WT 
CD59 3’UTR. Transfections were done in triplicate with 50nM of miR-183 
mimic or a negative control mimic that does not target any known human 






Altered miRNA expression is a common hallmark of cancer, with 
general down regulation miRNAs compared to normal tissues occurring 
in patterns that can be used as classifiers of tumor type (Lu et al., 2005). 
Conversely, gain of miRNA expression can be oncogenic or tumor 
suppressive depending upon the specific mRNA targets co-expressed and 
the cellular context (reviewed in Lujambio and Lowe, 2012). An increasing 
body of work has implicated altered miRNA regulation both in breast 
cancer metastasis suppression and promotion (Wang and Wang, 2012), 
with miR-335 and miR-126 known to regulate metastasis in the model 
system interrogated here (Png et al., 2011, Tavazoie et al., 2008). By 
applying the AGO HITS-CLIP methodology in this well-established and 
molecularly characterized model of breast cancer metastasis with known 
miRNA regulatory components, we aimed to identify both miRNAs 
differentially bound to AGO with respect to metastatic potential and the 
resulting sites of altered AGO-mRNA regulation on a genome-wide scale. 
 
This study has generated a comprehensive binding map of 
endogenous human AGO bound to endogenously expressed miRNA and 
cognate mRNA targets in the human metastatic breast cancer cell line, 
MDA-MB-231, and its aggressively metastatic sub-lines with tissue 
tropism to lung, bone and brain (Bos et al., 2009, Kang et al., 2003, Minn et 
al., 2005a). This is in contrast to previously published human AGO-mRNA 
data sets that have been generated after transfection with exogenous 
tagged-Argonaute or miRNA mimics (Chi et al., 2009, Hafner et al., 2010, 
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Helwak et al., 2013), or were done in virally infected cells (Riley et al., 
2012). The transcriptome-wide AGO-mRNA binding sites described here 
provide a valuable reference set for researchers; providing independent 
and direct biochemical evidence of robust, endogenous AGO-mRNA 
interactions to supplement experimental validation of miRNA mediated 
effects on predicted target mRNA and (reporter) protein levels. As an 
example, several reports have implicated miR-29a in the regulation of 
SPARC in both breast cancer cells (MCF-7 (Wang et al., 2012), MDA-MB-
435 (Gerson et al., 2012)) and osteoblasts (Kapinas et al., 2009). The 
greatest relative AGO occupancy on the SPARC 3’UTR (Figure 3.10) 
occurs in a cluster comprised of two peaks directly corresponding to two 
TargetScan predicted, conserved miR-29 seed sequences. Given that miR-
29a is one of the most abundantly CLIPed miRNA in all four cells lines, 
and the consistent finding that the most frequently cloned AGO-miRNAs 
have significantly more seed pairs within the AGO-mRNA binding sites 
than the least cloned miRNAs (Chi et al., 2009, Zisoulis et al., 2010), 
binding at this site is highly predictive of miR-29a regulation of SPARC in 
lung and brain metastatic sub lines on MDA-231.  
 
The most frequently CLIPed miRNA in all four cell lines, miR-27a, 
has previously been identified as a potential oncomiR in gastric cancer 
(Liu et al., 2009) and MDA-MB-231 cells (Mertens-Talcott et al., 2007), and 
high levels are associated with poor prognosis in invasive breast cancers 
(Tang et al., 2012b). The abundance of the top 20 AGO-miRNA derived 
from HITS-CLIP in MDA-231 cells was found not to correlate with 
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previously published high-throughput sequencing profiles of MDA-MB-
231 total miRNA (data not shown, (Mayr and Bartel, 2009)). This is in 
contrast to previous reports of high degree of correlation between 
Photoactivatable-Ribonucleoside-Enhanced Crosslinking and 
Immunoprecipitation (PAR-CLIP) derived AGO-miRNA counts and the 
total miRNA abundance profile in HEK293 cells (Hafner et al., 2010). PAR-
CLIP is a HITS-CLIP variation that utilizes the incorporation of 4-
thiouridine (4SU) into transcripts of cultured cells, which upon UV 365nm 
irradiation causes T to C transitions in the cloned CLIP library. The 
discrepancy between published miRNA profiles and the AGO-miRNA 
HITS-CLIP profile in MDA-231 may reflect true biological differences 
between absolute expression levels and preferential incorporation into 
RISC, or could result from technical differences in cloning (Jayaprakash et 
al., 2011), cell stocks or culture conditions; for example, increasing cell 
density is known to lead to widespread increase in miRNA abundance 
(Hwang et al., 2009). Parallel high-throughput miRNA sequencing of the 
cell lines used in this study will be required to distinguish between these 
two possibilities.  
 
Assessment of the AGO-miRNA profiles obtained from MDA-231, 
4175LM2, 1833BoM2 and 831BrM2 cells revealed a striking degree of 
correlation within the 30 most frequently CLIPed miRNAs, with very few 
having statistically significant differences in the HITS-CLIP profiles. This 
was unanticipated given the number of miRNA previously identified as 
differentially expressed in these cells with respect to both metastatic 
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ability and tissue tropism (Tavazoie et al., 2008). The virtual absence from 
the MDA-231 AGO-miRNA profile of the previously validated anti-
metastatic miR-335 (0.0009 % of miRNA) and miR-126 (not cloned) 
indicates that the previously reported correlation between miRNA 
expression and AGO-miRNA CLIP profiles may not extend to minority 
miRNA species. This represents an unforeseen limitation on the use of 
differential AGO HITS-CLIP to determine on a genome-wide scale the 
mRNA targets of known metastasis-inhibitory endogenous miRNAs in 
MDA-MB-231 cells. 
 
Comparative analysis of the HITS-CLIP derived AGO-miRNA 
profiles identified one miRNA, miR-142-3p, with read counts significantly 
decreased in 4175LM2 and increased in both 1833BoM2 and 831BrM2 
relative to MDA-231. Expression of miR-142 has previously been reported 
to be highly specific to hematopoietic cells (Landgraf et al., 2007), with 
high levels of expression in naïve CD8+ T cells (Wu et al., 2007) and a 
reported role in the regulation of monocyte terminal differentiation 
(Lagrange et al., 2013). Recent studies have implicated miR-142-3p in 
tumor suppression of both colon cancer and hepatocellular carcinoma, 
while mutations in both strands of pre-miR-142 have been found in 
diffuse large B cell lymphoma (Kwanhian et al., 2012, Shen et al., 2013, Wu 
et al., 2011a). While miR-142-3p is a relatively minor miRNA in all four 
cell lines, small changes in miRNAs expressed at low levels have been 
shown to have profound functional consequences, for example the anti-
metastatic miR-335, miR-126 and miR-206 (Tavazoie et al., 2008) and the 
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miR-183/96/182 cluster in light adaption in the retina (Krol et al., 2010). 
The differential AGO-CLIP profiles obtained for miR-142-3p identify it as 
an interesting candidate for further investigation to determine whether it 
functions as a cell type specific metastasis suppressor (4175LM2) or 
activator (831BrM2 and 1833BoM2), and whether differential expression 
clinically correlates with the site of distal metastases in breast cancer 
patients. 
 
 The AGO-miRNA profiles of three additional miRNAs represented 
in top 30 most abundant seed families were found to be specific decreased 
in 4175LM2 cells; let-7c, miR-99a and miR-20b. miR-99a and let-7c, along 
with miR-125b-2, are expressed as a cluster derived from an intron of the 
non-coding RNA, C21orf34. The miR-99a/let-7c/125b-2 cluster is located 
on chromosome 21 in in a region commonly deleted in both primary 
breast (Ohgaki et al., 1998) and lung cancers (Calin et al., 2004, Yamada et 
al., 2008). Interestingly, miR-125b is transcribed from two locations within 
the genome and while the mature miR-125b AGO-miRNA counts were 
unchanged between cell lines, miR-125b-2* was significantly lower in 
4175LM2 than all other cell lines (LM2/MDA log2 FC=-2.58 p=0.024, 
BoM/LM2 log2 FC=4.0 p=1.61e-4, BrM/LM2 log2 FC=3.5 p=6.2e-5). This 
strongly suggests specific decrease in the incorporation of all three 
members of the miR-99a/let-7c/125b-2 cluster into AGO in lung 
metastatic cell lines, identifying this cluster as a potential novel regulator 
of lung specific metastasis. 
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 Given the unexpectedly similar AGO-miRNA profiles of MDA-231, 
4175LM2, 1833BoM2 and 831BrM2 and the relatively low expression of 
those miRNA that showed significantly altered AGO-miRNA profiles, the 
potential scope for seed-directed searches for alternatively regulated 
mRNAs were limited. This was further compounded by the potential for 
redundant targeting by other seed family members, as the seed sequences 
of individual miRNA showing significant differences in AGO-miRNA 
profiles were still abundantly represented in all cell lines. For example, let-
7c has been demonstrated to negatively regulate the oncogene HMGA2 in 
uterine leiomyoma via multiple target sites in the 3’UTR (Klemke et al., 
2010). However, this regulation has also been demonstrated when using 
exogenous let-7a (Mayr et al., 2007), mixtures of let-7b/d/g (Guo et al., 
2013) or let-7b/e (Lee and Dutta, 2007), and by family member miR-98 in 
head and neck squamous cell cancer (Hebert et al., 2007). Accordingly, the 
multiple robust AGO-mRNA peaks corresponding to HMGA2 3’UTR let-7 
seed sites are unchanged in 4175LM2 when compared to the other four 
cell lines (data not shown). 
 
 Therefore, differential AGO-mRNA binding was assessed without 
prior assumption as to the miRNA involved in targeting, with the 
simplistic view that commonly gained or lost clusters in aggressively 
metastatic sub-lines would identify deregulated targets related to breast 
cancer biology. This approach allowed for inclusion of both miRNA-
driven binding changes resulting from miRNA expression level changes, 
and non-miRNA driven effects such as shortening of 3’UTRs via 
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alternative splicing or polyadenylation site usage. Unexpectedly, very few 
AGO-mRNA binding sties were either commonly gained or lost in the 
highly metastatic sub-lines of MDA-231, however those transcripts 
identified in this study as having altered AGO-mRNA binding sites with 
corresponding changes in transcript level include several with strong links 
to metastasis.  
 
Gain of AGO-mRNA binding was identified in the 3’UTR of 
TUSC2, a gene that is located in a region of the genome frequently deleted 
in breast and lung cancer (3p21.3 (Zabarovsky et al., 2002)). TUSC2 is pro-
apoptotic when ectopically expressed in non-small cell lung cancer cells 
harboring 3p21.3 deletions (Ji et al., 2002, Kondo et al., 2001), and ectopic 
re-expression via nanoparticle delivery is currently in phase I clinical trials 
for the treatment of recurrent or metastatic lung cancer (Lu et al., 2012). 
Previously described miRNA regulation of TUSC2 by miR-93 and miR-98 
corresponds with the AGO-mRNA binding peaks commonly found in all 
four breast cancer cell lines (Du et al., 2009). Interestingly, deletion of the 
distal portion of the TUSC2 3’UTR, the region containing metastatic sub-
line specific AGO-mRNA de novo binding, leads to increased TUSC2 
protein level in human lung cancer cells (Lin et al., 2011) suggesting that 
these sequences contain potent negative regulators of translation.  
 
CD59 is a membrane-bound protein that protects against 
complement-mediated lysis by interacting with C8 and C9 to preventing 
membrane attack complex (MAC) formation (Meri et al., 1990). Up 
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regulation of CD59 has been described in multiple malignant cell types 
(Fishelson et al., 2003) including in breast cancer, where CD59 has a role in 
both resistance to complement-mediated lysis and HBXIP-mediated 
proliferation and migration (Cui et al., 2012). CD59 is expressed 
throughout the human respiratory tract (Varsano et al., 1995), with 
increased levels reported in lung cancer cell lines (Varsano et al., 1998). 
Decreased AGO binding, the correlated increase in both mRNA and 
protein levels of CD59 seen in 4175LM2 cells may be beneficial in 
providing protection against complement attack during colonization and 
out growth in the lung metastatic niche. It will be interesting to determine 
whether knockdown of CD59 in these cells negatively influences their 
ability to form metastatic lesions in the lung. 
  
Both HMGA1 and HMGA2 are oncofetal proteins, with high levels 
of expression found during embryogenesis and several tumor types and 
undetectable or very low expression in differentiated adult tissues 
(Chiappetta et al., 1996, Zhou et al., 1995). While HMGA proteins can 
function as anti-proliferative components of cellular senescence, they can 
also promote proliferation depending on cellular context (Narita et al., 
2006) and are overexpressed in multiple human malignancies (Fedele and 
Fusco, 2010). Overexpression of HMGA1 in MCF-7 cells leads to enhanced 
tumor formation and metastasis (Liu et al., 1999, Reeves et al., 2001) with 
reciprocal decrease in both orthotopic tumor growth and lung metastasis 
found with HMGA1 knockdown in MDA-231 cells (Shah et al., 2013).  
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While the posttranscriptional regulation of HMGA2 by let-7 is well 
documented and corroborated by the robust AGO HITS-CLIP binding 
data generated in this study, the regulation of HMGA1 by miRNAs in 
breast cancer is less clear. AGO-mRNA binding is seen in regions 
corresponding to previously validated miR-26, miR-15/16 and let-7 sites 
(Figure 16, (Palmieri et al., 2012)), however none of the previously 
validated regulatory miRNA seed sites found in the literature map to the 
region of differential AGO binding identified by HITS-CLIP. Mutation of 
the most likely candidate miRNA seeds within these sites (based on AGO-
miRNA profiling) failed to lead to consistent significant derepression in 
MDA-231. It remains to be tested whether other relatively minor miRNA 
are able to regulate HGMA1 at the sites identified by HITS-CLIP. 
However, the seemingly anomalous result whereby removal of the distal 
portion of the 3’UTR allows for mutation-mediated derepression of 
HGMA1 reporter constructs specifically in 4175LM2 would suggest that 
other cis-regulatory elements may be responsible for the loss of AGO-
binding seen in these cells under endogenous full length 3’UTR 
conditions. Such antagonistic regulation has been described in zebrafish, 
where cis-regulatory elements in the 3’UTR of nanos1 are sufficient to 
inhibit ubiquitously expressed miR-430-mediated deadenylation and 
translational repression in primordial germ cells but not the soma 
(Mishima et al., 2006).  
 
Identification of the miRNAs involved in targeting AGO to the sites 
of differential binding described in this chapter has proven challenging. 
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Potential regulatory miRNAs were selected for mutational reporter assay 
analysis based on both the seed sequences within the AGO footprint of 
differential binding and the abundance of the complementary miRNA in 
the AGO-miRNA profile. While miRNAs known to mediate metastasis 
suppression were below the threshold of AGO-miRNA HITS-CLIP 
detection, it is not clear how this lack of detectable miRNA binding 
translates in the AGO-mRNA profile. Rare miRNA targeting may result in 
robust AGO-mRNA clusters under certain conditions, for example, if 
regulated targets were present at high concentration and/or the miRNA 
in question regulated relatively few transcripts thereby increasing the 
relative concentration of a rare AGO-miRNA at the target sites. Such 
binding may help to explain the “orphan” clusters found in previous AGO 
HITS-CLIP experiments that do not contain seed matches to the top 30 
miRNAs in the AGO-miRNA profile (Chi et al., 2009).  
 
The AGO-mRNA footprints derived from HITS-CLIP are valuable 
for delimiting the sequence space in which to search for miRNA seed 
matches, however increasing HITS-CLIP-derived evidence points to 
substantial non-canonical yet functional AGO-miRNA-target pairing. For 
example, it has been recognized for some time in C.elegans that the lin-
4::lin-14 interaction accommodates a C-bulge (Ha et al., 1996, Wightman et 
al., 1993), and that the let-7::lin-41 interaction involves a G:U wobble (Vella 
et al., 2004), with both of these direct interactions confirmed by alg-1 HITS-
CLIP (Zisoulis et al., 2010). Analysis of multiple AGO HITS-CLIP libraries 
indicates a high degree of functional miRNA-mediated AGO-mRNA 
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regulation at non-canonical sites including various seed-like motifs (G-
bulges at position 5-6 (Chi et al., 2012), single mismatches (Loeb et al., 
2012)) and interactions outside of the seed that are complementary to the 
middle and 3’ end of the miRNA (Helwak et al., 2013). Furthermore, it has 
been noted that AGO binds mRNA preferentially in G-rich motifs in a 
similar genomic distribution in mouse embryonic stem cells with or 
without mature miRNAs (Leung et al., 2011). These alternate rules of 
regulation add a further layer of complexity to the search for miRNAs 
responsible for targeting AGO to the de novo clusters identified in MDA-
231 and its derivatives. The newly developed protocol CLASH, in which 
intermolecular ligation is used to drive the formation of chimeric miRNA-
target mRNA AGO HITS-CLIP tags (Helwak et al., 2013), may be useful 
for identifying the miRNAs involved in regulating the differentially AGO 
bound targets identified in this study. 
 
Close inspection of the previously published expression data 
comparing MDA-231 and 4175LM2 (Minn et al., 2005a) or 831BrM2 (Bos et 
al., 2009) revealed an additional potential variable regarding regulation of 
AGO-mRNA binding, namely altered expression of other RNA binding 
proteins. Muscleblind 2 (MBNL2) is among the downregulated genes 
identified in 4175LM2 cells (Minn et al., 2005a), with CUGBP2/CELF2 and 
ELAVL4/HuD being upregulated in 831BrM2 (Bos et al., 2009, Li et al., 
2011a). Additionally, two-dimensional difference gel electrophoresis has 
identified hnRNPA2B1 as upregulated in independently derived brain 
metastatic clones of MDA-231 (Yoneda et al., 2001, Li et al., 2011b). Both 
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MBNL2 and CUGBP2 have been implicated in accelerated mRNA decay 
mediated by 3’UTR binding of targets (Du et al., 2010, Masuda et al., 
2012), with recent HITS-CLIP data confirming that the majority of MBNL2 
binding occurs in 3’UTRs (Charizanis et al., 2012). Conversely, 
hnRNPA2BP1 has been shown to stabilize long-lived mRNA transcripts in 
MDA-231 cells via interactions with RNA structural motifs in their 3’UTRs 
(Goodarzi et al., 2012).  
 
While no direct link between the 3’UTR binding of these proteins 
and AGO-mediated regulation has been investigated to date, the potential 
for ELAV-modulation of miRNA target site accessibility is known. 
Jacobsen et al. (2010) have shown that the binding motif for ELAVL4 is the 
most enriched motif in mRNAs with altered expression levels following 
small RNA transfection in HeLa cells. ARE motifs were found to be 
significantly enriched in regions ~50nt upstream of endogenous miRNA 
targets previously defined by AGO HITS-CLIP, correlating with both 
attenuated and augmented transfected miRNA-dependent destabilization. 
Significantly, overlapping genome-wide patterns of HuR and AGO 
binding have been described using PAR-CLIP in HEK293 cells (Mukherjee 
et al., 2011) and with endogenous proteins via HITS-CLIP in resting and 
activated human T-cells (Darnell Lab, unpublished data), suggesting a 
potential role for agonistic or antagonistic HuR regulation of AGO 
binding on common target transcripts. Indeed examples of both types of 
interaction exist. HuR binding is required for let-7 mediated c-Myc 
repression (Kim et al., 2009a) and has been shown to relieve miR-122 
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repression of CAT-1 mRNA (Bhattacharyya et al., 2006). Comparing AGO-
mRNA binding across cell lines where potential “unseen” RBP 
modulators of transcript stability and AGO targeting are known to be 
differentially expressed further complicates the seed-directed approach 
towards validation of differential AGO-mRNA binding. 
 
Perspectives 
By pairing differential AGO–mRNA HITS-CLIP analysis with 
expression data, we have identified potential for miRNA-mediated 
regulation of metastatic organotropsim, with miR-142-3p and the miR-
99a/let-7c/miR-125-b2 cluster specifically downregulated in lung 
metastatic cell lines. We have shown that it is possible to identify 
transcripts in which gain or loss of AGO binding correlates with decrease 
or increase in steady state mRNA levels and, in the case of CD59, protein 
levels. Those transcripts identified as having de novo AGO-mRNA binding 
have well documented roles in cancer biology and metastasis. While the 
particular miRNA involved at the identified differential AGO binding 
sites are currently unknown, it will be interesting to investigate the 
function of metastasis-specific de novo AGO-mRNA binding in the 
promotion or inhibition of metastasis via transfection with antisense 
oligonucleotides that block AGO binding to specific target mRNA. For 
simplicity we have focused on identifying differential binding common to 
the aggressively metastatic phenotype in 3’UTRs, however the genome-
wide nature of the data presented allows for future analysis of binding in 
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other regions of transcripts and in identifying differentially regulated 
targets with respect to tissue tropism.   
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CHAPTER 4: TRANSCRIPTOME-WIDE TARGET IDENTIFICATION 
OF THE ANTI-METASTATIC miR-335 
 
INTRODUCTION 
Deregulation of miRNA expression in tumors can be accomplished 
by multiple mechanisms. Many miRNA loci are located in fragile sites, 
common breakpoint regions, and cancer-associated sites of loss of 
heterozygosity or amplification (Calin et al., 2004, Zhang et al., 2006). 
miRNAs may be epigenetically silenced by promoter DNA methylation 
(Choudhry and Catto, 2011) and histone modifications (Scott et al., 2006). 
Furthermore, mature miRNA abundance can be affected by post-
transcriptional regulation of miRNA processing and stability. For 
example, DNA-damaged induced up regulation of a subset of mature 
miRNAs is dependent upon p53 interaction with Drosha (Suzuki et al., 
2009), while estrogen receptor-alpha can suppress the maturation of miR-
125a and miR-145 in breast cancer cells (Yamagata et al., 2009). 
 
Using the xenograft model outlined in Chapter 3, (Tavazoie et al., 
2008) have identified three endogenously expressed human miRNAs, 
miR-126, miR-206 and miR-335, that robustly suppress breast cancer 
metastasis to lung and bone, and whose expression levels negatively 
correlate with patient metastasis free survival. Loss of miR-206 expression 
has been independently associated with lymph node metastasis and poor 
prognosis in a cohort of breast cancer patients (Li et al., 2013), and has 
been reported to enhance metastatic spread of rhabdomyosarcoma 
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(Missiaglia et al., 2010), endometrioid adenocarcinoma (Chen et al., 2012), 
and lung cancer cells (Wang et al., 2011c). Loss of miR-126 in breast cancer 
leads to increased proliferation and number of metastatic nodules in lung, 
indicating a role in the regulation of metastatic initiation and colonization. 
Interestingly, de-repression of miR-126 targets IGFBP2, MERTK and 
PITPNC1 leads to enhanced endothelial cell recruitment and angiogenesis 
(Png et al., 2012) indicating a non-cell autonomous role for miR-126 in 
metastasis suppression. Loss of both miR-126 and miR-126* expression 
has been shown to enhance metastasis in a murine model of breast cancer 
via up regulation of the endothelial cell recruiting chemokine SDF-1& 
(Zhang et al., 2013). 
 
The miR-335 locus is located in the second intron of mesoderm 
specific transcript (MEST). Decrease in miR-335 expression is associated 
with enhanced invasiveness of breast cancer (Heyn et al., 2011, Png et al., 
2011, Tavazoie et al., 2008), gastric cancer (Xu et al., 2012) and 
neuroblastoma (Lynch et al., 2012). For miR-335, both genetic loss and 
promoter hypermethlyation of the MEST host gene has been described in 
clinical breast cancer samples (Png et al., 2011) and hepatocellular 
carcinoma (Dohi et al., 2013), with loss of expression correlating with 
higher rates of distal metastasis formation. In contrast, miR-335 expression 
is pro-oncogenic in malignant astrocytoma where it promotes growth and 
invasion (Shu et al., 2011). Expression of miR-335 has been proposed to 
control proliferation in U2OS cells in a p53-dependent manner via direct 
retinoblastoma 1 (Rb1) targeting (Scarola et al., 2010), while this same Rb1 
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interaction is proposed to enhance meningioma cell growth (Shi et al., 
2012). MDA-231 cells express a non-functional mutant p53 (Petitjean et al., 
2007), and therefore this pathway is unlikely to influence metastatic 
potential in these cells or its derivatives. An additional a role for miR-335 
in the regulation of stem cell self-renewal has been proposed. Low miR-
335 expression in breast cancer stem cells promotes cell growth 
(Polytarchou et al., 2012), while up-regulation of miR-335 in mouse 
epithelial stem cells promotes differentiation by targeting Oct-4 and 
retinoblastoma protein (Schoeftner et al., 2012). Conversely, miR-335 has 
been found at high levels in human mesenchymal stem stems where it 
both prevents differentiation and inhibits motility (Tome et al., 2011).  
 
miR-335, miR-126 and miR-206 were identified as potent 
endogenous inhibitors of metastasis by comparative microarray profiling 
of the relatively weakly metastatic MDA-231 cell line and its aggressively 
metastatic sub-lines with tropism to lung and bone (Tavazoie et al., 2008). 
While the fold changes in expression level of these miRNAs were large, 
between 50-70% for miR-335, the absolute levels of each miRNA were low 
in the parental cells. Consequently, these miRNA were not amenable to 
the differential AGO HITS-CLIP analysis carried out on MDA-231 and 
4175LM2 cells where miR-335 and miR-335* together comprise <0.01% of 
all MDA-231 crosslinked AGO-miRNA clones. Therefore to globally 
identify miR-335 targets, we made use of previously characterized lung 
metastatic cell lines with restored miR-335 expression and reduced 
metastatic ability. These cells were created by cloning an approximately 
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500bp region of the second intron of MEST (spanning the miR-355 
genomic location) into a pMSCV-Blasticidin vector, allowing stable 
integration and overexpression of pre-miR-335 under the control of a 
CMV promoter (miR-Vec, (Tavazoie et al., 2008, Voorhoeve et al., 2007). 
This system requires the normal cellular processing machinery to produce 
both pre- and mature- miRNA guide strand so maintaining any 
endogenous regulation of processing and miRNA stability.  
 
Given the multiple roles described for miR-335 in metastasis 
progression and the strong negative correlation between expression levels 
and clinical metastasis-free survival, miR-335 was selected for further 
analysis using AGO HITS-CLIP. By mapping AGO-mRNA interactions in 
the presence and absence of miR-335 expression, we aimed to generate a 
comprehensive catalog of directly regulated miR-335 target mRNAs to 





AGO HITS-CLIP in 4175LM2 Control and 4175LM2 pre-miR335 
overexpressing cells 
 Argonaute HITS-CLIP was carried out in triplicate as described in 
Chapter 3 using stable 4175 LM2 cell lines expressing either a control, non-
targeting hairpin designed against inhibitor of DNA binding 1, ID1 (Minn 
et al., 2005a) or pre-miR-355 (Tavazoie et al., 2008), termed LM2 Control 
and LM2 335OE, respectively. Overexpression of miR-335 and miR-335* 
were confirmed by Q-PCR before HITS-CLIP experiments were 
undertaken, with both detected at ~120 fold higher levels in LM2 335OE 
compared to LM2 Control (Figure 4.1). The resulting high-throughput 
sequencing data was processed and filtered as in Figure 3.5, with the 
number of miRNA and unique mRNA tags obtained from each replicate 
library outlined in Table 4.1. Read depth between the two experiments 
was more equally distributed than previously described for MDA-231 
cells and metastatic sub lines, with ~1.7 million unique mRNA tags 
obtained for LM2 Control cells and ~1.4 million unique mRNA tags from 
LM2 335OE.  
 
Characterization of the AGO-miRNA profiles of LM2 control and LM2 335OE 
AGO-miRNA data sets were analyzed to determine whether 
overexpression of pri-miR-335 disrupts the global miRISC profile of LM2 
cells. Read counts per miRNA tallied as previously described, miRNAs 
grouped by 7-mer seed family and the percentage of reads calculated 
















FIGURE 4.1: Verification of miR-335/* over expression in stable cells 
lines. Q-PCR verification of miR-335 and miR-335* over-expression in 
LM2 335OE prior to AGO HITS-CLIP analysis. N=3, expression levels 


















Table 4.1: AGO HITS-CLIP sequencing results from triplicate LM2 
Control and LM2 335OE cell lines. Read counts are shown for each data 






family was plotted in pair-wise scatter plots comparing LM2 Control and 
LM2 335OE with each other, and to the previously described 4175LM2 
AGO-miRNA data set. Extremely high Pearson correlation coefficients 
were obtained when comparing all three data sets, indicating that neither 
the selective overexpression of pri-miR-335 nor the non-targeting control 
shRNA lead to a significant shift in the overall composition of miRNAs 
bound to AGO in 4175LM2 cells (Figure 4.2). Correlation coefficients were 
unaffected by removal of the top three most CLIPed miRNAs (data not 
shown). 
 
AGO HITS-CLIP reveals strand bias towards miR-335* 
Plotting the percentage of miRNA CLIP tags from each LM2 cell 
line on a log scale revealed a clear increase in the representation of both 
miR-335 and miR-335* in LM2 335OE compared to both LM2 Control and 
4175LM2 (Figure 4.3). The miRNA profiles of LM2 335OE and LM2 
Control cells were compared using EdgeR software as described 
previously, with miRNAs having counts per million>2 in >4/6 HITS-CLIP 
AGO-miRNA profiles retained for analysis (Table 4.2). Surprisingly, while 
miR-335 showed a significant increase in the LM2 335OE AGO-miRNA 
profile, this fold change did not pass the FDR threshold (log2FC=4.01, 
p=0.0025, FDR=0.12). However miR-335*, the presumed pre-miR-335 
passenger strand, had the greatest and most significant positive fold 
change of all AGO-miRNA (log2FC=6.65, p= 7.61E-15, FDR= 5.29E-12). Six 






FIGURE 4.2: AGO-miRNA profiles in LM2 cell lines are unaffected by 
pri-miR-335 over expression. Expressed miRNAs (BC≥2 tags≥10) 
common to 4175LM2, LM2 Control and LM2 335OE cells were 
compressed into seed families based on position 2-8 (7-mer) seed match. 
The percentage of reads per miRNA was calculated per library using the 
total number of reads mapping to miRNAs in that library as a 
denominator. Percentages were then averaged across replicates per cell 
line. Upper half: Pairwise scatter plots of miRNA family % in 4175LM2, 







FIGURE 4.3: Over expression of pri-miR-335 leads to an increase in the 
percentage of AGO-miR-335 and AGO-miR-335* in LM2 335OE. 
Percentage of miRNAs as in Figure 4.2 on a log scale. miR-335 and miR-







compared with LM2 Control (FDR≤0.05), however the majority of these 
miRNA are rare components of the miRNA profile (average%<0.1). 
Despite ~120 fold increased expression of miR-335 and miR-335* in LM2 
335OE cells, both mature miRNAs processed from this precursor remain 
minor components of the AGO-miRNA profile representing only 0.42% 
and 0.045% of the total miRNA population respectively. 
 
The asymmetrical increase in miR-335 and miR-335* representation 
in AGO-miRNA HITS-CLIP libraries raised the possibility that miR-335* is 
the dominant guide strand in LM2 335OE cells. Given that the selected 
strand determines the functional specificity of the miRISC complex, this 
would have profound implications for the targets regulated by pre-miR-
335. The stem-loop structure of human miR-335 is shown in Figure 4.4. 
Functional miRNAs have been found to have lower thermodynamic 
stability at the 5’ end, leading to more efficient loading into RISC 
(Khvorova et al., 2003). The 5’ end of miR-335 contains multiple G-C base 
pairs, while the miR-335* 5’ end is comprised of a stretch of five A-T base 
pairs, suggesting that miR-335* 5’ end would be relatively less stable. 
Consistent with miR-335* being the guide strand, it is detected at 
significantly higher levels than miR-335 in MDA-MB-231and all LM2 cell 
lines used in this study indicating that processing of exogenous pre-miR-














TABLE 4.2: Analysis of the AGO-miRNA profiles of LM2 Control and 
LM2 335OE. Percentage of AGO-miRNA CLIP tags is shown as the 
average across the tree libraries for each data set, log2 fold change, p-value 













miR-335* 0.007 0.419 6.647 7.61E-15 5.29E-12 
miR-548o 0.134 0.009 -3.155 1.03E-05 0.0024 
miR-3182 0.022 0.001 -4.317 1.03E-04 0.0179 
miR-665 0.046 0.003 -2.936 1.56E-04 0.0217 
miR-574-5p 0.643 0.132 -1.724 2.54E-04 0.0295 
miR-519d 0.025 0.001 -3.966 3.34E-04 0.0332 
miR-663 0.015 0.000 -5.080 3.82E-04 0.0332 
 






















Figure 4.4: The stem-loop structure of human pre-miR-335. miR-335* 
(miR-335-3p ) has a 5nt A-T base paired stretch at its 5’ end compared the 















FIGURE 4.5: miR-335* is consistently detected at higher levels than 
miR-335 in MDA-231 and lung metastatic sub-lines. Q-PCR for miR-335 
and miR-335* were carried out in triplicate for each cell line indicated with 
expression normalized to Snord44. Error bars = s.e.m, p-values calculated 
by t-test.  
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Global characterization of AGO-mRNA binding in LM2 Control and LM2 
335OE 
 Uniquely mapped mRNA libraries were clustered independently 
for LM2 Control and LM2 335OE, and the resulting robust, reproducible 
clusters annotated (BC≥2 tags≥5). As previously described, clusters 
mapping to chrY, RNA genes and pre-miRNA loci were removed before 
genomic distribution was assessed, resulting in 21,403 LM2 335OE and 
31,359 LM2 Control clusters. The genomic localization of both LM2 
Control and 335OE clusters were highly similar, with the largest 
proportion of clusters mapping to 3’UTRs plus 10kb immediately 
downstream of annotated gene ends (44% and 44.1%, control and 335OE 
respectively), and consistent with the previously described distribution of 
AGO-mRNA binding in 4175LM2 (see Figure 3.7). The majority of the 
remaining LM2 Control and 335OE clusters were distributed between 
coding sequence (30.5% and 27% respectively), introns (13.8% and 17.9% 
respectively), with a small degree of binding occurring in 5’UTR and deep 
intergenic regions (Figure 4.6). 
 
 To assess reproducibility between the AGO-mRNA binding sites in LM2 
Control and LM2 335OE cells, all unique tags were pooled and clustered. 
These clusters were filtered to retain those with a minimum of five unique 
tags originating from two replicate libraries of either LM2 Control or 
335OE, and by removing clusters mapping to chrY, RNA genes and pre-
miRNA loci (39,109 AGO binding sites). The number of tags per cluster 














FIGURE 4.6: Genomic distribution of robust and reproducible AGO-
mRNA clusters in LM2 Control and LM2 335OE cells. The three 
independently derived AGO-mRNA libraries for each cell line were 
pooled and clustered with a minimum overlap of 3nt. Clusters were 
removed that did not meet the minimum criteria of BC≥2 tags≥5, or that 
mapped to chrY, RNAgenes and pre-miRNA loci. Clusters were annotated 














FIGURE 4.7: AGO-mRNA binding is highly reproducible between LM2 
Control and LM2 335OE cells. All unique AGO-mRNA reads from LM2 
Control and 335OE cells were pooled together and clustered, retaining 
only those clusters with BC≥2 and tags≥5 in either cell line. The scatter 
plot of CLIP tag per cluster originating from Control and LM2 cells shows 
a high degree of reproducibility in AGO-mRNA biding between cells lines 
(R2=0.838). The overexpression of pri-miR-335 in LM2 335OE does not 




R2=0.838), suggesting that overexpression of pri-miR-335 does not globally 
perturb the AGO-mRNA profile of LM2 cells.  
 
Identification of miR-335/* dependent de novo AGO-mRNA clusters 
 The basic principles used to identify miR-335 or miR-335* 
dependent AGO binding events from AGO HITS-CLIP data are in 
outlined in Figure 4.8. First, AGO-mRNA clusters were identified that 
showed significant enrichment in AGO-mRNA binding LM2 335OE cells 
(dark blue) when compared to the non-targeting hairpin expressing LM2 
Control cells (light blue) as previously described for differential AGO-
mRNA analysis in Chapter 3. miR-335/*-dependent binding de novo 
binding events were then screened for the canonical miR-335 and/or miR-
335* seed sequence (CTCTTG and TGAAAA) as evidence of direct miR-
335/*-mediated AGO de novo binding.  
 
A total of 1,283 BC≥2 tag≥5 clusters were identified with significant 
enrichment of AGO-binding in the presence of pri-miR-335 (log2 fold 
change 335OE/Control ≥1, p-value≤0.01). 368 clusters (28.7%) contained a 
minimum 6-mer sequence match to miR-335 or miR-335* within position 
1-8, while 210 (16.4%) contained a canonical seed match corresponding to 
position 2-7. Of those clusters with a canonical seed match, 71 contained 
seed matches to miR-335 and 139 to miR-335* consistent with the 
relatively higher abundance of miR-335* in the LM2 335OE AGO-miRNA 




FIGURE 4.8: Experimental schematic of miR335/* dependent AGO-
binding event identification. Triplicate AGO HITS-CLIP unique mRNA 
tags from 4175LM2 cells stably expressing either a control hairpin (LM2 
Control, highly metastatic, light blue) or pri-miR-335 (LM2 335OE, weakly 
metastatic, dark blue) were mapped to the human genome (hg18). Sites of 
robust, reproducible binding were identified as either as clusters derived 
from pooled unique reads from both cell lines, or as significant peaks in 
the LM2 335OE data set (both requiring a minimal BC≥2 and tag≥5). Tag 
numbers from each cell line in the AGO-mRNA footprint region were 
counted and those AGO binding sites showing enrichment in the LM2 
335OE libraries interrogated for the presence of miR-335 or miR-335* seed 
sequences as evidence of direct, de novo miR-335/* regulation. Lung 





downstream region left a total 107 miR-335/* canonical seed match 
containing, pri-miR-335-dependent clusters. Given that the definition of a 
cluster can encompass relatively large stretches of transcripts with 
multiple peaks, de novo miR-335/* AGO-mRNA binding was assessed in 
the -30/+32nt footprint centered on the single largest peak of each cluster 
(Chi et al., 2009). Seed search in this narrower sequence space returned 
106 miR-335* and 66 miR-335 6mer seed matches to positions 1-8 (13.4% of 
de novo AGO-miR335 clusters). Of these peaks, 64 and 35 contained 
canonical 2-7 seed matches to miR-335* and miR-335 respectively, with 44 
canonical seed matches occurring in 39 3’UTR and 10kb downstream 
clusters (Table 4.3). 
 
Detailed analysis of AGO HITS-CLIP data sets have revealed 
alternative rules for miRNA:mRNA target recognition involving the 
inclusion of position 6 nucleation bulges (Chi et al., 2012) and various 
“seed-like” sequences (Loeb et al., 2012). Interestingly, G:U wobbles can 
be tolerated in various positions within the lsy-6-::cog-1 targeting site, 
which like miR-335* seed pairing contains a stretch of four A-U base pairs 
(TACAAAA – lsy-6, ATGAAAA - miR-335*) (Didiano and Hobert, 2006). 
Taking these potential alternative seed pairing sequences into 
consideration, a further 133 potential seed matches for miR-335* were 
identified in the 62nt AGO footprint of those de novo clusters with no 
evidence of a canonical 6nt seed (Figure 4.9). The ability of miR-335* to 
regulate these non-canonical seed-matched transcripts is yet to be 

















TABLE 4.3: LM2 335OE 3’UTR clusters containing canonical seed 
matches in the 62nt AGO footprint. De novo mR-335/* 3’UTR clusters 
whose largest peak (-30/+32nt) contain a canonical seed match to either 
miR-335 or miR-335*. Unique mRNA counts and biological complexity are 
given for LM2 335OE and LM2 Control cells with log2 fold change in 
binding events (normalized to read depth per cell line), associated p-value 
and FDR (Benjamini-Hochberg correction). The genomic coordinates of 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.9: Non-canonical miR-335* seed sites in the AGO 62nt footprint 
in LM2 335OE enriched AGO clusters. AGO footprint regions enriched in 
LM2 335OE cells were searched for potential non-canonical miR-335 and 
miR-335* seed sites with bulged nucleotides at position 6 (Chi et al., 2012), 
and G:U wobbles in the 4nt A-U pairing region of miR-335* (Didiano and 
Hobert, 2006). 133 additional binding sites were found that contained a 






clusters identified two significant motifs, which did not match the seed 
sequences of any miRNA in the HITS-CLIP profile, or the G-rich motifs 
associated with miRNA-independent AGO binding sites identified in 
mouse embryonic stem cells (Leung et al., 2011). 
 
Identification of miR-335/* dependent de novo AGO-mRNA significant peaks 
Unique mRNA tags from LM2 335OE were used to identify 
significant peaks of AGO binding. 9,183 significant peaks were identified 
with p≤0.01, 7305 of which contained five or more tags from two or more 
replicate LM2 335OE libraries (BC≥2 tags≥5). The number of LM2 Control 
AGO-mRNA tags overlapping the +/-30nt region centered on the LM2 
335OE significant peak was calculated and difference analysis carried out 
as for clusters. 253 LM2 335OE significant peaks showed significant 
enrichment of AGO-mRNA binding (log2 fold change ≥1, p<0.01), with 82 
containing a minimal 6-mer match to either miR-335 or miR-335* between 
positions 1-8. Only 15 peaks contained canonical position 2-7 seed 
matches, of which 9 were located in 3’UTR regions. Table 4.4 shows all 
canonical seed-matched significant peaks in 3’UTRs and coding sequence. 
The low number of seed containing significant peaks identified as 
enriched in LM2 335OE is unsurprising considering the small proportion 
of the miRNA profile represented by miR-335 and -335*, and the generally 


















Table 4.4: LM2 335OE enriched significant peaks in CDS and 3’UTRs 
with canonical miR-335/* seed sequences. Significant peaks were defined 
in LM2 335OE cells (BC≥2 tags≥5), and overlapping tags from LM2 
Control cells counted in a +/-30nt AGO footprint centered on the 335OE 
significant peak coordinate. Difference analysis was carried out as 
described for cluster analysis. 3’UTRs and CDS significant peaks that 
contain a canonical miR335 or miR335* seed site and have significant 





























































































































































































































































































































































































































































































































































































Initial selection of miR-335/* targets for validation 
The list of candidate miR-335/* enriched targets was refined by 
comparing to RNAseq analysis of transcript abundance in LM2 Control 
and 335OE cells. Single-end, 50nt polyA-selected single replicate RNA 
libraries were prepared from LM2 Control and LM2 335OE cells harvested 
at the same time as those used for HITS-CLIP. The resulting high-
throughput sequencing data was filtered based on quality score then 
aligned to the human genome (hg18), giving ~20million reads for LM2 
Control and ~21million reads for LM2 335OE. Gene expression levels 
(RPKM) were obtained by aligning reads to a non-redundant set of 
constitutive exons, and difference in expression calculated using tools 
developed by Chaolin Zhang in the Darnell laboratory for use within the 
Galaxy bioinformatics platform.  
 
RPKM values per gene from LM2 Control and LM2 335OE cells are 
plotted in Figure 4.10, with the previously identified miR-335 
downregulated gene set (Tavazoie et al., 2008) highlighted in blue as a 
positive control. A high degree of correlation in transcript abundance 
(R2=0.927) was observed between LM2 335OE and LM2 Control indicating 
very few transcripts with altered steady state levels. Filtering the LM2 
335OE enriched clusters by log2 fold change of 335OE/Control RNAseq 
reads (≤0.2, p-value≤0.01) returned 9 clusters, of which 8 clusters 
contained canonical miR-335* seed matches, one contained a miR-335 seed 










FIGURE 4.10: RNAseq analysis of steady state transcript levels in LM2 
Control and LM2 335OE cells. Scatter plot of RPKM values per gene 
obtained from high-throughput polyA-selected RNAseq. Genes 
highlighted in blue comprise the six miR-335 downregulated genes 
previously identified in LM2 335OE cells (Tavazoie et al., 2008), with all 






































































































































































































































































































































































































































































































































































































































































































































Validation of centrin EF-hand protein 3 (CETN3) as a miR-335* target 
 CETN3 was selected for validation based on the high relative 
enrichment of CLIP tags and fold change in abundance compared with the 
other candidates. Additionally, the de novo AGO binding site identified by 
differential analysis was the only AGO binding site in this relatively short 
3’UTR (~350nt, Figure 4.11A), and contained extensive complementarity 
to miR-335*; a canonical miR-335* 1-7nt seed match with an additional G-
U wobble base-pair at position 8 (Figure 4.11B). Endogenous CETN3 
transcript levels were assayed by Q-PCR in MDA-231 parental cells (miR-
335/* expressing), 4175 LM2 (miR-335/* negative) and LM2 335OE. 
CETN3 steady state mRNA levels were significantly higher in 4175LM2 
cells suggesting derepression of the transcript (Figure 4.12A). To 
determine whether this derepression was a direct consequence of 
decreased levels of miR-335*, 4175LM2 cells were transiently transfected 
with miR-335* mimic. This resulted in significant down regulation of 
endogenous CETN3, while no effect on transcript level was seen in cells 
transfected with miR-335 mimic or a negative control mimic that is non-
targeting in the human genome (p=0.006, Figure 4.12B). 
 
 To determine whether the miR-335* seed site identified within the 
CETN3 3’UTR de novo AGO cluster mediated miR-335*-dependent 
transcript repression, full length WT CETN3 3’UTR was cloned into a dual 
luciferase reporter construct (psiCheck2). A mutant construct was made 
altering the miR-335* seed site at two positions, from TGAAAA to 









FIGURE 4.11: Differential AGO binding identifies CETN3 as a miR-
335* target. A: Binding map of AGO:mRNA unique tags (top panel) and 
normalized reads (bottom panel) from LM2 Control (light blue) and LM2 
335OE cells (dark blue) showing increased binding in a discrete site on the 
3’UTR of CETN3 in LM2 335OE. B: The footprint of the differential AGO 















FIGURE 4.12: CETN3 mRNA level is repressed by miR-335*. A: 
CETN3 mRNA levels are significantly higher in 4175 LM2 cells (miR-
335/* negative) than in MDA-231 cells (miR-335/* positive). CETN3 
mRNA levels return the baseline level seen in MDA-231 cells in LM2 
335OE cells. B: CETN3 mRNA level is negatively regulated by transient 
transfection of 50nM miR-335* mimic into 4175LM2 cells, but not miR-
335 mimic. Mock is transfection reagent alone, negative control miRNA 
mimic is non-targeting in human. n=3 cell line, n=4 transfection Q-PCR, 
expression levels normalized to TBP, error bars = s.e.m, p-values 






carried out in the presence of either negative control miRNA mimic or 
miR-335* mimic. WT CETN3 3’UTR luciferase reporter activity was 
significantly inhibited in the presence of miR-335* mimic (p=4.6e-5), while 
the mutant CETN3 3’UTR was unaffected (Figure 4.13A). This miR-335* 
seed-dependent regulation of the CETN3 3’UTR was verified in an 
independent cell line (HEK 293T, Figure 4.13B). 
 
 The ability of endogenous miR-335* to repress the CETN3 3’UTR 
was assayed in MDA-231 cells. Initial transfections of 50ng WT and 
mutant CETN3 3’UTR reporter constructs into MDA-231 and 4175LM2 
indicated increased basal reporter activity of WT CETN3 3’UTR in 
4175LM2 compared to the MDA-231 parental line, however transfections 
with the mutant construct failed to reveal derepression in MDA-231 (data 
not shown). In attempt to introduce reporter construct at more 
stoichiometric concentrations, 5ng of plasmid was transfected into cells 
with high replicate numbers (n=10). Expression of WT CETN3 was 
significantly repressed when compared to mutant CETN3 3’UTR in MDA-
231 cells where miR-335* is expressed. No significant difference between 
WT and mutant reporter activity was seen in 4175LM2 cells where miR-
335* expression is extremely low (Figure 4.14). 
 
 To investigate whether upregulation of CETN3 in miR-335* 
expressing cells could enhance or restore invasive capability, stable MDA-












FIGURE 4.13: miR-335* represses the 3’UTR of CETN3. 3’UTR reporter 
assays were carried out in 4175LM2 cells (A) and verified in HEK-293T 
(B). 50ng of dual luciferase reporter constructs encoding the full length 
WT or mutant CETN3 3’UTR, or empty vector (psiCheck2) were 
transfected in the cell line indicated either alone, or with 50nM miRNA 
mimic as indicated. Luciferase activity was assayed 30h after 
transfection and values normalized to WT CETN3 transfected with 
negative mimic. Co-transfection of miR-335* mimic leads to significant 
repression of the luciferase activity of WT CETN3 3’UTR, which is 
abrogated by mutating the miR-335* seed site identified in the 
differentially bound AGO-footprint. n=4, error bars = s.e.m, p-values 














FIGURE 4.14: Endogenous miR-335* represses the CETN3 3’UTR. 
Mutation of the miR-335* seed site bound by AGO in CETN3 3’UTR leads 
to derepression of reporter constructs in MDA-231 cells where miR-335* is 
expressed but not in 4175LM2 cells. Cells were transfected with 5ng of 
psiCheck2 empty vector, full length WT CETN3 or MUT CENT3 3’UTR 
and assayed for luciferase activity at 30h. Values are shown normalized to 






CETN3 cDNA. Overexpression was validated by Q-PCR (Figure 4.15A) 
and the effect of increased CETN3 expression on invasiveness assayed by 
matrigel invasion. CETN3 overexpression in LM2 335OE cells had no 
effect on invasion compared to empty vector control cells. Overexpression 
of CETN3 in MDA-231 lead to a significant increase in invasion (p=0.0106) 
compared to MDA-231 uninfected controls (n=4, shown in Figure 4.15B), 
however this result failed to repeat in independent experiments, therefore 
the role of CETN3 in tumor cell invasion is currently undetermined. 
 
Clinical association of CETN3 and metastasis free survival 
 Given that low miR-335 expression is negatively correlated with 
metastasis free survival in breast cancer patients (Tavazoie et al., 2008), it 
would be anticipated that high levels of miR-335/*- regulated targets 
would negatively correlate with prognosis. To determine the relationship 
between CETN3 expression levels and human breast cancer metastasis 
two data sets were probed. The first, “Kaplan-Meier Plotter” 
(www.kmplot.com, 2012 release, (Gyorffy et al., 2010)) uses a background 
database of publicly available primary breast cancer GEO expression data 
and survival information (n=2,978). In this data set, high levels of CETN3 
were significantly correlated with poor metastasis-free survival (Figure 
4.16A, p=0.00018 using default settings). However, using a second data set 
derived from patients after taxane-anthacycline chemotherapy treatment 
(Hatzis et al., 2011) that is not included in the Kaplan-Meier Plotter data 
set showed an opposite correlation, with high levels of CETN3 predictive 




FIGURE 4.15: Investigating the role of CETN3 in invasion. Stable 
CETN3 overexpressing MDA-231 and LM2 335OE cell lines were 
generated via viral transduction with CETN3 cDNA. Empty pBabe-Puro 
vector was used as a control. A: Over expression of CETN3 was assayed 
by Q-PCR with RNA independently prepared from triplicate samples, as 
in Figure 4.12. B: Trans-well invasiveness of CETN3 OE cell lines was 
assessed by comparison to empty vector transduced cells and non-infected 
cells. Cells that had invaded through the matrigel inserts were counted 
24h post seeding. Each cell line was tested in quadruplicate with cell 
triplicated cell counts taken per insert. No effect of CETN3 overexpression 
on invasion was seen in LM2 335OE cells, while over expression of CETN3 
in MDA-231 cells lead to a significantly enhanced invasion (t-test) 
compared to MDA-231 uninfected controls but not to MDA-231 empty-

















FIGURE 4.16: Clinical association of CETN3 expression level and 
metastasis-free survival. A: High levels of CETN3 correlate with shorter 
metastasis-free survival in breast cancer patients included in the Kaplan-
Meier Plotter database (N=2978). CETN3 (209662_at) expression level 
classified based on median probe intensity with all settings at default. B: 
Low levels of CETN3 correlate with shorter metastasis-free survival in a 




the survdiff function in R by Hani Goodarzi, Tavazoie Lab). Whether this 
difference is attributable to chemotherapy treatment, and how CETN3 
expression correlates with miR-335/* levels in these patient cohorts is 
unknown. 
 
Further validation of predicted miR-335/* targets identified by AGO-HITS CLIP 
 SEL1L (miR-335 and -335* seed), FAM105B (miR-335*) and SMAD5 
(miR-335*) steady state transcript levels were assayed by Q-PCR in MDA-
231, 4175 LM2 and LM2 335OE. These genes have significant enrichment 
in a miR-335/* seed containing AGO binding site in LM2 335OE cells 
(Figure 4.17A, log2 FC≥1, p<0.01) and a predicted decrease in transcript 
level by RNAseq, although predicted expression level changes were small 
(Table 4.5). All three transcripts had increased steady state levels in 
4175LM2 cells compared to pre-miR-335 expressing MDA-231, although 
this increase failed to reach significance for FAM105B. Transcript levels 
failed to show statistically significant repression in LM2 335OE cells when 
compared to 4175LM2 (Figure 4.17B).  
 
Transient transfection of relevant miR-335/* mimics in LM2 cells 
also failed to repress these endogenous transcripts when compared to 
mock transfection controls (Figure 4.17C). Up regulation of both SEL1L 
and FAM105B was seen upon transfection with negative control mimic, 
which for FAM105B was significantly reversed by either miR-335 or miR-
335* mimic transfection.  This indicates both the potential for target-
dependent general derepression of transcripts as a result of off-target  
 
 
Figure 4.17: Steady state mRNA levels of predicted miR-335/* targets 
show weak or no regulation by endogenous or exogenous miR-335/*.  
A: Extensive AGO binding is seen in the 3’UTRs of SEL1L, FAM105B and 
SMAD5 in both LM2 Control and LM2 335OE (normalized AGO binding). 
The pre-miR335 seen containing de novo AGO binding site is highlighted. 
B: Steady state levels of miR-335/* bound transcripts in MDA-231 (pre-
miR-335 positive), 4175LM2 (pre-miR-335 negative) and LM2 335OE 
consistently show up regulation in 4175LM2 that is not reduced to MDA-
231 levels in LM2 335OE. C: Transient transfection of 50nM miRNA 
mimics in LM2 cells fails to repress endogenous predicted target mRNAs 
when compared to mock transfection. For SEL1L and FAM105B, negative 
control mimic leads to target up-regulation, possibly though competition 
for AGO. The non-specific up regulation of FAM105B is reduced by miR-
335 or miR335* mimic transfection, however miR-335 is not predicted to 
target FAM105 by HITS-CLIP. n=3 cell line, n=4 mimic transfection, 
expression levels normalized to TBP, error bars = s.e.m, p-values 




effects of exogenous miRNA mimic transfection (Khan et al., 2009), and 
the potential for false positive result from reporter assays. FAM105B 
contains multiple miR-335 seed sequences within its 3’UTR that show no 
evidence of direct AGO binding by HITS-CLIP, suggesting that the miR-
335 repressive effect is an artifact. As can be seen in Figure 4.17A, the de 
novo pre-miR-335 dependent AGO binding sties in these 3’UTRs are a 
relatively minor component of the total AGO-mRNA binding profile. The 
majority of AGO binding is common between LM2 Control and 335OE, 
suggesting that any additional anticipated negative regulation exerted by 
de novo miR-335/* binding sites in these transcripts is negligible or below 
the level detection by our assays in the background of high levels of 
shared repressive binding. Alternatively, these binding events may reflect 
a degree of bioinformatically-generated noise due to the low tag numbers 
associated with de novo miR-335/*-dependent AGO binding sites. Whether 
miR-335* can regulate SEL1L, FAM105B and SMAD5 protein level is yet to 
be determined. 
 
miR-335/* regulation associated with de novo pri-miR-335 AGO 
binding is detectable in other transcripts that have a shared background of 
AGO binding. For example, enriched de novo AGO binding in twisted 
gastrulation homolog 1, TWSG1 (Log2 FC CLIP cluster=1.97, p-
value=0.016), centered on a miR-335 seed with extensive additional 
complementarity (Figure 4.18A) correlates with steady state expression 
level changes with respect to endogenous or exogenous miR-335 (Figure 
4.18B). This relatively small yet significant repression of the TWSG1  
 
 
FIGURE 4.18: Differential AGO binding identifies TWSG1 as a miR-
335 target. A: The de novo AGO binding site identified on the 3’UTR of 
TWSG1 contains including a miR-335 seed match in position 2-9. The 
miR-335 seed conservation is restricted to primates. A background of 
multiple common AGO binding sites is seen in other regions of the 
TWSG1 3’UTR. B: TWSG1 mRNA levels track with endogenous pre-
miR-335 in MDA-231, 4175LM2 and are reduced to MDA-231 levels in 
LM2 335OE cells. TWSG1 mRNA is downregulated by transient 
transfection of miR-335 mimic into 4175LM2 cells. Mock is transfection 
reagent alone, negative control miRNA mimic is non-targeting in 
human. n=3 cell line, n=4 mimic transfection, expression levels 




mRNA failed to translate into reduced luciferase activity in TWSG1 3’UTR 
reporter assays with exogenous miR-335 mimic transfection (data not 
shown).  
 
Relaxing the criteria for cluster selection identified a further two 
miR-335 and miR-335* targets regulated at the protein level. SDAD1 
contains an AGO peak with log2 FC CLIP cluster binding of 2.84 (10 tags 
LM2 335OE, 2 tags LM2 Control, p-value=0.006) with complementarity to 
miR-335* in positions 2-7 with an additional G:U wobble at position 8. 
Luciferase reporter assays with WT full length SDAD1 3’UTR revealed 
exogenous mir-335* mimic repression of luciferase activity (Figure 4.19A) 
that was reproducible in replicate experiments. Similar results were seen 
with CDH11, a transcript with de novo AGO binding on a miR-335 seed 
(log2 FC CLIP cluster=3,32, p-value=0.010) and whose 3’UTR is regulated 
at the translational level by miR-335 mimic in luciferase reporter assays 
(Figure 4.18B). Both SDAD1 and CDH11 were unchanged at the mRNA 
level with miR-335/* mimic transfection when compared to mock control 
(data not shown) indicating that a portion of the de novo miR-335/* 
regulation identified by AGO HITS-CLIP may lead to translational 
repression of targets rather than transcript degradation. 
 
Comparison of AGO HITS-CLIP derived de novo clusters miR-335/* targets and 
previously published targets 
 Literature search identified multiple reported miR-335 targets in a 
variety of different cell types, including the LM2 335OE cells used in this  
 
 
FIGURE 4.19: SDAD1 and CDH11 are regulated at the protein level by 
miR-335* and miR-335. A: Left - Genomic location of the pre-miR-335 
dependent de novo AGO-mRNA binding site in the SDAD1 3’UTR, 
centered on a miR-335* seed site (2-7 match with G:U wobble in position 
8). Right - Repression of luciferase reporter activity of WT full length 
SDAD1 3’UTR dual luciferase reporter construct when transfected into 
LM2 cells with 50nM miR-335* mimic, but not negative control mimic. B: 
As in A for miR-335 target CDH11. The reduction in luciferase activity for 
both 3’UTR constructs was observed in two independent experiments. All 
transfections n=4, mRNA expression levels normalized to TBP. Error bars 




study (Table 4.6 with associated references). Of the previously published 
targets of miR-335, only DKK1 was identified by AGO HITS-CLIP as 
having gain of binding in LM2 335OE, although the miR-335/* seed 
sequence containing peaks identified here do not map to the non-
conserved, non-canonical miR-335 seed site previously described (Zhang 
et al., 2011). Two miR-335/* dependent, LM2 335OE enriched AGO 
binding sites were identified in the 3’UTR of DKK1 by differential AGO 
HITS-CLIP (Figure 4.20A (raw tags) and B (normalized)). Significantly, the 
miR-335/* seed containing de novo binding events identified in LM2 
335OE are also present in MDA-231 cells where miR-335/* is 
endogenously expressed.  
 
 Surprisingly, Q-PCR analysis of DKK1 steady state transcript levels 
revealed a strong decrease in 4175LM2 cells compared to MDA-231 
parental cells that was not further decreased with the stable expression of 
pre-miR-335 in LM2 335OE cells (Figure 4.21A). Additionally, DKK1 
mRNA levels were unchanged by the addition of exogenous miR-335/* 
mimics in 4175LM2 cells (Figures 4.21B& 4.21C). Similarly, full-length WT 
DKK1 3’UTR luciferase reporter constructs were unaffected by exogenous 
miR-335/* transfection in either MDA-231 or 4175LM2 cells (data not 
shown). It remains to be tested whether relieving miR-335/* binding of 
DKK1 by LNA inhibition of miR-335/* or target protection of the miR-
335/*-dependent AGO-mRNA binding sites leads to derepression of the 










TABLE 4.6: Previously published miR-335 target sites compared to LM2 



















MDA-231 SOX4 None (Tavazoie et al., 2008) 
 PTPRN2 None  
 MERTK None  
U2OS Rb Weak, no differential binding (Scarola et al., 2010) 
MLO-A5 DKK1 miR-335 site not conserved in human (Zhang et al., 2011)  
  
Strong evidence of differential binding 
elsewhere on transcript  
hMSCs RUNX2 None (Tome et al., 2011) 
Rat Kidney SOD2 None, site not conserved (Bai et al., 2011) 
Malignant 
Astrocytoma DAAM1 None (Shu et al., 2011) 
Human 
neuroblastoma ROCK1 None 
(Lynch et al., 
2012) 
 MAPK1 None  
 LRG1 None  
mESCs OCT4 None (Schoeftner et al., 2012) 
 Rb Weak, no differential binding  
Gastric Cancer SP1 None (Xu et al., 2012) 
 Bcl-w None  
    









FIGURE 4.20: The DKK1 3’UTR shows evidence of two miR-335/* 
dependent binding events. A: Two peaks of differential AGO binding in 
the 3’UTR were detected by both differential cluster (1&2) and significant 
peak analysis (1) between LM2 Control and LM2 335OE cells. Both miR-
335/* dependent peaks are evident in MDA-231 parental cells (red) that 
endogenously express pri-miR-335. B: Normalized AGO binding peaks 
(left) reveal strong depletion of binding in two regions of the DKK1 3’UTR 










FIGURE 4.21: Endogenous DKK1 transcript levels are strongly 
repressed in LM2 cells compared to MDA-231 and show no further 
repression by exogenous miR-335/*. A: Q-PCR analysis revealed a 
significant decrease in the steady state levels of endogenous DKK1 in 
4175LM2 cells compared to MDA-231 that was not further decreased in 
LM2 335OE. B: Transient transfection of miR-335 mimic had no effect on 
DKK1 levels in 4175LM2 cells. C: Transient transfection of miR-335* mimic 
had no effect on DKK1 transcript levels compared to mock transfected 
4175LM2 cells. N=3 for each condition, mock transfections carried out 






 Multiple potential seed matches are present in the 62nt footprint of 
AGO on DKK1 in the region of significant peaks 1 and 2 (Figure 4.20B, 
right panel), however the majority of seed-matched miRNAs are either not 
present in the AGO-miRNA LM2 libraries, or are present at levels lower 
that than miR-335 and miR-335*. In peak 2, no other miRNA with a seed 
match is present at higher levels than miR-335, while peak 1 contains seed 
matches to both miR-335* and the miR-374a/b family. miR-374a/b 
represents  2.40% of the LM2 Control miRNA profile and 3.24% of LM2 
335OE, however this increase was not found to be significant by EdgeR 
analysis. Additionally, miR-374a/b is not significantly different between 
the MDA-231 and 4175LM2 AGO-miRNA profiles. This strongly suggests 
that the de novo binding identified by differential HITS-CLIP represents 
direct miR-335/* mediated AGO binding in the 3’UTR of DKK1, however 
the biological consequence of de novo miR-335/*-mediated AGO binding 






In an attempt to map on a genome-wide scale the targets of miR-
335, a potent inhibitor of breast cancer metastasis, we have applied 
differential AGO HITS-CLIP to a previously characterized lung metastatic 
derivative of MDA-231 breast cancer cells, 4175LM2, over-expressing 
either a non-targeting control short hairpin or the pri-miR-335. 
Overexpression of miR-335 in 4175LM2 cells significantly reduces the 
invasive capability of these cells both in vitro and in vivo (Tavazoie et al., 
2008). Comparative analysis of the AGO-miRNA HITS-CLIP profiles of 
LM2 335OE and LM2 Control indicates that pri-miR-335 overexpression 
does not globally alter the miRNA repertoire covalently bound to AGO in 
LM2 cells. Furthermore, despite over 100-fold increase in expression 
levels, we have found that miR-335 and miR-335* remain relatively minor 
components of the AGO-miRNA landscape.  
 
In LM2 335OE, miR-335* represents 0.42% of the miRNA 
population and is the 21st most sequenced miRNA, with those miRNAs 
ranked above representing 92.9% of all AGO-miRNAs. This would 
suggest that despite using a strong promoter, pri-miR-335 is not expressed 
at supra-physiological levels, mitigating the effect of potential off-target 
effects through AGO saturation (Khan et al., 2009). Several rare miRNAs 
decrease in AGO-miRNA tag count in LM2 335OE indicating that some 
displacement of endogenous miRNA may occur with miR-335 
overexpression. The relatively small shift in miR-335/* AGO-miRNA 
representation with stable overexpression of pri-miR-335 is in sharp 
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contrast to published data using transient transfection of miR-124 mimic 
into HeLa cells. In that system miR-124 becomes the 3rd most frequently 
cloned miRNA in transfected HeLa cells, a shift in the percentage of AGO 
HITS-CLIP miRNA reads from 0.15% to 8.4%, with the top two miRNAs 
comprising approximately ~32% of cloned AGO-miRNA (Chi et al., 2009).  
 
The AGO-miRNA profile derived from LM2 335OE cells revealed 
an unexpected bias towards binding to the star, and presumed passenger 
strand of pre-miR-335. By convention mature miRNAs have been defined 
as the duplex strand that accumulates at a higher steady-state level than 
the partner strand, with bias observed towards strands with lower 
internal stability at the 5’ end (Khvorova et al., 2003). Consistent with both 
these observations miR-335* contains a 5nt stretch of A-T base pairs at its 
5’ end compared to the more G-C rich 5’ end of miR-335, and is 
consistently detected at ~2-3 fold higher levels in MDA-231 and all LM2 
cells used in this study. Additionally, miR-335* is highly conserved, 
particularly in the region spanning the seed sequence, a feature which 
implies potential for regulatory function (Guo and Lu, 2010, Yang et al., 
2011).  
 
Microarrays used in the initial discovery of the anti-metastatic 
property of miR-335 did not contain probes for miR-335* as the sequence 
was not added to miRBase until a later date. It is clear from in vivo 
metastasis assays with LNA knockdown in MDA-231 cells, that miR-335 
functions a mature targeting miRNA with anti-metastatic properties 
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separate from any potential concurrent miR-335* regulation of targets 
(Tavazoie et al., 2008). Both miR-335 and miR-335* have been shown to 
have equally repressive effects against perfect-match antisense luciferase 
reporter assays when simultaneously expressed from the pri-miRNA 
(Yang et al., 2011). Similar dual regulation of targets has been described 
for miR-199a-3p/-5p in the promotion of melanoma metastasis (Pencheva 
et al., 2012), miR-126/* in inhibition of breast cancer metastasis through 
modulation of the tumor microenvironment (Zhang et al., 2013), and miR-
24-2/* in suppression of cell survival in MCF-7 breast cancer cells (Martin 
et al., 2012). Given the predominance of miR-335* de novo peaks identified 
by differential AGO HITS-CLIP cluster analysis in LM2 335OE cells, it is 
probable that miR-335* also regulates the metastatic ability of these cells. 
 
13.4% of the pri-miR-335 dependent de novo AGO clusters identified 
contain a miR-335 or miR-335* 6nt seed sequence corresponding to 
position 1-8 located within the 62nt AGO footprint. This is lower than the 
proportion of de novo miR-124 canonical 6mer seed-containing sites 
detected in HeLa cells after mimic transfection (22.4% (Chi et al., 2009, Chi 
et al., 2012)), and miR-155-dependent AGO binding sites identified by 
differential AGO HITS-CLIP in WT and miR-155 knockout activated 
CD4+ T cells, (~57% (Loeb et al., 2012)). Positive correlation between the 
fraction of the AGO HITS-CLIP derived miRNA profile and the number of 
seed containing mRNA binding sites has been reported in multiple 
settings, including mouse brain, embryonic stem cells and CD4+ T cells, 
C.elegans and several cell lines (Chi et al., 2009, Hafner et al., 2010, Leung 
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et al., 2011, Loeb et al., 2012, Zisoulis et al., 2010). miR-155 and exogenous 
miR-124 mimic each represent a major component of the AGO-miRNA 
profile in their respective data sets, accounting for the high signal to noise 
in identification of directly targeted de novo binding sites.  
 
The total number of miR-335/* targets identified by AGO HITS-
CLIP in LM2 335OE, including the potential non-canonical bulged and 
G:U wobbles, is less than that reported for the most abundant miRNAs in 
previous AGO HITS-CLIP experiments (>300 miR-155 (Loeb et al., 2012), 
691 miR-126 (Chi et al., 2009, Chi et al., 2012)). However, the number of 
miR-335/*-dependent seed containing AGO binding sites are similar in 
magnitude to the number of targets identified for less abundant miRNAs 
in mouse embryonic stem cells (Leung et al., 2011). The relatively minor 
combined contribution that AGO-miR-335/* make to the overall LM2 
335OE miRNA profile is reflected in the low total tag numbers in AGO 
clusters delimiting functional binding sites. This represents an 
unanticipated limitation of the AGO HITS-CLIP technique in identifying 
statistically significant and robust miR-335/* mediated binding sites this 
cellular context.  
 
Despite low signal to noise, we have used differential AGO HITS-
CLIP to successfully identify several previously unknown, direct targets 
of miR-335/* regulation. De novo cluster analysis identified CETN3 as a 
direct target of miR-335*, an interaction that was found to decrease both 
the mRNA levels of endogenous CETN3 and protein levels of reporter 
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constructs in miR-335* seed-dependent manner. Human CETN3 has 
described roles in centrosome duplication, nucleotide excision repair via 
putative interactions with xeroderma pigmentosum group C (XPC), and 
in the connecting cilium of photoreceptor cells (Cox et al., 2005, Dantas et 
al., 2011, Middendorp et al., 1997, Trojan et al., 2008). Human CETN3 is 
closely related to the Saccharomyces cerevisiae Cdc31 protein, which along 
with roles in cell cycle control and spindle body duplication (Paoletti et 
al., 2003, Schild et al., 1981), has been implicated in both protein 
degradation (Chen and Madura, 2008) and maintenance of genome 
integrity as part of the THP1-SAC3- SUS1-CDC31 complex coupling 
transcription and mRNA export (Gonzalez-Aguilera et al., 2008, Jani et al., 
2009).  
 
While the previously described cellular functions of human CETN3 
do not mirror those of miR-335/* loss in metastasis (altered morphology 
and increased invasive capacity (Tavazoie et al., 2008)), other miR-335/* 
targets identified and verified in this study have been implicated in the 
regulation of breast morphology or enhanced invasiveness of tumor cells. 
For example, TWSG1, a secreted protein that functions as a BMP4 agonist 
in Drosophila and vertebrate embryos (Scott et al., 2001), is required for 
normal mammary gland ductal elongation and lumen formation (Forsman 
et al., 2013). Additionally, CDH11 (OB cadherin), a mesodermally 
expressed member of the cadherin superfamily (Hoffmann and Balling, 
1995), is expressed in invasive breast cancer and positively regulates cell 
migration (Li et al., 2011c, Pishvaian et al., 1999, Sarrio et al., 2008).  
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We did not direct AGO-mRNA binding in the seed regions of any 
previously published miR-335 targets. SOX4, a previously validated miR-
335 target in MDA-231 cells (Tavazoie et al., 2008), was not bound by 
AGO in any of the cell lines assayed by AGO HITS-CLIP in this study. The 
previously published miR-335 targeting of SOX4 was validated using dual 
luciferase reporter constructs encoding a 60nt region of the SOX4 3’UTR 
spanning a region of complementarity to miR-335 (TCTTGG, 
corresponding to a position 2-6 seed match with G-U wobble at position 
1). Given the lack of biochemical evidence of AGO binding in the SOX4 
3’UTR, the miR-335-dependent regulation of luciferase activity reported 
may reflect off-target effects rather than endogenous regulation in the 
context of the full length 3’UTR. Similar off target effects were seen with 
3’UTR reporter assays using FAM105B, where both miR-335 and miR-335* 
mimics were able to repress luciferase activity due to the presence of seed 
matches in the 3’UTR, despite only miR-335* seed containing regions 
showing differential AGO binding in LM2 335OE. However, it is noted 
that lack of binding at the SOX4 3’UTR seen in AGO HITS-CLIP may also 
result from binding occurring below the threshold of detection of HITS-
CLIP for a minor miRNA, and that the lack of binding at other previously 
validated miR-335 target sites may also reflect false negatives. 
 
The apparent lack of miR-335 or miR-335* mediated regulation of 
DKK1 is difficult to reconcile with the robust, pre-miR-335 dependent 
binding seen on the DKK1 3’UTR. No other miRNAs with canonical seed 
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matches in the 62nt AGO footprint are expressed at higher levels than 
miR-335/*in either MDA-231, LM2 Control or LM2 335OE cells nor do 
they show significant differences in AGO-miRNA counts that correlate 
with the gain and loss of AGO-mRNA binding observed between cell 
lines. The regulation by miR-335/* may be below the threshold of 
detection by the assays used in this study, or the 3’UTR of DKK1 may 
potentially function as a neutral target with respect to miR-335/* 
regulation. AGO binding to the DKK1 3’UTR may sequestering miR-335/* 
in MDA-231 and LM2 335OE allowing it to function as a competitive 
endogenous RNA by (Salmena et al., 2011, Seitz, 2009). Interestingly, 
competitive, DICER-dependent antagonistic regulation has been 
documented between the DKK1 and PTEN 3’UTRs in diabetic 
cardiomyocytes through sequestration of miR-93 and miR-106a (Ling et 
al., 2013). 
 
The ability of endogenous non-coding transcripts and coding 
mRNA 3’UTRs to influence tumorigenesis, presumably through titration 
of miRNAs or other regulatory RNA binding proteins, is being 
increasingly recognized. miRNA-mediated regulation of the tumor 
suppressor PTEN can be modulated by the expression of the pseudogene 
PTENP1 (Poliseno et al., 2010) or concomitant expression protein-coding 
transcripts targeted by common miRNAs in a DICER dependent manner 
(Tay et al., 2011). Similarly the 3’UTRs of versican (Fang et al., 2013a), 
prohibitin (Manjeshwar et al., 2003), &-tropomyosin (Rastinejad et al., 
1993) and CD44 (Rutnam and Yang, 2012) have been shown to regulate 
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tumorigenesis and metastasis in various cancer types, separating the 
regulatory function of non-coding regions of transcripts from any protein-
mediated effect.  
 
Loeb et al. (2012) have suggested that the relatively few highly 
bound targets of miR-155 identified by AGO HITS-CLIP would argue 
against the endogenous miRNA sponge hypothesis, as very few 
transcripts appear to bind the miRNA-AGO complex at high enough 
levels to lead to sequestration. However, given that the threshold of 
regulation by miRNAs has been shown to be determined by both the level 
of target and miRNA (Mukherji et al., 2011), regulation by a low 
abundance miRNA such as miR-335/* may be more sensitive to 
endogenous sponges.  The decrease in the steady state levels of DKK1 
mRNA in lung metastatic derivatives occurs concomitantly with copy 
number loss in the miR-335 locus, increased MEST promoter methylation 
in LM2 cells and increased invasive capacity (Png et al., 2011). If DKK1 
3’UTR functions as a sponge for miR-335/*, overexpression of this region 
of the DKK1 transcript should enhance the invasive capacity of both 
MDA-231 and LM2 335OE through sequestration of miR-335/* away from 
its endogenous targets, while mutant constructs with disrupted seed sites 
should have no effect on invasion.  
 
An increasing body of work implicates altered miR-335 expression 
in multiple tumor types, with low miR-335 levels detected in breast, 
ovarian, neuroblastoma, and gastric cancer (Png et al., 2011, Polytarchou 
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et al., 2012, Sorrentino et al., 2008, Tavazoie et al., 2008, Lynch et al., 2012, 
Xu et al., 2012), and miR-335 up regulation reported in malignant 
astrocytoma and meningioma (Shi et al., 2012, Shu et al., 2011). While 
experimental validation of the role of miR-335* in in vivo metastasis is 
currently on going, our discovery that miR-335* can function as a guide 
strand opens up new directions in the search for regulated downstream 
transcripts and for potential for therapeutic intervention in multiple 
cancer settings. The data we have presented provides a first look at the 
network of transcripts regulated by both miR-335 and miR-335* in breast 
cancer, and provides direct biochemical evidence of multiple new targets 





CHAPTER 5: CHARACTERIZATION OF RBM47, AN RNA-BINDING 
SUPPRESSOR OF BREAST CANCER METASTASIS 
 
INTRODUCTION 
High-throughput crosslinked immunoprecipitation (HITS-CLIP) 
was initially developed to identify in vivo directly bound targets of the 
neuron-specific alternative splicing regulator Nova (Ule et al., 2003, Ule et 
al., 2005b, Licatalosi et al., 2008). Since UV-irradiation leads to covalent 
bond formation only between proteins and RNA that are in direct contact 
(within Angstroms (Darnell, 2010)), the resulting sequence data can be 
used to determine both the target RNAs bound by an RNA binding 
protein (RBP) and the specific region within the transcript that is bound. 
Furthermore, HITS-CLIP data can be used to validate the sequence 
specificity of the protein in question with single-nucleotide resolution 
(Hafner et al., 2010, Zhang and Darnell, 2011). The HITS-CLIP technique 
has now been applied to multiple RBPs, particularly those involved in 
neurological diseases, to identify both bona fide disease-related sets of 
RNA targets and to elucidate normal biological functions.  
 
The genome-wide nature of the data derived from HITS-CLIP has 
lead to discovery of new regulatory functions for previously well-
characterized proteins indicating that the technique can also be use 
prospectively. For example, Nova HITS-CLIP has greatly expanded the 
repertoire of Nova-regulated alternative splicing events to >600 (Zhang et 
al., 2010a), and lead to the identification of a previously unknown role for 
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Nova in the regulation of alternative polyadenylation (Licatalosi et al., 
2008) and steady-state target expression levels through direct regulation of 
NMD exons (Eom et al., 2013). Additionally, CLIP has revealed 
unexpected roles in miRNA maturation for hnRNP-A1. This extensively 
studied RNA splicing regulatory protein was found to directly bind the 
stem-loop sequences in pri-miR-18a to facilitate Drosha-mediated 
processing (Guil and Caceres, 2007, Michlewski et al., 2010) 
 
In this study, we propose using HITS-CLIP to identify the targets 
and elucidate the biological function of a previously uncharacterized, 
presumed RNA binding protein with direct links to breast cancer 
metastasis. RNA binding motif protein 47 (RBM47) is so named due to the 
predicted presence of three RNA recognition motifs (RRM domains). The 
combination of one or more RRM domains allows for recognition of single 
stranded RNA sequences of 8-10 nucleotides, although RRM domains also 
been demonstrated to mediate protein-protein interactions (Maris et al., 
2005). The previously mentioned ELAVL proteins all contain three RRM 
domains. Increased expression of the ubiquitously expressed ELAVL 
family member ELAVL1 (HuR) has been shown to promote a more 
tumorigenic phenotype in xenograft models of breast cancer (Mazan-
Mamczarz et al., 2008a), and has been associated with poor prognosis in 
multiple cancers, including invasive ductal breast carcinoma (Denkert et 
al., 2004, Heinonen et al., 2005). 
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RBM47 was first identified by Ding et al, 2010 as a gene of interest 
in the metastatic progression of breast cancer. Deep sequencing of 
genomic DNA derived from a patient’s primary basal-like aggressive 
tumor and subsequent cerebellar metastases revealed a point mutation in 
the coding sequence of RBM47 that was highly enriched in brain 
metastases (79.15% mutant allele frequency, FDR=0.03). This point 
mutation leads to a G-deletion at nucleotide position 1280, a frame shift 
and the introduction of a premature stop codon (Ding et al., 2010) 
suggesting that loss of wild type function of RBM47 (or gain of function in 
the mutant allele) was selected for during metastasis to the brain. 
Additionally, RBM47 expression levels have been shown to decrease over 
ten-fold during the epithelial-mesenchymal transition (EMT) of human 
mammary epithelial cells expressing a tamoxifen-inducible Twist-ER 
fusion protein (Shapiro et al., 2011). 
 
RBM47 is currently an uncharacterized protein; therefore we 
propose using HITS-CLIP to determine its RNA binding abilities. 
Furthermore, by mapping robust RBM47 interactions on target RNAs we 
aim to identify both the functional of RBM47 in RNA metabolism and to 





RBM47 expression is decreased in the metastatic derivatives of MDA-231 
Re-analysis of published microarray data from MDA-231 and its 
metastatic derivatives with tissue-specific metastasis to lung (4175LM2), 
bone (1833BoM2) and brain (831BrM2) revealed down regulation of 
RBM47 in all metastatic sub lines (data not shown) (Bos et al., 2009, Kang 
et al., 2003, Minn et al., 2005a). In particular, RBM47 expression is 
dramatically decreased in 831BrM2 (Figure 5.1A), with corresponding 
decrease in protein expression as assayed by Western blot (Figure 5.1B). 
RBM47 protein levels were also lower in lung and bone metastatic 
derivatives when compared to the parental MDA-231 cell lines suggesting 
that downregulation of RBM47 is a common feature associated with 
increased metastatic potential. Data analysis and Western carried out by 
Sakari Vanharanta, Joan Massagué laboratory, MSKCC.  
 
Wild-type RBM47 functions as a metastasis suppressor  
Doxycycline-inducible 831BrM2 triple reporter stable cell lines were 
generated that express either wild type FLAG-tagged RBM47 (Tet-On 
Flag-RBM47 WT) or a mutant RBM47 harboring the same frame shift 
mutation identified by Ding et al., 2010 (Tet-On Flag-RBM47 MUT). Mice 
were injected in the left ventricle with of 50,000 Tet-On Flag-RBM47 WT or 
MUT cells, and fed a diet containing doxycycline (dox) starting three days 
after injection. Metastatic spread to the brain was assayed by ex vivo 
photon flux six weeks post injection. In control animals that were injected 





FIGURE 5.1: RBM47 expression is decreased in the highly metastatic 
derivatives the breast cancer cell line MDA-MB-231. A: Q-PCR showing 
decreased RBM47 transcript levels in 831BrM2 cells compared to MDA-
231. Expression level normalized to TATA box binding protein (TBP). n=3, 
error bars = s.e.m, p-values calculated by t-test. B: Western-blotting 
reveals decreased RBM47 protein levels in the highly metastatic 
derivatives of MDA-MB-231 with tissue specificity towards the lung 
(4175LM2), bone (1833BoM1) and brain (831BrM2). Loading control 





degree of brain metastasis was evident that was suppressed by dox-
induced expression of WT RBM47 (Figure 5.2A and 5.2B). Expression of 
Mutant RBM47 had no effect on the metastatic potential of 831BrM2 cells 
(Figure 5.2B). RBM47 expression levels were found also to be clinically 
associated with human metastasis, with patients whose primary tumors 
expressed low levels of RBM47 having significantly shorter time to distal 
metastatic relapse to both brain (p=0.0025) and lung (p=0.0023, Figure 
5.2C). All experiments and data analysis carried out by Sakari Vanharanta, 
Joan Massagué laboratory, MSKCC. 
 
 
Domain architecture of RBM47 
The RBM47 gene is located on the negative strand of chromosome 4 
at position 40,120,029-40,326,640. Refseq indicates two alternatively 
spliced transcripts that are translated into 593 and 524 amino acid proteins 
respectively (Figure 5.3A). Conserved domain analysis shows the 
presence of three RNA recognition motif (RRM) domains in both RBM47 
isoforms, with a variable region occurring between amino acids 374 and 
414, C-terminal to the RNA binding motifs that corresponds to the 
alternatively spliced exon. RRM1 and RRM2 contain RNP-1 consensus 
motifs (RGYSFVMY and RGFAFVEY respectively) while RRM3 contains 
an RNP-2 consensus motif (LYVRNL).  The mutant RBM47 identified in 
patient cerebellar metastases produces a truncated protein containing only 















FIGURE 5.2: RBM47 functions as a metastasis suppressor in vivo, with 
low expression clinically associated with poor metastasis-free survival. 
A: Mice were injected with clonal populations if BrM2 cells stably 
expressing either WT or mutant RBM47 then fed a diet plus/minus 
doxycycline to induce transgene expression. At 6 weeks post injection, 
brains were imaged ex vivo to assess level of metastasis (photon flux). B: 
Dox-induced expression of WT RBM47 in 831BrM2 inhibits metastatic 
colonization of the brain in vivo when compared to non-dox treated 
animals (6 weeks post intercardiac injection). Expression of Mutant 
RBM47 has no effect on the metastasis (n=8). Kaplan-Meier curves for the 
combined Memorial Sloan Kettering and Erasmus Medical Center breast 
tumor cohorts (368 tumors) showing brain (C) and lung (D) metastasis 
free survival of patients whose primary tumors expressed low levels of 
RBM47. All experiments carried out by Sakari Vanharanta, Joan Massagué 




















FIGURE 5.3: RBM47 gene and protein domain organization. A: The 
RBM47 gene encodes two RefSeq annotated isoforms with alternative 
5’UTRs and one alternative coding exon. The longer isoform of RBM47 
was used for all subsequent analyses of RBM47 function. B: Conserved 
domain analysis reveals the presence of three RRM domains (black) in 
both long and short isoforms of RBM47, with a variable region (white) 
corresponding to the alternative exon. Mutant RBM47 produces a 
truncated protein due to a G deletion at position 1280 and subsequent 




Protein BLAST of RBM47 reveals sequence similarities to the known RNA-
binding proteins 
Protein BLAST of RBM47 reveals high sequence identity and 
similarity with both apobec-1 complementation factor (A1CF, 58.5% and 
72.65%, respectively) and hnRNP-Q/SYNCRIP (55.3% and 73%), proteins 
that also contain three RRM domains. Identity and similarity were 
calculated using the EBOSS6.3.1 matcher (Rice et al., 2000). RBM47 
alignments with A1CF and hnRNP-Q (generated by ClustalW2 (Goujon et 
al., 2010)) are shown in Figures 5.4. High sequence identity is evident in 
the N-terminal regions spanning the RRM domains (red dashed line), with 
more sequence divergence at the C-terminal ends.  Both A1CF and 
hnRNP-Q have been shown to directly bind RNA and to regulate RNA 
editing (Mehta et al., 2000, Blanc et al., 2001). Additionally, hnRNP-Q has 
multiple functions in RNA metabolism including RNA localization, 
splicing and stability (Bannai et al., 2004) (Chen et al., 2008) 
(Weidensdorfer et al., 2009). Together this would strongly suggest that the 
RRM domains in RBM47 are capable of binding RNA. 
 
RBM47 is an RNA binding protein 
RBM47 has been identified as a component of the protein-mRNA 
interactome in two independent studies of oligo(dT) affinity purified 
mRNA-RBP complexes in HeLa and HEK293 cells (Baltz et al., 2012, 
Castello et al., 2012) although direct RNA binding activity has not been 
confirmed.  To test whether RBM47 can directly bind RNA, we made use 









FIGURE 5.4: Protein alignment of RBM47 with A1CF and hnRNP-Q. A: 
RBM47 is most similar in amino acid sequence to apobec1 
complementation factor (A1CF). High sequence conservation can be seen 
in the N-terminal regions, particularly those spanning the three RRM 
domains (red dashed line), with more sequences divergence evident in the 
C-terminal domain. B: Alignment of RBM47 to hnRNP-Q shows less 
similarity overall, with the highest degree of sequence conservation in the 
RRM domains. Alignments carried out using ClustalW2 (Goujon et al., 
2010), * fully conserved residue, : conservation across groups with 






between RNA and proteins that are in direct contact (on the order of 
Angstroms apart (Darnell, 2010)).  Commercially available RBM47 
antibodies were unsuitable for immunoprecipitation due cross-reaction 
with multiple proteins, therefore 831BrM2 Tet-On empty vector control 
and 831BrM2 Tet-On Flag-RBM47 WT stable cells lines (generated by 
Sakari Vanharanta in the Massagué laboratory and henceforth referred to 
as Tet-On and RBM47-WT) were grown for 3 days in the presence of 
1ng/ml doxycycline before UV-irradiation and harvesting. Non-
crosslinked RBM47-WT cells grown in the same manner were used as a 
negative control. Lysed cells were RNaseA digested to reduce the modal 
size of any bound RNA to that of the footprint protected by protein 
binding, and stringently immunoprecipitated using an anti-Flag antibody. 
Bound RNA was end-labeled with "-32P-ATP using T4 PNK, protein 
separated by SDS-PAGE and complexes transferred to nitrocellulose.  
 
Exposing the nitrocellulose to x-ray film (Figure 5.5A) revealed 
radioactive signal at the predicted size of RBM47 only lanes 
corresponding to dox-treated, UV-irradiated RBM47-WT cells. The lanes 
for non-irradiated RBM47-WT and the UV- treated Tet-On Control cells 
were clear of radioactivity indicating UV-dependent RNA 
immunoprecipitation and lack of non-specific antibody pull down. 
Western blotting of the nitrocellulose membrane with a second Flag 
antibody (Figure 5.5B) showed no signal in the Tet-On control lanes 
indicating the specificity of the Flag antibody, and strong, equal intensity 
protein signal at the predicted size of RBM47 in both lanes corresponding  
 
 
FIGURE 5.5: RBM47 is an RNA binding protein. A: 831BrM2 cells stably 
expressing tet-inducible WT Flag-RBM47 (RBM47-WT) or empty vector 
(Tet-On) were UV-irradiated before lysis and stringent anti-FLAG IP. 
Bound RNA was end-labeled with !-32P-ATP and IPed protein size 
separated via SDS-PAGE. Transfer to nitrocellulose and subsequent 
exposure to x-ray film revealed the presence of radioactively labeled RNA 
only in those lanes corresponding to WT-RBM47 crosslinked cells, 
indicating that RNA pull down was both UV and FLAG epitope 
dependent. B: Western blotting of the same nitrocellulose membrane 
reveals the presence of FLAG-RBM47 protein in both cross-linked and 






to dox-treated RBM47-WT. A second flag-reactive band is seen at a lower 
molecular weight and is presumed to be a degradation or cleavage 
product of the full length RBM47-WT. This experiment indicates the 
presence of RNA in physiologically relevant contact with RBM47 in vivo, 
and confirms RBM47 as an RNA binding protein. 
 
Mapping direct RBM47-RNA interactions using a modified HITS-CLIP protocol 
To identify direct RBM47 targets in 831BrM2 cells, a modified 
version of the HITS-CLIP protocol was employed that was developed by 
Aldo Mele in the Darnell laboratory (Figure 5.6). This protocol combines 
polyA tailing and a specially designed RT-PCR primer that reduces the 
number of linker ligation reactions while also utilizing cDNA 
circularization to capture fragments that may prematurely truncate during 
RT at the crosslink site (Konig et al., 2010). Both of these enhancements 
can theoretically increase the complexity of the sequenced HITS-CLIP 
libraries by reducing linker-ligation bias (Jayaprakash et al., 2011), 
removing inefficient ligation steps, and by capturing fragments that 
would normally not be PCR amplified due to lack of 5’ complementary 
sequences.  
 
Duplicate dishes of RBM47-WT and Tet-On Control cells were 
grown in the presence of 1ng/ml dox for 3 days before UV-crosslinking 
and harvesting for HITS-CLIP. A triplicate dish was harvested without 
crosslinking for RNAseq analysis. The Flag-RBM47 HITS-CLIP protocol 
differs slightly from the previously used AGO HITS-CLIP protocol in that 
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anti-Flag antibody was used for IP, and 3’ linker ligation was omitted in 
favor of CIP treatment and 5’ end labeling with "-32P-ATP (Figure 5.6A). 
As seen in Figure 5.5A, the autoradiogram shows no radioactive signal in 
both the Tet-On control and the non-crosslinked RBM47-WT control lanes 
while high levels of RNAseA treatment in crosslinked RBM47-WT cells 
reveals a sharp radioactive RNA band at the predicted size of RBM47. 
Reducing the concentration of RNAseA added pre-IP to crosslinked 
RBM47-WT lysates lead to a smear of radioactivity rising above the 
predicted weight of RBM47, corresponding to RNA-protein complexes of 
increasing RNA modal size. The red boxes indicate the region of the 
nitrocellulose that was excised (~30kD, equivalent to ~100nt RNA), 
proteinaseK treated, and from which the two RBM47-bound CLIP libraries 
were independently prepared. 
 
In order to clone the RBM47-bound RNA library and prepare it for 
Illumina high throughput sequencing (Figure 5.6B), the isolated RNA 
fragments (green bar) were first polyA tailed then reverse transcribed 
using a primer with several important features. At the 5’ end of the RT 
primer are two hexamers (purple bar); the first is a known-sequence 6-mer 
index used for identification of multiplexed samples, the second is a 
degenerate 6-mer barcode used to distinguish unique cDNA clones from 
PCR duplicates. Downstream from the index and barcode is a 21nt partial 
reverse complement to the Illumina forward sequencing primer (orange 
bar), an abasic furan that serves as an ApeI cut site (x), and the full sense 









FIGURE 5.6: Outline of the modified HITS-CLIP protocol used with 
RBM47. A: 831BrM2 Flag-RBM47 WT and Tet-On control cells were 
treated with 1ng/ml doxycycline for 3 days before UV irradiation to 
induce covalent bonds between direct RNA-protein interactions. After cell 
lysis and partial RNaseA digestion, RBM47-protein complexes were 
stringently purified by IP with an anti-Flag antibody followed by CIP 
treatment and radioactive labeling with 5’ "32P-ATP. Complexes were 
separated by SDS-PAGE and transferred to nitrocellulose. Exposure of the 
nitrocellulose membrane to x-ray film revealed the presence of radioactive 
RNA in only those lanes with both Flag-RBM47 expression and UV-
crosslinking. Treatment with high RNaseA (+++) reduced the radioactive 
signal to a sharp band at the anticipated molecular weight of Flag-RBM47. 
Low RNaseA treatment (+) of WT-RBM47 crosslinked cells leads to a 
smear of radiation above RBM47 indicating the presence of RBM47-RNA 
complexes of increasing RNA length. Small sections of nitrocellulose were 
excised from two independent replicate experiments as indicated by red 
boxes, and RBM47 bound RNA purified from the membrane by proteinase 
K digestion. B: Purified RBM47 CLIP tags were polyA tailed then reverse 
transcribed in the presence of BrdU, using a polydT-NV primer containing 
Solexa primer sequences (forward – orange, reverse – blue) separated by 
an abasic furan (), with a short 6nt degenerate region plus a 6nt index 
sequence (purple). The resulting BrdU-cDNA was stringently purified by 
IP, circularized and digested with ApeI to re-linearize the cDNA fragment 
with Solexa sequences now flanking the original cloned RBM47-bound 















This is then followed by a stretch of T20 plus a 3’ VN to allow for 
anchoring of the RT primer at the 5’ end of the polyA tail partially 
overlapping into the purified RNA fragment. RT-PCR was carried out in 
the presence of Brd-U (red *) to allow for stringent purification of the 
resulting cDNA (red bar) from the RT reaction by anti-Brd-U IP.  
 
While still on-bead, CircLigase was used to catalyze intramolecular 
ligation, bringing the sequences needed for Illumina sequencing into the 
correct orientation with respect to the cloned fragment, so that upon ApeI 
linearization and Brd-U elution cDNA fragments are ready for PCR 
amplification and deep sequencing. Unpublished data from our 
laboratory has shown that more complex CLIP libraries can be generated 
from samples with low total PCR amplification, therefore having a single 
PCR step before Illumina sequencing in this modified protocol further 
enhances the complexity if the final data set. 
 
Summary of RBM47 HITS-CLIP data 
The processing and bioinformatic manipulation of the data 
obtained from RBM47-WT HITS-CLIP are summarized in Figure 5.7A. 
Briefly, sequencing of the two pooled RBM47-WT HITS-CLIP libraries 
gave a total of ~38.9 million reads. Reads were filtered based on quality 
score, exact duplicates collapsed, and adapter sequences and 3’ polyA 
stretches trimmed. Alignment to the human genome (hg18) left 
~14.0million reads mapping to single locations. Splitting the data by index 
assigned ~4.4million reads to replicate A and ~9.6million reads to  
 
 
FIGURE 5.7: Summary of RBM47 HITS-CLIP sequencing data and 
reproducibility. A: Multiplexed sequences were filtered based on quality 
score and exact sequence duplicates collapsed. Adapter sequences were 
trimmed from both 5’ and 3’ ends, and A nucleotides trimmed from the 3’ 
end. Sequences originating from each replicate library were separated 
using the 6nt index and reads aligned to hg18. Collapsing sequences based 
on degenerate linker and genomic position generated ~1.5million unique 
RBM47 tags for replicate A, and ~4.3 million for replicate B. B: Unique 
tags from each replicate were pooled together to define regions of 
reproducible RBM47 binding (BC2≥2 tags). Plotting the number of tags 
each replicate contributes to a cluster reveals an extremely high degree of 
correlation, indicating a high degree of reproducibility between data sets. 
This correlation remains when increasing the stringency of cluster 





replicate B. Sequences were further collapsed based on degenerate linker 
sequence and genomic start site to remove PCR duplicates, leaving 
~2.14million Replicate A and ~7.98million Replicate B unique reads, 
referred to as RBM47 tags.  
 
Reproducibility of RBM47 HITS-CLIP data sets 
To identify reproducible sites of RBM47-RNA binding, all RBM47 
tags were clustered together to return binding sites with greater than or 
equal to 3nt overlap between tags, and the minimal presence of one tag 
from each replicate library (biological complexity=2 and tags≥2 or 
BC2≥2tags, minimal definition of a cluster). 635,499 BC2≥2tags clusters 
were identified on 10,547 genes (55% of annotated genes). Replicate 
experiments were found be highly reproducible with strong correlation 
between the number of tags per BC2≥2tags cluster from each experiment. 
This strong correlation between replicate libraries remained constant 
when cluster definition stringency was increased to BC2≥10tags (both 
R2=0.99, Figure 5.7B).  
 
Genomic distribution of RBM47 binding 
While requiring reproducibility between replicates at any given 
binding site reduces the potential for background noise in CLIP data sets, 
multiple additional measures are routinely applied to increase stringency 
of cluster definition. These include increasing the number of overlapping 
tags (BC2≥10tags, 98,298 RBM47 clusters) or applying the previously 
described significant peak threshold (statistically significant observed 
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binding above that expected by random distribution of CLIP tags on a 
transcript; BC2 sigpeak≥10tags, 30,277 peaks). Another measure of 
robustness can be calculated by chi-squared analysis of tags per cluster 
per experiment (detailed in (Darnell et al., 2011)) then applying an 
empirical threshold on the returned p-value (BC2 '2 p≤0.01). For RBM47 
HITS-CLIP the minimal tag number per cluster that passes this threshold 
was 26, leaving 19,908 clusters. All resulting clusters were annotated and 
the percentage of clusters per genomic location represented in a pie chart 
(Figure 5.8A). The same increasing stringency filtering criteria were 
applied to the previously described 831BrM2 AGO-mRNA HITS-CLIP 
clusters for comparison (Figure 5.8B). 
 
Annotation of BC2≥2tags clusters revealed predominant RBM47 
binding in intronic regions (53%) followed by deep intergenic sequences 
(21%). Binding to deep intergenic regions is considered to be a 
combination of both real, unannotated transcribed targets and noise, since 
many of the clusters result from mapping errors to low complexity 
sequences and repeat elements. Given the uncertain nature of deep 
intergenic binding events they were omitted from further analysis. The 
remainder of BC2≥2tags clusters segregate almost equally into 3’UTR 
(9%), the 10kb sequence immediately downstream of annotated 3’UTR 
ends (presumed to be unannotated alternative 3’UTRs, 8%), and coding 
sequence (7%). Only 2% of BC2≥2tags clusters map to 5’UTR regions 
(Figure 8A). A similar distribution of binding is seen for AGO in 831BrM2 
cells at this low stringency cluster threshold, BC≥2 tag≥2. Increasing the  
 
 
FIGURE 5.8: Genomic distribution of RBM47 clusters defined with 
increasing stringency indicates robust and reproducible binding 
predominantly in 3’UTR regions. A: Unique RBM47 tags from each 
replicate were clustered requiring a minimum of 3nt overlap between 
adjacent tags, then filtered with increasingly stringent criteria to reveal the 
most robust binding locations within the genome. At the highest level of 
stringency (Chi squared test of robustness), the majority of RBM47 
binding is found in 3’UTR regions plus the 10kb region immediately 
downstream of annotated polyA sites (DS 10kb). B: Filtering of the Ago-
mRNA HITS-CLIP data set from 831BrM2 cells shows a similar shift in 
distribution of binding from predominantly intronic to 3’UTR with 
increasing stringency of cluster definition. The number of clusters retained 





stringency of cluster definition for both RBM47 and AGO HITS-CLIP 
clusters lead to a decrease in the percentage of tags mapping to introns 
and deep intergenic regions, retention of coding sequence clusters and 
enrichment for 3’UTR binding. A similar trend towards enrichment in 
3’UTR binding through selective loss of intronic binding has been 
reported for the distribution of neuronal Elavl HITS-CLIP clusters with 
increasingly stringent biological complexity requirements (Ince-Dunn et 
al., 2012).  
 
Motif enrichment in RBM47 Binding sites  
 Robust HITS-CLIP binding sites have consistently been found to be 
enriched in validated binding motifs of the RNA binding protein 
interrogated. For example, the YCAY binding motif, which is necessary 
and sufficient to confer Nova-dependent regulation on alternatively 
spliced transcripts (Dredge and Darnell, 2003, Dredge et al., 2005, Jensen 
et al., 2000) is highly enriched in Nova HITS-CLIP clusters (Licatalosi et 
al., 2008). Furthermore, binding motifs can be identified at single 
nucleotide resolution through analysis of crosslink-induced mutations 
(CIMS) in HITS-CLIP data, with reproducible deletions in robustly bound 
sites defining the crosslinked nucleotide for multiple RNA binding 
proteins (Zhang and Darnell, 2011). 
 
To identify the RBM47 binding motif from HITS-CLIP, word 
enrichment was assessed in robust RBM47-binding sites. Sequences 
corresponding to the entire footprint of BC2≥10tags clusters, the 50nt 
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region centered on significant peaks (BC2 sigpeak≥10tags), and the 20nt 
region centered on RBM47-deletion CIMS (FDR≤0.01 and ≥5 deletion 
harboring tags, 537) were used for motif analysis. For each subset of 
RBM47 binding sites a matching set of randomly generated background 
sequences were generated with the same base composition and nucleotide 
length.  MEME analysis (Bailey and Elkan, 1994) was carried out using the 
smaller CIMS data set.   
 
Motif enrichment for each increasingly stringent subset of RBM47 
binding sites consistently returned U10 as the most enriched 10mer (Figure 
5.9A-C).  Additionally, this sequence was the most enriched motif 
identified by MEME analysis of robust CIMS sites (Figure 5.9D). Analysis 
of nucleotide bias around the CIMS site revealed an average base 
composition of 27.5% A, 18.6% C, 19.9% G and 33.9% U, with 51.8% of all 
CIMS occurring at a U residue (Figure 5.9E). Together this would strongly 
suggest that RBM47 preferentially binds predominantly U-stretches or 
AU-rich sequences (AREs) in target RNA.  
 
RBM47 re-expression in 831BrM2 cells leads to steady state levels changes of 
RBM47-bound transcripts 
To gain insight into the potential functional role of RBM47 RNA 
binding, transcript level changes associated with RBM47 re-expression in 
831BrM2 cells were assessed. RNAseq libraries were prepared from one 
dish each of Tet-On and RBM47-WT cells treated with 1ng/ml dox for 
three days prepared at the same time as those used for HITS-CLIP.  
 
FIGURE 5.9: Motif enrichment in RBM47 binding sites with increased 
stringency of binding site definition. Word enrichment in sequences 
corresponding to all BC2≥10tags clusters (A), a 50nt footprint centered on 
significant peaks BC2≥10tags (B), or in a 20nt footprint centered on 
crosslink-induced deletions (CIMS FDR≤0.001 m≥5, C). All RBM47-bound 
sequences were compared to randomly generated sequences of equal 
number, length and base composition. D: MEME analysis of the 20nt 
CIMS footprint revealed significant enrichment for a polyT motif (63/537 
sites p=3.0e-19). E: Sequence composition anchored at RBM47 CIMS reveals 




~169million 100nt paired-end RNAseq reads were mapped to the human 
genome (hg18), ~51million from the Tet-On control cells and ~118million 
from RBM47-WT cells. Fold change and associated p-value for each 
transcript was calculated based on a binomial distribution of reads per 
transcripts, and an FDR calculated using the Benjamini-Hochberg 
correction for multiple hypothesis testing. Transcripts were considered 
“expressed” given a minimum of two RNAseq reads per transcript in both 
experimental conditions (16,466 genes with ≥2 RNAseq reads per 
transcript). 
 
Plotting read count per expressed gene from Tet-On cells against 
those from RBM47-WT revealed a high correlation between steady state 
transcript levels (R2=0.67) suggesting that global transcription was not 
altered by the expression of RBM47 (Figure 5.10). To identify transcripts 
with robust RBM47-dependent changes in expression level, genes were 
filtered by fold change≥|2| and FDR≤0.01. A highly conservative filter 
was then applied to identify genes with expression level changes greater 
than two standard deviations from the linear regression line to isolate 
those transcripts with robust total RNAseq counts in an attempt to reduce 
noise inherent in the interpretation of expression level changes derived 
from single replicate RNAseq libraries.  
 
39 upregulated and 64 downregulated targets were identified, all of 
which had evidence of RBM47 binding at a minimal definition of one 









FIGURE 5.10: RNAseq analysis reveals RBM47-dependent steady state 
transcript level changes. The transcript levels of all expressed genes 
(greater than two RNAseq reads in both samples, grey) correlate well 
between Tet-On control and RBM47-WT expressing 831BrM2 cells. To 
identify differentially expressed targets, genes were selected that showed 
fold changes in RNAseq reads of ≥2 (light red) or ≤2 (light blue), FDR 
≤0.01 and level changes greater than two standard deviations (dotted line) 
from the linear regression (black line). Genes were then screened for direct 
RBM47 regulation by the requiring ≥100 total RBM47 HITS-CLIP tags in 
clusters (BC2≥2tags) per upregulated (dark red) and downregulated (dark 




total tags in BC2≥2tags clusters further refined the set of transcripts to 32 
RBM47-bound and upregulated genes, and 46 RBM47-bound and 
downregulated genes (Figure 5.10). RBM47 itself passed the threshold for 
upregulation with a fold change of 240 and FDR 4.55e-15. Interestingly 
2,060 RBM47 tags mapped to the RBM47 transcript, suggesting potential 
for RBM47 auto-regulation. The RBM47-bound up- and downregulated 
genes are listed in Table 5.1 and 5.2 respectively. The DAVID 
Bioinformatics database was used to analyze the gene ontology (GO) 
terms associated with RBM47 bound and regulated transcripts but no 
enrichment in terms was found (FDR≤0.05). 
 
For those genes positively regulated by RBM47, RNAseq transcript 
level fold change was positively correlated to the total number of RBM47 
CLIP tags in BC2≥2tags clusters bound to the transcript (R2=0.42, Figure 
5.11A) while RBM47-downregulated genes had no correlation between the 
number of RBM47 tags and transcript fold change. The majority of RBM47 
binding in upregulated transcripts occurred in 3’UTRs (~85%), with 
binding in downregulated transcripts more evenly distributed between 
CDS, intron and 3’UTR (Figure 5.11B). RNAseq reads per gene in RBM47-
WT cells were plotted against the total number of tags in BC2≥2tags 
clusters in the gene (Figure 5.12). No overall correlation was found 
between the abundance of transcript and RBM47 binding (R2=0.06) 




TABLE 5.1: RBM47-bound transcripts showing RBM47-dependent 
increase in steady state transcript level by RNAseq 
 
!




22943 DKK1 8.77 7.94E-15 20505 
3576 IL8 6.93 1.57E-14 17390 
1490 CTGF 2.66 4.58E-15 10543 
27063 ANKRD1 8.01 1.14E-14 7590 
7009 TMBIM6 2.23 8.43E-15 7219 
5552 SRGN 2.60 5.52E-15 7001 
6781 STC1 2.24 4.56E-15 5005 
4312 MMP1 4.37 1.72E-14 4478 
23204 ARL6IP1 2.50 3.61E-15 3925 
55161 TMEM33 3.92 3.15E-15 3552 
5055 SERPINB2 6.96 6.97E-15 3038 
481 ATP1B1 2.73 5.53E-15 2904 
1075 CTSC 3.55 4.11E-15 2445 
3552 IL1A 2.30 4.57E-15 2152 
54502 RBM47 239.03 4.55E-15 2060 
7056 THBD 2.18 3.63E-15 1868 
1974 EIF4A2 2.23 5.05E-15 1476 
8878 SQSTM1 2.12 1.38E-14 1467 
57823 SLAMF7 4.29 2.26E-15 1324 
5954 RCN1 2.30 3.64E-15 1312 
2919 CXCL1 5.33 5.52E-15 1132 
378 ARF4 2.02 5.05E-15 971 
9741 LAPTM4A 2.17 4.56E-15 914 
3383 ICAM1 2.23 4.11E-15 729 
5806 PTX3 3.21 4.10E-15 645 
58505 OSTC 2.82 4.55E-15 556 
55969 C20orf24 3.27 4.08E-15 527 
10627 MYL12A 2.06 3.17E-15 367 
9550 ATP6V1G1 3.15 3.62E-15 214 
6520 SLC3A2 3.00 6.97E-15 192 
3553 IL1B 2.82 4.57E-15 144 






TABLE 5.2: RBM47-bound transcripts showing RBM47-dependent 
decrease in steady state transcript level by RNAseq. 
 
Gene ID Gene Fold Change FDR RBM47 CLIP tags 
667 DST -2.54 1.35E-98 10437 
6711 SPTBN1 -2.50 1.58E-99 5803 
23499 MACF1 -2.60 7.54E-100 4672 
3655 ITGA6 -2.22 3.02E-99 4401 
4853 NOTCH2 -2.94 2.23E-99 3766 
23215 PRRC2C -2.14 7.92E-100 3358 
79026 AHNAK -2.54 5.35E-100 2991 
64750 SMURF2 -2.08 5.43E-100 2806 
8829 NRP1 -2.59 1.22E-99 1659 
7837 PXDN -2.62 1.36E-99 1590 
2317 FLNB -2.26 4.21E-99 1590 
3673 ITGA2 -2.76 3.00E-99 1385 
4134 MAP4 -2.71 2.59E-99 1227 
10075 HUWE1 -3.15 9.90E-100 1118 
3069 HDLBP -2.04 3.45E-99 920 
4898 NRD1 -2.23 2.21E-99 811 
51520 LARS -2.03 6.59E-100 793 
3376 IARS -3.01 3.18E-99 641 
5591 PRKDC -2.79 1.89E-99 525 
6574 SLC20A1 -2.53 1.64E-99 520 
54443 ANLN -2.69 6.47E-100 439 
7468 WHSC1 -3.20 1.40E-99 438 
9448 MAP4K4 -2.37 1.13E-99 435 
3949 LDLR -3.25 2.77E-99 418 
3609 ILF3 -2.42 3.07E-99 412 
7153 TOP2A -2.77 1.46E-99 406 
23524 SRRM2 -3.51 7.49E-100 392 
81 ACTN4 -2.85 9.69E-98 356 
7175 TPR -2.52 1.45E-99 328 
9793 CKAP5 -2.85 1.04E-99 281 
8570 KHSRP -2.42 1.27E-99 270 
1305 COL13A1 -2.50 7.48E-99 257 
11100 HNRNPUL1 -2.07 8.79E-100 247 
3371 TNC -3.20 3.19E-99 246 
2335 FN1 -3.97 4.17E-99 245 
5339 PLEC -3.64 1.99E-99 230 
5327 PLAT -2.45 2.01E-99 214 
7094 TLN1 -2.85 1.47E-99 194 
10594 PRPF8 -2.90 9.25E-100 186 
1063 CENPF -4.36 8.81E-99 183 
5214 PFKP -2.37 2.08E-99 154 
3675 ITGA3 -3.02 3.003E-99 150 
4017 LOXL2 -2.13 2.68E-99 130 
1786 DNMT1 -2.46 5.84E-99 112 
3710 ITPR3 -3.00 2.94E-99 108 








FIGURE 5.11: RBM47 binding in 3’UTRs positively correlates with 
transcript up regulation. A: RBM47 CLIP tags per transcript were plotted 
against RBM47-dependent transcript fold change for upregulated (red) 
transcripts, revealing a positive correlation between the RBM47 CLIP tags 
in clusters and RBM47-dependent fold induction. No correlation between 
number of binding events and fold change was seen for RBM47-bound 
downregulated targets (blue). B: The percentage of RBM47 CLIP tags in 
BC2≥2tags clusters in each region of RBM47-bound and regulated 
transcripts were calculated and averaged for up- and downregulated 
genes.  The ~85% of RBM47 binding associated with RBM47-dependent 
transcript upregulation occurs in 3’UTRs, while binding is more even 














FIGURE 5.12: RBM47 binding does not correlate with transcript 
abundance. RNAseq reads/transcript in RBM47-WT cells are plotted 
against RBM47 unique CLIP tags in BC2≥2tags clusters/transcript.   
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Independent validation of RBM47 mediated transcript level changes 
 Validation of RBM47-mediated transcript level change was carried 
out using a clonal cell line derived from the original RBM47 WT cell line 
used for HITS-CLIP and RNAseq analysis. 831BrM2 Flag-RBM47 WT 
clone#10 (RBM47-WT#10) has tightly regulated inducible RBM47 
expression compared to the original non-clonal line, and was used in the 
in vivo metastasis suppression assays outlined in Figure 5.2. Cells were 
treated for 3 days with 10ng/ml dox and RBM47 induction validated by 
Q-PCR and Western blot (Figure 5.13) with the original non-clonal 
831BrM2 Tet-On cell line used as a negative control. Transcript level of 
bound targets was assessed by Q-PCR comparing RBM47-WT#10 to Tet-
On control, and by comparing MDA-231 (RBM47 positive) to 831BrM2 
(RBM47 negative, see Figure 5.1) to determine whether presence of 
endogenous RBM47 recapitulated exogenous RBM47-dependent 
transcript level changes. 
 
Comparison of RBM47 bound and regulated targets to previously identified 
831BrM2 signature expression changes 
An extensive reference data set of genes whose expression levels 
change in 831BrM2 relative to the less metastatic MDA-231 cells (Bos et al., 
2009) was compared to the genes listed in Tables 5.1 and 5.2. None of the 
genes identified as upregulated RBM47 targets had previously identified 
as genes downregulated in 831BrM2 compared with MDA-231.  A subset 
of the RBM47-bound and upregulated transcripts had previously been 







FIGURE 5.13: Verification of dox-inducible Flag-RBM47 expression in 
the clonal population of 831BrM2 Tet-On Flag-RBM47 WT used for 
validation assays. A: Total RNA was prepared in triplicate from Tet-On 
control and WT-RBM47#10 cells treated with 10ng/ml dox for three days. 
Q-PCR for RBM47 revealed greater than 2000-fold induction of RBM47 
transcripts level (CT values in Tet-On cells were >30). Expression levels 
were normalized to TBP, p-value calculated by t-test. B: Protein lysates 
were prepared in triplicate from dox-treated cells. Flag-RBM47 protein 






STC1, MMP1, SERPINB2, CTSC, IL1A and IL1B (Bos et al., 2009), 
suggesting that while RBM47 can positively regulate the levels of multiple 
genes whose up regulation is associated with gain of brain metastatic 
potential, loss of positive RBM47 transcript regulation in 831BrM2 may be 
compensated for by some other undetermined transcriptional or post-
transcriptional mechanism. 
 
RBM47 binding to SERPINB2 (serpin peptidase inhibitor, clade B, 
member 2) is shown in Figure 5.14A (black) with the corresponding 
normalized RNAseq abundance data from Tet-On (red) and RBM47-WT 
(green, RNAseq reads/million in that library). RBM47-dependent increase 
in SERPINB2 transcript level is evident in the RNAseq data, and was 
independently verified by Q-PCR (Figure 5.14B). The expression level of 
SERPINB2 in MDA-231 and 831BrM2 cells was found to be consistent 
with previous reports, with significant increase in transcript level in brain 
metastatic cells (Figure 5.14C). Transcript levels of a second RBM47-bound 
target, CTGF (connective tissue growth factor), were found to correlate 
with RBM47 expression in both the RBM41-WT#10 cells and, 
unexpectedly, between MDA-231 and 831BrM2 contrary to previously 
reported expression level changes (Figure 5.15).  
 
Comparing the published lists of transcripts upregulated in brain 
metastatic cells with those identified as RBM47-bound and downregulated 
revealed only one common gene, COL13A1. However this RBM47-






FIGURE 5.14: SERPINB2 transcript levels are positively regulated by re-
expression of RBM47 in 831BrM2. A:  The SERPINB2 gene is shown 
overlaid with Flag-RBM47 HITS-CLIP data (black, y-axis= number of 
overlapping tags in BC2≥2tags clusters). SERPINB2 is bound by RBM47 
predominantly its 3’UTR, with low levels of binding occurring in clusters 
on CDS exons and in introns. Shown above the HITS-CLIP binding map 
are normalized RNAseq profiles from Tet-On control (red) and RBM47-
WT cells (green, y-axis=tags/million reads), with clear increase in 
SERPINB2 expression in the presence of RBM47 (fold change=6.96, 
FDR=6.97e-15). B: SERPINB2 expression levels were increased in WT 
RBM47#10 when compared to similarly dox-treated empty vector Tet-On 
control cells (fold change=8.62, p=0.0004). C: SERPINB2 expression levels 
in MDA-231 (RBM47-positive) and 831BrM2 (RBM-47 negative) concur 
with previously published reports of up regulation in brain metastatic 
cells (fold change=3.23, p=0.0003). RNA prepared from three 
independently treated cells lines, expression levels normalized to TBP, p-











FIGURE 5.15: CTGF transcript levels correlate with RBM47 expression. 
A:  The CTGF gene overlaid with Flag-RBM47 HITS-CLIP data and 
normalized RNAseq profiles from Tet-On control (red) and RBM47-WT 
(green) as in Figure 5.14A (Fold change=2.66, FDR=4.58e-15). B: Up 
regulation of CTGF in RBM47 expressing brain metastatic cells was 
confirmed by Q-PCR (Fold change=2.35, p=0.048). C: CTGF expression 
levels in MDA-231 and 831BrM2 correlate with endogenous RBM47 
expression (fold change=0.67, p=0.027). RNA prepared from three 
independently treated cells lines, expression levels normalized to TBP, p-





shown). Q-PCR validation was attempted for several of the RBM47-bound 
and downregulated targets that had shown the largest predicted fold 
changes by RNAseq, including MACF1, CENPF/CUGBP2 and NOTCH2. 
All transcripts were found to be unchanged in the presence of exogenous 
RBM47 and when comparing MDA-231 to 831BrM2 cells (data not 
shown). Closer inspection of the RNAseq data for downregulated 
transcripts revealed an anomaly in the distribution of RNAseq reads along 
the length of transcripts in the RBM47-WT library as illustrated in Figure 
5.16 on the AHNAK transcript (fold change=-2.54, FDR=5.35e-100).  
 
While a 3’-end bias is known to occur in polyA selected RNAseq 
libraries (Levin et al., 2010, Tariq et al., 2011), it is not clear when 
comparing single RNAseq libraries whether the apparent increased 
rapidity of signal decay in the 3’-5’ direction in RBM47-WT cells results 
from technical error in library preparation, or reflects a biological 
consequence of RBM47 binding. RBM47 bound downregulated transcripts 
were found to be significantly longer than all expressed transcripts (Figure 
5.17). Longer transcripts have higher probability of high RNAseq reads 
therefore statistical analysis of even small fold changes are more robust 
and have lower FDRs (Oshlack and Wakefield, 2009). Visual inspection of 
multiple non-RBM47 bound transcripts of similar genomic length and 
equal differential expression by RNAseq revealed similar RNAseq profiles 
suggesting that the apparent RBM47-dependent downregulation of long 
















FIGURE 5.16: RBM47-bound and downregulated genes show strong 
3’end bias in the RNAseq profile. The AHNAK transcript (fold change=-
2.54, FDR=5.35e-100) is shown as an example of the rapid 3’-5’ decay of 
RNAseq reads that is exaggerated in the RBM47-WT RNAseq data set 














    
FIGURE 5.17: Cumulative distribution plots of genomic gene length of 
RBM47-bound genes showing RBM47 dependent transcript level 
changes. Genomic length of all expressed genes in the RNAseq data sets 
are shown in black, the 32 RBM47-bound and up regulated transcripts in 
red, the 46 down regulated genes in blue. RBM47-bound up regulated 
genes are significantly shorter than the general transcript population 
(p=4.661e-08), while down regulated are significantly longer (p<2.2e-16). 
Gene length was calculated using coordinates from obtained from Refseq, 





Further RNAseq sampling, preferably prepared using a ribo-minus 
protocol, needs to be carried out before any conclusions can be made 
about the role of RBM47 in transcript down regulation. 
 
Validation of RBM47-mediated expression level changes in transcripts not 
previously identified as altered in metastasis 
Ankyrin repeat domain 1 (ANKRD1) was the second most 
differentially expressed RBM47-bound transcript identified by RNAseq 
(fold change=8.01, 7590 RBM47 CLIP tags) (Figure 5.18A). The positive 
regulation of ANKRD1 transcript levels by RBM47 was confirmed in 
RBM47-WT#10 dox-treated cells (Figure 5.18B), while decrease in 
expression was also seen in 831BrM2 relative to MDA parental cells 
(Figure 5.18C). Dickkopf 1 (DKK1) was identified as both the most 
upregulated of RBM47-bound transcripts (fold change = 8.77) and the 
most highly bound RBM47-regulated transcript (20,505 RBM47 tags in 
BC2≥2tags clusters). The majority of DKK1 RBM47 CLIP tags map to the 
3’UTR (96.7%), with low level binding also evident on exons and the 5’ 
UTR (Figure 5.19A). Q-PCR revealed ~4-fold up-regulation of DKK1 in 
dox-treated RBM47-WT#10 cells compared with similarly treated Tet-On 
controls, independently confirming the RNAseq data (Figure 5.19B).  
Reciprocal decrease in DKK1 transcript levels were seen in 831BrM2 




FIGURE 5.18: ANKRD1 transcript levels correlate with RBM47 
expression. A:  The ANKRD1 gene overlaid with Flag-RBM47 HITS-CLIP 
data (black) and normalized RNAseq profiles from Tet-On control (red) 
and RBM47-WT (green) (Fold change=8.01, FDR=1.14e-14). ANKRD1 is 
bound by RBM47 predominantly its 3’UTR, with lower levels of binding 
occurring in clusters on CDS exons and along the entire length of multiple 
introns. B: Up regulation of ANKRD1 in RBM47 expressing brain 
metastatic cells was confirmed by Q-PCR when compared to similarly 
dox-treated empty vector Tet-On control cells (Fold change=1.77, 
p=0.023). C: ANKRD1 expression levels in MDA-231 and 831BrM2 
correlate with endogenous RBM47 expression (fold change=0.70, p=0.04). 
RNA prepared from three independently treated cells lines, expression 






FIGURE 5.19: DKK1 transcript levels correlate with RBM47expression. 
A:  The DKK1 gene overlaid with Flag-RBM47 HITS-CLIP data (black) and 
normalized RNAseq profiles from Tet-On control (red) and RBM47-WT 
cells (green) (Fold change=8.77, FDR=7.94e-15). Extensive binding of 
RBM47 is seen in an extended region beyond the annotated polyA site that 
is accompanied by low level RNAseq reads suggesting the presence of a 
minor DKK1 isoform with an extended 3’UTR. B: Up regulation of DKK1 
in RBM47 expressing brain metastatic cells was confirmed by Q-PCR 
when compared to similarly dox-treated empty vector Tet-On control cells 
(Fold change=4.07, p=0.0014). C: DKK1 expression levels in MDA-231 and 
831BrM2 correlate with endogenous RBM47 expression (fold change=0.59, 
p=0.0004). RNA prepared from three independently treated cells lines, 





Treatment of RBM47-WT#10 cells with &-amanitin to block 
transcription indicates that RBM47 binding to DKK1 leads to transcript 
stabilization, with the half-life of DKK1 mRNA increasing from 3.5hrs in 
the absence of dox-induction to 12.1hrs in the presence of RBM47 (Figure 
5.20, assayed by Sakari Vanharanta, Joan Massagué laboratory, MSKCC). 
Given the extensive AGO binding on the DKK1 transcript identified by 
AGO HITS-CLIP in Chapter 4, it was hypothesized that RBM47 
stabilization of the DKK1 transcripts may in part result from disruption of 
AGO regulation in the 3’UTR. Normalized AGO binding (tags/million 
unique reads in that cell line) on RBM47-dependent upregulated 
transcripts validated by Q-PCR (DKK1, CTGF and ANKRD1) is shown in 
Figure 5.21. While the normalized AGO-mRNA peaks in MDA-231 (red) 
and 831BrM2 (orange) are the same height on the DKK1 3’UTR (Figure 
5.21A), DKK1 transcript levels are ~0.6-fold lower in 831BrM2 cells 
(Figure 5.19C) and therefore, on a per transcript basis, AGO binding is 
enhanced in RBM47-negative 831BrM2. Similarly, increase in AGO-mRNA 
binding is clearly seen in the 3’UTR of CTGF (Figure 5.21B) and ANKRD1 
(Figure 5.21C) in 831BrM2 cells. SERPINB2 was not bound by AGO in 
either MDA-231 or 831BrM2 (not shown). 
 
It has been previously demonstrated by PAR-CLIP that a positional 
relationship exists between exogenous tagged-HuR and tagged-AGO 
3’UTR binding sites, with the peak of binding for both proteins 
predominantly overlapping at exactly the same nucleotide (Mukherjee et 










FIGURE 5.20: RBM47 expression leads to increased stability of the 
DKK1 transcript. RBM47-WT#10 cells were cultured in the absence 
(control) or presence of dox for three days before %-amanitin treatment to 
block RNA polymerase II transcription. The presence of RBM47 increases 
the half-like of the DKK1 transcript ~3.5 fold. Experiment carried out by 








FIGURE 5.21: Normalized Ago-mRNA binding maps in MDA-231 
(RBM47 positive) and 831BrM2 (RBM47 negative) on RBM47-dependent 
up regulated transcripts. A: Normalized Ago binding in MDA-231 (red) 
and 831BrM2 (orange) is shown above RBM47 binding (black) on the 
DKK1 transcript. DKK1 steady state transcript level is reduced in 831BrM2 
cells (Figure 5.19C) so that on a per transcript basis, less Ago binding is 
evident in MDA-231 cells (in the absence of RBM47). A reduction in Ago 






CLIP for endogenous protein binding sites in T cells (Darnell laboratory, 
unpublished data), and has been suggested to either agonize or 
antagonize AGO binding. To see whether such a positional relationship 
exists between RBM47 and AGO, significant peak 3’UTR footprints of 
AGO in 831BrM2 cells (+/-25nt centered on peak in BC≥2 tags≥10 
significant peaks) were overlapped with 3’UTR significant peaks from 
RBM47 HITS-CLIP (BC2≥10, 19,455 total). Of 2,832 AGO significant 3’UTR 
peaks, 43% overlapped the footprint coordinates of RBM47 significant 
3’UTR peaks by a minimum of 1nt. The position of RBM47 peak binding 
was calculated relative to the peak of AGO binding in overlapping 3’UTR 
clusters (Figure 5.22). While a slight enrichment in peak binding of RBM47 
is seen in regions corresponding to the +/-10nt region of AGO peak 
binding, RBM47 appears to bind in a much more dispersed pattern than 
has been described for HuR with respect to AGO. This suggests that AGO 
and RBM47 do not bind exactly the same sites within 3’UTRs rather that 
RBM47 coats the entire footprint region in which AGO targeting occurs. 
 
Analysis of paired-end RNAseq identifies extensive RBM47-dependent 
alternative splicing 
Reproducible binding of RBPs in intronic regions is predictive of a 
role in pre-mRNA processing. To explore the relationship between RBM47 
intronic binding and alternative splicing, the previously described paired 
end 100nt RNAseq data sets were analyzed as described for the 
identification of Muscleblind-like 2 (Mbnl2) regulated alternative splicing 









FIGURE 5.22: Histogram of the overlap of RBM47 and Ago significant 
peak binding in 3’UTRs. The center of all Ago significant peaks in 
3’UTRs was determined and a +/-25nt footprint assigned centered on the 
peak coordinate. The Ago coordinates were intersected with similarly 
derived footprints of RBM47 significant 3’UTR peaks, resulting in 1,218 
overlapping significant binding sites. The distance of the RBM47 peak 
from the Ago peak was calculated as is shown as a histogram. While some 
enrichment of overlap is seen in the -/+10nt region spanning Ago peak of 
binding, RBM47 peaks are more dispersed on 3’UTRs with respect to Ago 
binding than previously described patterns of HuR and Ago binding sites 
(Mukherjee et al., 2011).  
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data set of cassette exons derived from mRNA/expressed sequence tag 
data, inclusion rates (IR) were calculated for each cassette exon as outlined 
in Figure 5.23, and the change in inclusion rate ((I) upon RBM47 
expression calculated. This method allows for the identification of 
reciprocal splicing changes between two samples with high sensitivity 
while normalizing for changes in RNA stability (Ule et al., 2005b). Positive 
(I indicates enhanced inclusion in the presence of RBM47, while negative 
(I indicates RBM47-dependent cassette exon skipping.  
 
To select high confidence alternative splicing events from single 
RNAseq libraries, alternative splices with ≥10 RNAseq tags mapping to 
cassette exon junctions and (I≤|0.2| were considered for further analysis. 
This gave 669 cassette exons with RBM47 enhanced inclusion and 756 
cassette exons with RBM47 enhanced exclusion. To assess direct 
regulation by RBM47, the genomic coordinates of the cassette exon locus, 
from the start of the 5’ flanking exon (5’FE) across the 5’ flanking intron 
(5’FI), cassette exon (CA), 3’ flanking intron (3’FI) to the end of the 3’ 
flanking exon (3’FE, see Figure 5.23), were cross-referenced to BC2≥2tags 
RBM47-WT HITS-CLIP cluster data. Surprisingly, direct RBM47 binding 
was evident in the genomic locus of a high proportion of alternative 
splicing events showing RBM47-dependence. 480 included and 464 
excluded splicing events showed evidence of at least one BC2≥2tags 
cluster (Figure 5.24). The DAVID Bioinformatics database was used to 
analyze the gene ontology (GO) terms associated with these 944 cassette 










FIGURE 5.23: Calculating change in inclusion rates of alternatively 
spliced isoforms from paired end RNAseq data. A schematic of an 
alternatively spliced exon with constitutive exons in blue (5’FE - 5’ 
flanking exon, 3’FE – 3’ flanking exon) and the alternatively spliced 
cassette exon (CA) in red. Paired end RNAseq reads were mapped to the 
genome allowing for split-segment alignment to splice junctions, then 
further processed to infer unobserved exon junctions between aligned 
paired reads. The number of reads spanning constitutive-cassette (5’FE-
CA and CA-3’FE) and constitutive-constitutive splice junctions (5’FE-3’FE) 
were used to calculate the inclusion rate (IR) of each cassette exon in a 
comprehensive database. The change in inclusion rate (&I) was calculated 
such that a positive ΔI indicates enhanced inclusion in the presence of 
RBM47, while negative ΔI indicates cassette exon skipping. A &I of |0.2| 














FIGURE 5.24: The majority of RBM47-dependent !I≥|0.2|alternatively 
spliced cassette exons are bound by RBM47. Cassette exons with greater 
than 10 RNAseq reads mapping to splice junctions in both Tet-On control 
and RBM46-WT libraries and with &I≥0.2 or &I≤0.2 are shown in light red 
and light blue, respectively. Alternatively spliced exons with RBM47 
binding in the genomic region spanning 5’-FE start to 3’FE end (minimum 





831BrM cells as the background (16,466 genes with ≥2 RNAseq tags per 
transcript). Proteins encoded by RBM47-bound alternatively spliced 
transcripts were weakly enriched in GO terms related to the cytoskeleton 
and RNA binding (p≤0.01, FDR≥0.01).  
 
The large number of RBM47-bound transcripts with RBM47-
dependent altered splicing patterns indicates an extensive role for RBM47 
in pre-mRNA processing. This is despite the relatively small proportion of 
RBM47 intronic clusters that pass the increasingly stringent cluster 
definition thresholds outlined in Figure 5.8. Analysis of the median tags 
number per BC2≥2tags cluster in genic regions (Figure 5.25) clearly 
demonstrates that individual intronic RBM47 clusters have a lower 
median tag count than binding sites in 5’UTR, coding sequence and 
3’UTRs. Given that pre-mRNA is estimated to be present at levels 1000x 
lower than mRNA (Reid et al., 2009), lower levels of tag numbers in 
intronic binding site are to be anticipated when compared to coding 
sequence or UTRs. Interestingly, increasing the cut-off for the presence of 
RBM47-binding in alternative splice locations by total tag numbers in all 
BC2≥2tags clusters rather than total tags per individual cluster still retains 
high numbers of RBM47-dependent alternative splicing events. For 
example, a cutoff of ≥100 unique tags in BC2≥2tags clusters identifies 206 
RBM47-dependent included and 196 excluded exons. Together this would 
suggest a pattern of dispersed, low-level binding surrounding alternative 
splices similar to those described for FUS (Ishigaki et al., 2012, Rogelj et 











FIGURE 5.25: Distribution of RBM47 unique tag numbers in 
BC2≥2tags clusters. The median tag number per cluster is lowest in 
intronic binding sites, with 95% of all intronic clusters having less 
than 5 tags per cluster. This explains the decrease in retained intronic 
clusters seen upon increase in cluster stringency definition (Figure 5.8) 
as applying a ≥10 tags per cluster threshold effectively eliminates 




robust binding sites identified by HITS-CLIP for other alternative splicing 
regulators such as Nova (Licatalosi et al., 2008), MBLN-1 (Wang et al., 
2012), MBNL-2 (Charizanis et al., 2012) and PTBP2 (Licatalosi et al., 2012). 
 
RBM47 binds multiple transcripts in the region of alternative splicing associated 
with the epithelial to mesenchymal transition (EMT) 
Extensive alterations in alternative splicing patterns have been 
reported during the EMT transition of human mammary epithelial cells 
expressing tamoxifen-inducible Twist (Shapiro et al., 2011), a transcription 
factor essential for developmental mesoderm specification and 
differentiation (Qin et al., 2012). RBM47 was among several RNA binding 
proteins whose expression was found to decrease during EMT. 
Interestingly, of the 168 alternative splicing events identified by (Shapiro 
et al., 2011), 47 are bound by RBM47, with 36 having the same directional 
change in exon inclusion with respect to the presence or absence of 
RBM47 expression (Table 5.3). 
 
Independent validation of RBM47-regulated splicing changes 
 Candidate RBM47-regulated alternative splicing events were 
selected for validation based on greatest observed |(I| and ≥100 RBM47 
HITS-CLIP tags in BC2≥2tags clusters in the cassette exon locus.  
Validation was carried out using the clonal cell line RBM47-WT#10 and 
831BrM2 Tet-On cells treated for 3 days with 10ng/ml dox. Alternative 
splicing was assessed by semi-quantitative radioactive RT-PCR using 
three independent RNA preparations from each cell line.  In addition,  
TABLE 5.3: RBM47-bound and dependent splicing changes previously 
identified as altered in EMT. Shown are RBM47-dependent splicing 
changes whose direction corresponds that seen in Shapiro et al., 2011 with 
respect to RBM47 expression. The number of RBM47 HITS-CLIP tags in 
BC2≥2tags clusters in the 5’FE-3’FE genomic region of each alternative 
splice is given. 
 
Gene Chrm 5’FE Start 3'FE End Strand Clip tags Delta I 
ADD3 chr10 111880110 111883338 + 83 0.68 
ARHGAP17 chr16 24850225 24838214 - 106 -0.27 
CD44 chr11 35188087 35193036 + 547 0.26 
CD44 chr11 35167957 35189571 + 3896 0.65 
CLSTN1 chr1 9723900 9718529 - 20 -0.65 
CTNND1 chr11 57285844 57319776 + 475 -0.27 
CUGBP2 chr10 11247454 11331169 + 139 -0.29 
DAG1 chr3 49482715 49489341 + 15 0.71 
EBPL chr13 49163600 49135193 - 85 0.25 
EPB41L1 chr20 34249194 34263711 + 4 -0.24 
FAM176A chr2 75641931 75606745 - 263 -0.21 
FAM62B chr7 158245032 158235100 - 310 0.58 
FER1L3 chr10 95145970 95138776 - 969 -0.29 
HMGN1 chr21 39641278 39639625 - 35 -0.27 
HMGN1 chr21 39642134 39638941 - 49 -0.21 
KIF13A chr6 17880268 17872364 - 62 0.56 
MARK3 chr14 103027866 103036289 + 136 -0.37 
MARK3 chr14 103027866 103039370 + 206 -0.49 
MARK3 chr14 103027866 103039370 + 206 -0.24 
MATR3 chr5 138642638 138671307 + 1190 0.37 
MBNL1 chr3 153645760 153648251 + 78 0.30 
NFYA chr6 41154745 41159908 + 52 -0.72 
NIN chr14 50296826 50291209 - 59 -0.41 
NISCH chr3 52489239 52493692 + 11 0.29 
PBRM1 chr3 52571023 52559802 - 86 0.24 
PLEKHA1 chr10 124176447 124179643 + 58 -0.31 
PLEKHA1 chr10 124176447 124179643 + 58 -0.26 
PLEKHM2 chr1 15918815 15924626 + 3 -0.44 
PLOD2 chr3 147279733 147277258 - 193 -0.32 
PPFIBP1 chr12 27720627 27723838 + 57 0.26 
RBM3 chrX 48318499 48319750 + 16 0.52 
SEC31A chr4 83984685 83969176 - 373 0.29 
SEC31A chr4 83984685 83969176 - 373 0.37 
SEC31A chr4 83982657 83969176 - 300 0.67 
SLK chr10 105757924 105768036 + 256 0.72 
SPAG9 chr17 46409580 46407130 - 72 -0.36 
STX2 chr12 129849132 129842039 - 38 0.42 
TEAD1 chr11 12840372 12843022 + 77 -0.28 
UBXN11 chr1 26505713 26500771 - 2 0.25 
WARS chr14 99912416 99897797 - 171 -0.35 
ZC3H11A chr1 202031397 202037378 + 1668 0.25 






splicing patterns were assessed in the parental MDA-231 cells (RBM47 
positive) and 831BrM2 cells (RBM47 negative) to identify those RBM47-
dependent alternative splicing events that may contribute to the more 
aggressive metastasis seen in the absence of RBM47.  
 
 Analysis of the RNAseq data identified MDM4 exon 6 (ex6) as a 
negatively regulated, RBM47-bound cassette exon ((I=-0.63, 145 RBM47 
CLIP tags in BC≥2tags). Figure 5.26A shows the genomic locus of the 
MDM4 gene, with normalized RNAseq reads from Tet-On control (red) 
and RBM47-WT (green), and RBM47 CLIP tags in BC2≥2tags clusters 
(black). RBM47 binding is present in the 5’ flanking intron of the 
alternatively spliced ex6, as well as in the 3’UTR and several additional 
non-alternatively spliced exons of MDM4. Zooming in on the region of the 
alternatively spliced exon (Figure 5.26B) clearly shows reduction in 
RNAseq signal corresponding to ex6 in RBM47 expressing cells. Semi-
quantitative RT-PCR of the region spanning MDM4 ex5-7 shows 
significant RBM47-dependent exclusion ofex6 in dox-treated RBM47-
WT#10 compared to Tet-On control ((I= -0.27, p=4.4x10-4). The level of 
MDM4 ex6 exclusion correlates with RBM47 expression in MDA-231 and 
831BrM2 cells ((I=IRMDA-IRBrM2= -0.12, p=1.4x10-3, Figure 5.26C). RBM47-
dependent splicing changes associated with intronic RBM47 binding were 
validated for alternative exons in MBNL1, MACF1 and KIFAP3 (Figure 
5.27) with the anticipated changes in MDA-231 and 831BrM2 cells with 
respect to RBM47 expression. Several alternative exons showing robust 











FIGURE 5.26: RBM47 binding correlates with RBM47-dependent exon 
exclusion in MDM4. A: The genomic MDM4 locus showing RBM47 HITS-
CLIP binding in BC2≥2tags clusters in black and normalized RNAseq 
tracks from non-RBM47 expression Tet-On control (red) and RBM47-WT 
cells (green). RBM47 binding is evident in the 3’UTR of MDM4, and in the 
intronic region between consitutive ex5 and the alternatively spliced ex6. 
B: Close-up of the ex5-ex7 region of MDM4 showing clear decrease in 
RNAseq signal corresponding to ex6 in RBM47-WT cells. Shown below 
the gene are the cassette exons used for RNAseq alignment and IR 
calculation. Two included isoforms are present including full or partial 
ex6 (red) and the ex6 excluded isoform (blue). C: Independent verification 
of splicing carried out by semi-quantitative radioactive RT-PCR 
amplifying a region spanning ex5-ex7 in dox-treated Tet-On  and RBM47-
WT#10 (top left pannel), and MDA-231 (RBM47 positive) and 831BrM2 
(RBM47 negative, top right pannel). In all splicing RT-PCRs the first three 
lanes consist of an equal-parts mixture of cDNA from all samples 
amplified at increasing cycle number to ensure amplfication in the linear 
range, and the fourth lane contains a –RT control from the same mix. The 
middle cycle number was used to amplify cDNA from samples prepared 
in triplicate from each cell line. The presence of both exogenous and 
endgogenous RBM47 correlates with preferential ex6 skipping. Average 
&I of RT-PCR reactions were calculated using ImageJ analysis of 
autoradiograms ((Schneider et al., 2012), lower panels), with p-value 








FIGURE 5.27: RBM47 expression correlates with RBM47-dependent 
exon inclusion and exclusion in bound targets. A: RBM47 binding in the 
region spanning ex4-ex8 of MBNL1 correlates with RBM47-dependent 
exclusion of ex7, an NMD exon, in both RBM47-WT#10 and MDA-231 
cells. B: RBM47 promotes inclusion of ex91 of MACF1. RT-PCR &IRBM47-
WT#10-TetOn=0.35, p=0.0003; &IMDA-831BrM2=0.22, p=0.00003. C: RBM47 promotes 
the inclusion of an unannotated exon between ex19-20 in KIFAP3. 
Inclusion rate (IR) of RT-PCR reactions were calculated using ImageJ 











FIGURE 5.28: Exogenous RBM47 expression correlates with RBM47-
dependent exon inclusion and exclusion not seen when comparing 
MDA-2321 and 831BrM2. A: RBM47 binding in the intron between ex12 
and ex13 promotes ex13 inclusion in SLK. This exon is excluded in both 
MDA-231 and 831BrM2. B: LIMCH1 ex9 (based on variant 1) shows robust 
RBM47-dependent exclusion in RBM47-WT (&IRBM47-WT#10-TetOn=-0.53, 
p=2.18e-5), however no change in splicing pattern was seen between 
MDA-231 and 831BrM2. Inclusion rate (IR) of RT-PCR reactions were 
calculated using ImageJ analysis of autoradiograms, p-value calculated by 





changes between MDA-231 and RBM47 (Figure 5.28). Together these 
results suggest a regulatory role for RBM47 in alternative splicing, with 
direct binding correlating with both exon inclusion and exclusion.  
 
RBM47alternative splicing RNA Binding Map 
By coupling protein-dependent splicing changes to the binding 
sites derived from HITS-CLIP it is possible to map on a composite pre-
mRNA patterns of binding associated with RBP-binding dependent exon 
inclusion and exclusion. To generate an RBM47 RNA binding map, the 
total number unique RBM47 CLIP tags within 1kb of each RBM47-bound 
alternatively spliced exon-intron junction (|(I|>0.2, BC2≥2tags cluster) 
were counted and assigned a weight to normalize for gene expression 
level, then assigned to the closest splice site. For each 50nt window, the 
weighted sum of CLIP tags was normalized by dividing by the total 
number of tags mapping onto the cassette exon and flanking introns and 
plotted as a function of distance from respective exon/intron junctions to 
generate normalized complexity map (Ince-Dunn et al., 2012, Licatalosi et 
al., 2008) (Figure 5.29).  
 
Unlike the RNA maps generated for other alternative splicing 
regulators such as Nova (Licatalosi et al., 2008) and FOX2 (Yeo et al., 
2009), the RBM47 normalized complexity map is strikingly symmetrical 
with respect to binding around both included and excluded intron. While 
some preferential binding to regions spanning the 250nt immediately 












FIGURE 5.29:  RBM47-RNA normalized complexity splicing map. All 
RBM47 unique CLIP tags mapping to the 944 identified alternative exons 
showing RBM47-dependent splicing changes and the presence of at least 
one BC2≥2tags cluster were placed onto a single composite pre-mRNA. 
Tags numbers were normalized both to the number and distribution of 
tags between transcripts, and to the number of transcripts showing 
binding at any given position to determine common potential regulatory 
sites. This map was generated twice, once for all included exons (red), and 
then for all excluded exons (blue). The normalized complexity binding 
map of RBM47 is strikingly symmetrical both in terms of binding in 
upstream and downstream regions relative to the cassette exons, and with 





which RBM47 binding promotes exon inclusion (red), there is no clear bias 
for upstream binding in the immediate vicinity of intron-exon boundary 
of included alternative exons (see Nova binding map (Licatalosi et al., 
2008)). Peaks of binding are also observed in the 5’FE and at both of the 
alternative intron-exon boundaries, extending 50nt into the exonic region 
and greater than 500nt out from the junction in both the upstream and 
downstream directions. A tail of low-level binding can be seen extending 
into more distal intronic regions with a relatively constant normalized 
peak height. Surprisingly, the RBM47 binding map for exon skipping 
(blue) was remarkably similar to that of the RBM47 included exons, with 
near symmetrical binding at the exon-intron boundaries and flanking 
intronic regions and no bias towards binding in downstream regions with 
respect to the cassette exon.  
 
The RBM47 binding seen in validated alternatively spliced 
transcripts occurs in multiple discrete clusters spanning the entire intron 
rather than occurring in clusters in close proximity to the splice site. Given 
the extended tails of binding seen in the RBM47 normalized complexity 
map, it was feasible that a bias towards upstream binding in excluded and 
downstream binding in included cassette exons could exist outside the 
1kb boundary of the RNA map. In order to look for binding patterns 
across large intronic distances, RBM47 tags in BC2≥2tags clusters located 
in the 5’FE- 3’FE region were counted, and a percentage binding in each 
sub-region calculated. This percentage was then averaged across all 
RBM47-dependent included or excluded alternative events (Figure 5.30). 
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No clear bias towards upstream or downstream binding was evident in 
the RBM47 HITS-CLIP profile. Additionally, no bias towards binding one 
or both introns with respect to inclusion or exclusion was detected. It has 
been suggested that internal cassette exons are predominantly excluded 
when flanked by two long introns while the presence of a shorter 
neighboring intron can rescue exon inclusion (Fox-Walsh et al., 2005), 
however no bias was found in distribution of intron lengths or ratio of 
intron lengths around RBM47-regulated cassette exons (data not shown). 
 
 It remains a possibility that due to the single replicate RNAseq 
experiment and the relatively low threshold set for evidence of RBM47 
binding noise is present in the current data set that obscures the RNA 
binding “rules” associated with RBM47 regulated alternative splicing. 
Increasing the stringency of identification of altered transcripts with 
replicate RNAseq libraries and increasing the threshold set for evidence of 
direct RBM47-binding, coupled with further RT-PCR validation should 
refine the list of regulated events to allow for further investigation into the 













FIGURE 5.30: No extended positional bias is evident in RBM47 binding 
flanking regulated alternative exons. The percentage of RBM47 CLIP tags 
in BC2≥2tags clusters mapping to the 5’ flanking exon, 5’ intron, cassette 
exon, 3’ flanking intron and 3’flanking exon were averaged across all 
RBM47-dependent inclusion and exclusion events. The average 
distribution of CLIP tags around the cassette exon is no different between 






In collaboration with the Massagué laboratory at MSKCC, we have 
been shown that RBM47 is a novel, potent breast cancer metastasis 
suppressor, and that decrease in RBM47 expression is clinically associated 
with poor metastasis-free survival to both brain and lung. Understanding 
the normal function of RBM47 is key to understanding how this anti-
metastatic effect is mediated. In this study we have validated the RNA 
binding ability of RBM47 and, by mapping the entire network of RBM47-
bound transcripts, we have determined that RBM47 is a multifunctional 
RBP with roles in both transcript stabilization and the regulation of 
alternative splicing. 
 
Motif analysis of robust RBM47 CLIP clusters revealed a preference 
for polyU-rich sequences, consistent with a Class III AU-rich binding 
element (ARE). Class I AREs contain 1-3 copies of an AUUUA pentamer 
surrounded by U-rich regions, class II contain multiple overlapping copies 
of AUUUA (usually 5-8), while class III are more loosely defined in that 
they lack the AUUUA pentamer but instead contain predominantly U-rich 
sequence (Chen and Shyu, 1995). ELAVL1/HuR, by binding AREs in the 
3’UTRs of GM-CSF and c-fos (Vakalopoulou et al., 1991) can promote 
increased half-life of both transcripts ((Fan and Steitz, 1998). By coupling 
HITS-CLIP binding maps with RNAseq analysis of RBM47-dependent 
steady state transcript level changes, we have identified a subset of targets 
in which robust RBM47 3’UTR binding correlates with both up regulation 
of steady state transcript levels and, in the case of DKK1, stabilization of 
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the transcript. The data presented here would suggest that RBM47, like 
ELAVL1 functions as a transcript stabilizing 3’UTR ARE-binding protein.  
 
PolyU binding sites have been identified via HITS-CLIP (or its 
variations) for hnRNP-C (iCLIP (Konig et al., 2010)), ELAVL1 (PAR-CLIP, 
(Lebedeva et al., 2011, Mukherjee et al., 2011), HITS-CLIP Darnell lab 
unpublished data), nELAVL (Ince-Dunn et al., 2012), U2AF65 (Rogelj et 
al., 2012), and PTBP2 (Licatalosi et al., 2012). Such low complexity 
targeting is difficult to reconcile with the specificity of target selection 
shown for each RBP, indeed for many low complexity motif binding 
proteins the presence of a canonical motif is neither necessary or sufficient 
to predict binding (for example, binding of FUS to its consensus motif 
GGUG in both mouse and human brain (Lagier-Tourenne et al., 2012)). 
This would suggest other modulatory factors in target choice such as RNA 
accessibility and secondary structure (Hoell et al., 2011) or recruitment via 
protein-protein interactions. Identification of RBM47 interacting proteins 
may help to further elucidate the mechanism by which specific targets are 
selected for stabilization or alternative splicing. 
 
In order to identify RBM47-bound transcripts whose RBM47-
dependent regulation has the potential to influence metastatic 
progression, transcript levels were assessed both in the exogenous over-
expression setting (RBM47-WT versus Tet-On control cells) and in the 
endogenous setting (MDA-231 versus 831BrM2). We have identified three 
RBM47-bound targets whose transcript levels positively correlate with 
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RBM47 expression: CTGF, ANKRD1 and DKK1. Given the stringent cut-
offs placed on RBM47-dependent expression level changes as measured 
by RNAseq this is unlikely to be an exhaustive list of metastasis associated 
RBM47-regulated transcripts. Interestingly, for each of the RBM47 targets 
validated a decrease in the total AGO binding in 3’UTRs was observed in 
MDA-231 cells compared to 831BrM2, suggesting that RBM47 may 
mediate its stabilizing effect in part by displacing AGO from regulatory 
regions on common targets.  
 
The complex interplay of RBPs in both agonistic and antagonistic 
modulation of miRNA regulation is becoming increasingly apparent. For 
example, PUF proteins have been shown to activate miRNA-mediated 
silencing of hbl-1 by let-7 in C.elegans (Nolde et al., 2007) and to facilitate 
miR-221/222 silencing of p27 in human fibroblasts by binding to and 
altering local 3’UTR secondary structure (Kedde et al., 2010). As discussed 
in Chapter 3, the RRM domain containing ELAVL family members have 
been ascribed both agonistic, required for let-7 mediated c-Myc repression 
(Kim et al., 2009a), and antagonistic roles in AGO-mediated transcript 
regulation, binding to miR-16 to inhibit targeting of COX-2 (Young et al., 
2012) and stress-mediated relief of CAT-1 mRNA repression by miR-122 
(Bhattacharyya et al., 2006). For c-Myc and CAT-1 regulation, regulatory 
HuR 3’UTR binding sites are located in regions not overlapping targeting 
miRNA seed sites, consistent with PAR-CLIP data suggesting enrichment 
of miRNA seed sequences adjacent to but not within HuR binding sites 
(Lebedeva et al., 2011). In vitro studies have shown that HuR 
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oligomerization is required for the attenuation of miRISC target cleavage 
through displacement of the RISC complex from target mRNA (Kundu et 
al., 2012). Spreading of HuR binding along transcripts may help to explain 
more recent PAR- and HITS-CLIP data that have indicated a significant 
enrichment for overlapping HuR and AGO binding sites within 10nt of 
each other suggesting direct competition for binding sites ((Mukherjee et 
al., 2011), Darnell Lab unpublished data). The peak overlap of RBM47 and 
AGO in 831BrM2 cells does not share this discrete enrichment, rather 
RBM47 binding is distributed more evenly throughout AGO peaks 
suggesting a potentially less site specific co-regulation of targets. 
 
The RRM domains of RBM47 bear high similarity (63.4%, (Rice et 
al., 2000)) to the single RRM domain containing protein dead end 1 
(Dnd1), a U-rich element binding RBP predominantly expressed in 
primordial germ cells (Youngren et al., 2005). Endogenous Dnd1 
expression in zebrafish germ cells and ectopic expression in human cells 
has been shown to broadly relieve miRNA repression through direct 
binding of target mRNA in regions proximal to or partially overlapping 
the targeting miRNA seed sequence (Kedde et al., 2007). Modulation of 
mRNA repression without changes in miRNA expression level has been 
observed in germ cells of Arabidopsis thaliana (miR-159, (Alonso-Peral et 
al., 2012)), zebra fish (miR-430, miR-221/222, miR-372, miR-1 and miR-206 
(Kedde et al., 2007, Mishima et al., 2006)) and mouse oocytes where 
deletion of Dicer1 (Ma et al., 2010a) or Dgcr8 (Suh et al., 2010) fails to lead 
to de-repression of mRNA levels. Downregulation of DND1 has been 
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associated with increased target sensitivity to miR-21 in transformed 
keratinocytes (Bhandari et al., 2013) and in increased proliferation with 
reduced apoptosis in oral squamous cell carcinoma of the tongue (Liu et 
al., 2010), suggesting that the miRNA modulatory function of Dnd1 is not 
limited to germ cells and can be tumor suppressive in transformed 
somatic cells.  
 
If RBM47 is able to modulate accessibility of AGO to common 
target 3’UTRs, loss of RBM47 in metastatic progression may allow for gain 
of function for multiple miRNAs by unmasking regulatory seed sites 
without requiring extensive alteration of miRNA expression patterns. 
Such transcript-wide increase in AGO binding in the absence of RBM47 
can be inferred from the AGO binding maps of MDA-231 and 831BrM2, 
although this is highly correlative data. It would be interesting to assess 
direct AGO HITS-CLIP binding maps in the presence and absence of 
RBM47, either by RBM47-WT +/-dox induction or by RBM47 knockdown 
in MDA-231. Careful normalization of AGO binding with respect to target 
expression levels should enable assessment of RBM47-dependent 
disruption of AGO binding both on a genome-wide and RBM47-target 
specific level. Furthermore, given that AGO HITS-CLIP in 831BrM2 cells 
has already delimited the discrete AGO binding sites on targets such as 
DKK1, ANKRD1 and CTGF, the relative ability of individual seed-
matched miRNA to repress target transcripts in the presence or absence of 
RBM47 can be assessed. Of note, additional miR-335/* mimic transfection 
into MDA-231 failed to decrease relative luciferase activity in full length 
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DKK1 3’UTR reporter assays (data not shown), consistent with a buffering 
of transcript level by endogenous RBM47 and suggesting that knockdown 
of RBM47 in MDA-231 cells may be required to unmask the regulatory 
potential of miR-335/* on the DKK1 transcript.  
 
Defining high confidence RBP targets by HITS-CLIP has relied 
upon stringent filtering to discern robust and reproducible binding sites. 
Non-reproducible binding, or reproducible binding with low tag 
numbers, could stem from alignment errors, low-affinity transient binding 
captured by crosslinking that presumably does not represent the major 
function of the RBP, or in the case of Flag-RBM47 may reflect fortuitous 
binding events occurring due to non-stoichiometric levels of protein and 
target RNA. While requiring reproducibility between replicate HITS-CLIP 
libraries at any given binding site reduces the potential for background 
noise, applying increasingly stringent thresholds to RBM47 clusters lead 
to a dramatic loss in the number of retained intronic clusters and a relative 
enrichment in 3’UTR binding. A similar shift in proportional binding has 
been reported for nELAVL with increasing stringency placed on biological 
complexity of peaks, but importantly, intronic nELAVL binding has been 
shown demarcate functional sites of regulation with respect to alternative 
splicing (Ince-Dunn et al., 2012). 
 
HITS-CLIP derived RNA binding maps associated with the 
inclusion or exclusion of alternatively spliced cassette exons have revealed 
a strong bias towards exon exclusion when binding occurs in the cassette 
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exon or upstream flanking intronic sequence, and exon inclusion with 
evidence of cassette exon-adjacent downstream intronic binding. Such 
patterns have been described for Nova (Ule et al., 2003, Ule et al., 2006, 
Licatalosi et al., 2008), FOX1/2 (Yeo et al., 2009), nELAVL (Ince-Dunn et 
al., 2012), Mbnl-1 (Wang et al., 2012) and Mbnl-2 (Charizanis et al., 2012) 
leading to the suggestion that this position dependent regulation may be a 
common feature of RBPs involved in alternative splicing regulation 
(Licatalosi and Darnell, 2010). Nova has been shown to promote exon 
skipping by inhibiting the action of U1 snRNP (Ule et al., 2006), therefore 
the discrete intronic binding seen in the immediate vicinity of 
alternatively spliced cassette exons and flanking constitutive exons may 
reflect the mechanism by which this and other RBPs regulate alternative 
splicing.  
 
The binding map of RBM47 does not show clear up/downstream 
binding bias within the 500nt flanking alternatively splice exon-intron 
junctions and is instead strikingly symmetrical with respect to cassette 
exon inclusion or exclusion. The lack of a positional relationship between 
RNA binding and splicing outcome has previously been described in 
mouse embryonic stem cells for the well-characterized splicing factors 
SRSF1 and SRSF2, although for both of these proteins enrichment in 
binding was also seen on the constitutive exons consistent with binding to 
exonic splicing enhancers (Pandit et al., 2013). Relatively symmetrical 
normalized complexity maps have been generated from HITS-CLIP data 
for both PTBP1 (Xue et al., 2009) and PTBP2 (Licatalosi et al., 2012), 
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however these maps demonstrate some asymmetric binding enrichment at 
intron-exon boundaries and lack the long tails of intronic binding seen 
with RBM47.  
 
Most similar to the RBM47-intronic binding patterns described here 
are those associated with alternative splicing of FUS and TDP-43. For both 
of these proteins multiple reproducible intronic peaks of low total tag 
number (in many cases below the 10 tag threshold at which ~90% of 
RBM47 intronic signal is in lost) are correlated with respective protein-
dependent regulation of alternative splicing ((Tollervey et al., 2011, Rogelj 
et al., 2012, Lagier-Tourenne et al., 2012). It has been suggested that 
binding to long introns in regions greater than 2kb from the exon-intron 
boundary is a salient feature of both TDP-43 and FUS regulation of pre-
mRNA stability and splicing (Lagier-Tourenne et al., 2012, Polymenidou 
et al., 2011), however alternative splicing of cassette exons in both human 
and Drosophilia is generally associated with long intron length (Fox-Walsh 
et al., 2005). The median length of RBM47-bound introns was found to be 
significantly longer than the total population of both constitutive and 
cassette exon-associated introns, with bias towards binding in the distal 
regions (data not shown). However, the same significant increase in 
bound intron length was also found when analyzing AGO intronic 
binding in 831BrM2 cells, suggesting that the preference for binding to 
long introns is not a unique feature of RBM47.  
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RBM47 intronic binding is associated with extensive patterns of 
altered alternative splicing, with several of the candidate RBM47-
regulated transcripts validated here also showing loss of RBM47-specific 
alternative splicing patterns in 831BrM2 compared to MDA-231. This 
would suggest that loss of RBM47 pre-mRNA splicing regulation might 
contribute towards enhanced metastatic potential in 831BrM2 cells. 
Shapiro et al. (2011) have reported extensive alternative splicing 
associated with a breast cancer cell line model of EMT, the majority of 
which they attribute to down regulation of PTB and ESRP1/2, and up 
regulation of RBFOX2 through comparison with previously published 
CLIP data sets to enrichment of binding motifs within a 250nt flanking 
region of regulated splice sites. RBM47 is also downregulated in this 
system, and based on the HITS-CLIP and RNAseq data presented here, 
has the potential to directly regulate approximately 25% of the reported 
EMT-associated splicing changes. The polyU RBM47 enriched-motif 
derived from HITS-CLIP clusters was not among the significantly 
enriched 5-mers in the sequences adjacent to EMT-associated splices, 
however this is not unexpected given the relatively deep intronic RBM47-
binding patterns discussed above. Together this data strongly suggests 
that RBM47 is a novel regulator in the EMT-associated splicing program, 
whose downregulation may promote a more invasive phenotype in 
831BrM2 cells.  
 
The RBM47-regulated transcript MDM4 encodes a p53 binding 
protein with significant homology to MDM2, a potent negative inhibitor 
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of p53 (Shvarts et al., 1996). Multiple alternatively spliced MDM4 
transcript variants have been described (reviewed in (Mancini et al., 
2009)), with exclusion of the RBM47-regulated exon 6 leading to a 
truncated but functional variant termed MDM4-S. MDM4-S associates 
with p53 with a 10-fold higher affinity than full-length MDM4 leading to 
enhanced suppression of p53 transcriptional activity, making MDM4-S a 
potent oncogene (Rallapalli et al., 1999, Rallapalli et al., 2003), however an 
opposing role for MDM4-mediated p53 stabilization under conditions of 
cellular stress has also been described (Di Conza et al., 2012). How 
MDM4-S and MDM4 interact with the mutant p53 expressed in MDA-231 
is unknown. It has been shown that decreased Mdm4 expression in mice 
can improve overall survival in a WT p53 Rb+/- background, but not in a 
hypomorphic p53 mutant Rb+/- background where the mutant p53 has 
partial capacity to induce apoptosis but is an inefficient transcriptional 
activator (Fang et al., 2013b). Full length MDM4 has been reported to 
interact with multiple other proteins, including MDM2, p21 and CK1&, 
using domains deleted from the truncated MDM4-S. These domains also 
contain multiple targets for post-translational modification (Mancini et al., 
2009), therefore any potential pro-metastatic benefit of decreasing MDM4-
S in 831BrM2 may be independent of any p53 regulation.  
 
RBM47 was found to bind to and regulate the alternative splicing of 
several other known RBPs that themselves have alternative splicing 
regulatory functions, including MBLN1 and PTBP2 (data not shown). 
MBNL1 is abundantly expressed in skeletal muscle, brain and heart, and 
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has been implicated in the genetic disease myotonic dystrophy (DM1) 
(Miller et al., 2000). RBM47 intronic binding is associated with inclusion of 
exon 7. Exon 7 is required for MBNL1 dimerization and enhances but is 
not required for binding to CUG repeats (Tran et al., 2011), however 
inclusion or exclusion does not alter MBNL1 splicing activity (Lin et al., 
2006). Interestingly, inclusion of exon 7 represents a fetal isoform of 
MBNL1, with failure of postnatal downregulation of exon 7 inclusion seen 
in mouse models of DM1 and human DM1 skeletal muscle tissue (Lin et 
al., 2006).  
 
That RBM47 is able to regulate other splicing factors may in part 
explain the presence of RBM47-dependent alternatively spliced transcripts 
that do not show evidence of direct RBM47 binding by HITS-CLIP. It will 
be interesting to investigate whether modulation of individual transcript 
RBM47-dependent alternative splicing is able to enhance metastatic 
ability. Given the relatively dispersed RBM47 binding observed in 
regulated introns, using oligonucleotides targeted to block RBM47 
binding in MDA-231 cells may be difficult, however steric-blocking 
oligonucleotides may be of use to prevent RBM47-enhanced cassette exon 
inclusion (reviewed in (Kole et al., 2012)).  
 
The tissue-specific expression pattern of endogenous RBM47 is 
currently unknown. BioGPS (Wu et al., 2009a) reports high expression in 
thyroid, prostate, small intestine and colon in addition to several immune 
cell types, while kidney has the highest expression (RPKM) seen in the 
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RNAseq Atlas (Krupp et al., 2012). Interpretation of the cytoplasmic 
subcellular localization of RBM47 reported in the Human Protein Atlas 
(Uhlen et al., 2010) is limited by the use of a single antibody known to 
have non-specific cross reactivity. The extensive intronic binding evident 
in the HITS-CLIP binding map and the role of RBM47 in regulating 
alternative splicing of a subset of targets would indicate that RBM47 is at 
least in part nuclear. Development of an antibody with high specificity 
and affinity for RBM47 will be crucial to establishing the expression 
patterns of RBM47 in normal and disease tissues, to determine 
endogenous subcellular localization and for endogenous HITS-CLIP. 
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CHAPTER 6: GENERAL DISCUSSION 
 
Summary 
HITS-CLIP has been used to study RNA regulation in a variety of 
systems, including neurons, T cells and stem cells, but prior to this study 
HITS-CLIP had not been applied to study RNA regulation in human 
cancer. Here we have described the first study of differential RNA 
regulation with respect to the acquisition of the aggressively metastatic 
phenotype, using HITS-CLIP as a genome-wide approach to identify 
AGO-regulated targets.  In this study, we have assessed the role of RNA 
binding proteins in metastasis suppression using an elegant human 
xenograft based system developed by the Massagué laboratory that 
accurately models breast tumor dissemination and metastatic colonization 
of distal tissues (Bos et al., 2009, Kang et al., 2003, Minn et al., 2005a, Minn 
et al., 2005b). This system has previously been used to identify anti-
metastatic miRNAs whose expression levels correlate with human 
metastatic relapse (Png et al., 2011, Png et al., 2012, Tavazoie et al., 2008), 
however the identity of directly regulated targets of these miRNAs is 
difficult to infer from correlative changes in expression levels and reporter 
assays.  
 
Using AGO HITS-CLIP in MDA-231 breast cancer cells and its 
highly aggressive metastatic sub-lines with tissue tropism to lung, bone 
and brain, we have generated transcriptome wide maps of AGO-mRNA 
interactions which delineate sites of regulatory action of AGO on target 
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mRNA in a genome wide manner. In so doing, a valuable resource has 
been generated that allows for narrowing of the sequence space in which 
to search for regulatory miRNA seed sites on any given AGO-regulated 
transcript in MDA-231 cells. Additionally by comparing the binding maps 
generated in these four cell lines, we have identified sites of differential 
AGO-mRNA binding that correlate with changes in expression levels of 
target mRNAs with known roles in metastasis. Furthermore, through 
analysis of the simultaneously derived AGO-miRNA libraries from HITS-
CLIP, we have identified several miRNAs with whose CLIP profiles are 
altered with respect to metastatic potential. Decrease in the AGO-miRNA 
counts of the miR-99a/let-7c/125b-2 cluster members were found to be 
specific to lung metastatic cells, while divergent decrease (lung) and 
increase (brain and bone) in the representation of miR-142-3p suggests 
further potential for miRNA regulation with respect to tissue tropism.  
 
Unexpectedly, the miRNAs previously identified as endogenous 
suppressors of metastasis were weakly represented in the AGO HITS-
CLIP profile of MDA-231 cells, indicating a previously unappreciated 
lower limit of sensitivity of the AGO HITS-CLIP approach. Therefore to 
identify the full repertoire of regulated transcripts for one such anti-
metastatic miRNA, differential AGO HITS-CLIP was carried out in lung 
metastatic cells stably expressing pri-miR-335, expression that is sufficient 
to significantly inhibit lung colonization, or a non-targeting control 
shRNA. As a result, we have uncovered a previously unappreciated 
regulatory role for miR-335*, the presumed passenger strand of pre-miR-
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335, expanding the potential for anti-metastatic target recognition and 
potential therapeutic modulation of metastasis. Additionally, we have 
identified several hundred transcripts miR-335/* seed containing de novo 
AGO binding sites, with the validation of several previously unknown 
miR-335/* targets providing proof of principle that de novo AGO-mRNA 
binding is an indicator of gain of miR-335/* regulation.  
 
By applying HITS-CLIP prospectively to a previously 
uncharacterized protein whose downregulation in primary breast tumor 
correlates with poor metastasis-free survival to lung and brain, RBM47, 
we have demonstrated that is a multifunctional RNA binding protein with 
roles in both transcript stability and alternative splicing. Through analysis 
of robust and reproducible RBM47 RNA binding sites we have shown a 
preference for RBM47 binding to AU-rich sequences, with the most robust 
binding occurring in the 3’UTRs of target mRNA. In a sub-set of these 
targets, including DKK1, ANKRD1 and CTGF, we have demonstrated that 
RBM47 binding is positively correlated with increase in target mRNA 
steady state levels, which in the case of DKK1 was shown to be due to 
enhanced transcript stability. Furthermore we have established a role for 
RBM47 as a regulator of alternative splicing, with binding of RBM47 in 
intronic regions flanking RBM47-dependent alternative splice cassette 




Comparison of AGO and RBM47 HITS-CLIP binding maps reveal 
convergence on regulatory nodes of the Wnt pathway 
While each dataset generated by HITS-CLIP is informative with 
respect to the individual RBP and targets it regulates, by undertaking 
multiple experiments within the same relatively homogenous population 
of cells it is possible to overlay binding maps to identify regions of 
potential agonistic or antagonistic regulation. By comparing AGO and 
RBM47 binding maps in 831BrM2 cells the 3’UTR of DKK1 was identified 
as a common target. DKK1 is a member of the DKK family of secreted 
Wnt inhibitors that binds to and sequesters the Wnt co-receptors LRP5/6, 
and can interact with Kremen1/2 to block Wnt signaling (Niehrs, 2006). 
Two other nodes of the canonical Wnt pathway were identified as either 
targets of RBM47 splicing or as miR-335 responsive genes (Tavazoie et al., 
2008, Oskarsson et al., 2011) (Figure 6.1).  
 
Wnt signaling is required for mouse mammary stem cell renewal 
(Alonso-Peral et al., 2012) and maintenance of the cancer stem cell 
phenotype in murine and human squamous cell carcinomas (Malanchi et 
al., 2008). Interestingly, Wnt signaling is required for metastatic outgrowth 
of breast cancer cells in the lung via periostin recruitment of Wnt ligands 
from the stroma in the murine MMTV-PyMT breast cancer model 
(Malanchi et al., 2012). In human epithelial stem cells (hESC) Wnt 
signaling has been proposed to promote survival and differentiation 
(Blauwkamp et al., 2012), however other reports indicate that Wnt 
signaling is required for self-renewal of hESCs and inhibition of 
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differentiation (Singh et al., 2012). The pro- or anti-metastatic role of Wnt 
signaling and DKK1 expression is both tumor type and distal-organ 
specific (Menezes et al., 2012). As a negative regulator of bone formation 
(Pinzone et al., 2009), DKK1 expression has been found to enhance bone 
metastasis of multiple tumor types including prostate (Hall et al., 2005) 
and breast (Bu et al., 2008). Conversely, DKK1 secreted from human 
mesenchymal stem cells can inhibit MCF-7 breast cancer cell growth (Qiao 
et al., 2008), while down regulation of DKK1 enhances the motility, foci 
formation and soft agar colonization of nontumorigenic-epithelial breast 
cells, and leads to partial EMT (Mitra et al., 2010). 
 
We have shown that DKK1 expression is decreased in lung and 
brain metastatic sub-lines of MDA-231, an expression level change that 
was not previously reported as part of respective metastasis signatures 
due to stringent >3-fold cut-offs of expression level change. DKK1 
expression is known to be regulated at the transcriptional level by 
canonical Wnt signaling (Gonzalez-Sancho et al., 2005), vitamin D3 
(Aguilera et al., 2007), and by epigenetic silencing through CpG island 
hypermethylation and histone deacetylation in multiple human cancers 
including colorectal (Aguilera et al., 2006) and breast (Suzuki et al., 2008). 
Post-transcriptionally, DKK1 has been reported to be negatively regulated 
by a family of related miRNAs (miR-93.hd/291-
3p/294/295/302/372/373/520; (Zovoilis et al., 2009, Zhou et al., 2012)), 
miR-335 (Zhang et al., 2011) and miR-29a (Kapinas et al., 2010), with AGO 
binding in MDA-231 and derivatives supporting a role for the first two 
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regulatory events in this system. The data presented here indicates that 
RBM47 is a novel, direct positive post-transcriptional regulator of DKK1. 
Preliminary data from our collaborators at MSKCC indicates an RBM47 
dose-dependent decrease in the expression of the endogenous Wnt target 
AXIN2 after Wnt3a stimulation (data not shown). Taken together, these 
data suggest downregulation (4175LM2) or loss of RBM47 (831BrM2) may 
lead to decreased DKK1 expression and increased activation of the Wnt 
pathway in metastatic derivatives. 
 
We also identified DKK1 as a robust target for AGO regulation, 
with two of the AGO-binding sites shown to be pre-miR-335 dependent. 
No impact on DKK1 transcript level or 3’UTR luciferase reporter activity 
was evident upon miR-335/* mimic transfection suggesting that DKK1 
levels may already be maximally downregulated in these cells, that our 
assay was not sensitive enough to detect subtle changes or that this 3’UTR 
may function as a neutral target or competitive endogenous miRNA 
sponge. Pre-miR-335 is among a cohort of anti-tumorigenic miRNAs 
reported to down regulate the Wnt pathway in HEK293 cells, although the 
directly regulated targets in this system were not elucidated (Anton et al., 
2011). Additionally, the miR-335 responsive gene TNC (Tavazoie et al., 
2008) has been shown in 4175LM2 cells to enhance Wnt signaling through 
promotion of LGR5 expression, and this Wnt signaling is required for 
lung metastasis outgrowth (Oskarsson et al., 2011). LGR5 forms a complex 
with LRP6 and Fzd5 that is rapidly internalized and degraded upon co-
stimulation with R-spondin1 and Wnt3a (Carmon et al., 2012). TNC is 
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itself a Wnt target gene, with activated )-catenin upregulating TNC in 
embryonic mouse lung through direct binding to the TNC promoter 
(Cohen et al., 2009). Reduction of DKK1 in 4175LM2 cells may result in the 
upregulation of TNC in these cells via enhanced Wnt signaling, however 
the mechanism by which miR-335/* re-expression mediates TNC 
downregulation is unknown as analysis of AGO HITS-CLIP data indicates 
that TNC is not directly targeted by miR-335/*. 
 
Additional links to Wnt signaling were found when analyzing the 
HITS-CLIP data associated with RBM47-bound alternatively spliced 
transcripts. The RBM47 splicing target microtubule actin cross-linking 
factor 1 (MACF1) is required for Wnt-mediated induction of TCF/LEF 
induction of Wnt target genes in Rat-1 embryonic fibroblast cells through 
proposed interactions with LRP6, APC, B-catenin and GSK3) (Chen et al., 
2006). In hair follicle stem cells Wnt signaling has been shown to inhibit 
GSK3) phosphorylation of MACF1, promoting MACF1 association with 
microtubules and enhancing cell polarization and motility during wound 
repair (Wu et al., 2011b). RBM47 regulates both the inclusion of the 
alternatively spliced exon shown in Figure 5.27B, located between the EF-
hand and Gas-2 related (GAR) domains of MACF1, and an additional 
exon between the GAR domain and the GSR-repeat domain (data not 
shown). The functional consequence of these in-frame exon inclusions on 
MACF1 activity is unknown. Given that RBM47 is known to be 
downregulated in EMT of breast cells (Shapiro et al., 2011) it is interesting 
to speculate that loss of RBM47 regulation of these exons might lead to 
 250 
enhanced microtubule association and motility in metastasis, particularly 
when coupled with RBM47-enhanced DKK1 inhibition of Wnt signaling-
dependent MACF1 phosphorylation. Taken together, the data presented 
here suggests that RNA binding proteins influence multiple nodes of the 
Wnt pathway. Concomitant loss of RBM47 and pre-miR-335 promote 
enhanced Wnt signaling, a previously unrecognized event in breast cancer 
metastasis (Figure 6.1). 
 
Future Directions 
In the work presented here, a cell culture model system was 
selected to interrogate the role of RNA binding proteins in metastasis. As 
a first step in the analysis of RNA regulation in metastatic versus primary 
cancers, the approach was chosen given the extensive previous molecular 
characterization of the xenograft and culture system, its demonstrated 
recapitulation of human breast cancer progression, and technical necessity 
due to the lack of RBM47 antibodies. However, multiple studies 
investigating a diverse array of RBPs have shown that HITS-CLIP can be 
successfully applied to whole tissues in order to identify in vivo sites of 
RNA regulation, with particular focus on neurological disorders. 
Preliminary studies obtained in the course of this thesis work have shown 
that it is also possible to apply HITS-CLIP technology to snap-frozen, 
human brain and to surgically resected tumors, specifically in the 
mapping of ectopic Nova on endogenous transcripts in neurons or in 
primary serous ovarian tumors, respectively (Christina Marney, Darnell 





FIGURE 6.1: Multiple nodes of the DKK1/Wnt pathway are regulated 
by RBM47 and AGO-miR-335/* with respect to metastatic potential. In 
the parental MDA-231 cells that show a relatively poor ability to 
metastasize, RBM47 expression leads to stabilization and up regulation of 
DKK1 transcript, DKK1 binds to LRP5/6 leading to inhibition of the Wnt 
signaling pathway. This allows GSK3) to phosphorylate the RBM47 
splicing target MACF1 preventing it from associating with microtubules. 
Additionally, higher levels of pre-miR-335 leads to indirect repression of 
TNC expression, while DKK1 3’UTR is able to bind miR-335/* potentially 
without negative regulation of the DKK1 transcript. In the highly 
aggressively metastatic lung and brain metastatic sub-lines, both RBM47 
and pre-miR-335 levels are reduced, leading to destabilization of the 
DKK1 transcripts and derepression of Wnt signaling. Loss of pre-miR-335 
allows for TNC-dependent LGR5 expression leading to further potential 
enhancement of Wnt signaling, while loss of GSK3) phosphorylation of 
MACF1 allows for association with microtubules that in hair follicle stem 
cells allows for cell polarization and directional movement. MACF1 may 
also promote translocation of Axin to the cell membrane. Figure adapted 
from (Schuijers and Clevers, 2012) 
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heterogeneous nature of primary tumors might make interpretation of 
tumor-derived AGO HITS-CLIP binding maps challenging. With careful 
selection of high density tumor-cell containing biological samples and 
paired analysis of normal adjacent tissues, and ongoing improvements in 
the sensitivity of the HITS-CLIP protocol, future studies of AGO and 
RBM47 with respect to metastasis progression may be possible in primary 
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